var title_f7_50_7968="Cronkhite-Canada syndrome";
var content_f7_50_7968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cronkhite-Canada syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Onychodystrophy in the case patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Sweetser S, Alexander GL, Boardman LA. A case of Cronkhite-Canada syndrome presenting with adenomatous and inflammatory colon polyps. Nat Rev Gastroenterol Hepatol 2010; 7:460. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7968=[""].join("\n");
var outline_f7_50_7968=null;
var title_f7_50_7969="CPAM type 2 gross pathology";
var content_f7_50_7969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross pathology of a type 2 congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross pathology specimen from the lung of an infant with a type 2 congenital pulmonary airway malformation (CPAM). The lesion is a mixture of relatively solid regions and small cysts.",
"    <div class=\"footnotes\">",
"     * CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher M Oermann, MD, and Claire Langston, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7969=[""].join("\n");
var outline_f7_50_7969=null;
var title_f7_50_7970="Calculator: Fractional excretion of magnesium";
var content_f7_50_7970=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"FractExcMg_form\" name=\"FractExcMg_form\" onkeydown=\"clrResults();\" onkeyup=\"FractExcMg_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Fractional excretion of magnesium",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          FEMg = 100 * (UrineMg * PlasmaCr) / (0.7 * PlasmaMg * UrineCr)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Mg",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Mg_param\" onblur=\"FractExcMg_fx(); minMaxCheck();\" onchange=\"FractExcMg_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Mg_unit\" onchange=\"FractExcMg_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mcg/dL\">",
"               mcg/dL",
"              </option>",
"              <option value=\"0.1|0|mcg/mL\">",
"               mcg/mL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"              <option value=\"0.0001|0|ng/mL\">",
"               ng/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Plasma Mg",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Plasma_Mg_param\" onblur=\"FractExcMg_fx(); minMaxCheck();\" onchange=\"FractExcMg_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Plasma_Mg_unit\" onchange=\"FractExcMg_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mcg/dL\">",
"               mcg/dL",
"              </option>",
"              <option value=\"0.1|0|mcg/mL\">",
"               mcg/mL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"              <option value=\"0.0001|0|ng/mL\">",
"               ng/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Cr",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Cr_param\" onblur=\"FractExcMg_fx(); minMaxCheck();\" onchange=\"FractExcMg_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Cr_unit\" onchange=\"FractExcMg_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mcg/dL\">",
"               mcg/dL",
"              </option>",
"              <option value=\"0.1|0|mcg/mL\">",
"               mcg/mL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"              <option value=\"0.0001|0|ng/mL\">",
"               ng/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Plasma Cr",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Plasma_Cr_param\" onblur=\"FractExcMg_fx(); minMaxCheck();\" onchange=\"FractExcMg_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Plasma_Cr_unit\" onchange=\"FractExcMg_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mcg/dL\">",
"               mcg/dL",
"              </option>",
"              <option value=\"0.1|0|mcg/mL\">",
"               mcg/mL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"              <option value=\"0.0001|0|ng/mL\">",
"               ng/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              FE Mg",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"FE_Mg_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"FE_Mg_unit\" onchange=\"FractExcMg_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|%\">",
"                %",
"               </option>",
"               <option value=\"100|0|fraction\">",
"                fraction",
"               </option>",
"               <option value=\"100|0|ratio\">",
"                ratio",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"FractExcMg_fx();\">",
"              <option selected=\"selected\">",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The fractional excretion of magnesium (",
"       <b>",
"        FEMg",
"       </b>",
"       ) can be calculated by entering the values from simultaneously obtained urine and blood samples.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Elliott C, Newman N, Madan A. Gentamicin effects on urinary electrolyte  excretion in healthy subjects.",
"        <i>",
"         Clin Pharmacol Ther",
"        </i>",
"        . 2000 Jan;67(1):16-21.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7970=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function FractExcMg_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.FractExcMg_form){",
"",
"",
"doCalc = true;",
"if (Urine_Mg_param.value.indexOf(',') >= 0){ Urine_Mg_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Urine_Mg_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Mg_unit.options[Urine_Mg_unit.selectedIndex].value.split('|');",
"Urine_Mg = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Plasma_Mg_param.value.indexOf(',') >= 0){ Plasma_Mg_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Plasma_Mg_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Plasma_Mg_unit.options[Plasma_Mg_unit.selectedIndex].value.split('|');",
"Plasma_Mg = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Urine_Cr_param.value.indexOf(',') >= 0){ Urine_Cr_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Urine_Cr_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Cr_unit.options[Urine_Cr_unit.selectedIndex].value.split('|');",
"Urine_Cr = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Plasma_Cr_param.value.indexOf(',') >= 0){ Plasma_Cr_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Plasma_Cr_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Plasma_Cr_unit.options[Plasma_Cr_unit.selectedIndex].value.split('|');",
"Plasma_Cr = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"FE_Mg =  100 * (Urine_Mg * Plasma_Cr) / (0.7 * Plasma_Mg * Urine_Cr);",
"",
"unit_parts = FE_Mg_unit.options[FE_Mg_unit.selectedIndex].value.split('|');",
"if (doCalc) FE_Mg_param.value = fixDP((FE_Mg - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.FractExcMg_form){",
"",
"if (Urine_Mg_param.value && Urine_Mg < 0) {",
"Urine_Mg = 0;",
"Urine_Mg_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Urine Mg is 0 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Urine_Mg_param.value && Urine_Mg > 250) {",
"Urine_Mg_param.value = \"\";",
"clrResults();",
"Urine_Mg = 0;",
"doCalc = false;",
"alert(\"The maximum value for Urine Mg is 250 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Plasma_Mg_param.value && Plasma_Mg < 0) {",
"Plasma_Mg = 0;",
"Plasma_Mg_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Plasma Mg is 0 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Plasma_Mg_param.value && Plasma_Mg > 60) {",
"Plasma_Mg_param.value = \"\";",
"clrResults();",
"Plasma_Mg = 0;",
"doCalc = false;",
"alert(\"The maximum value for Plasma Mg is 60 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Urine_Cr_param.value && Urine_Cr < 0) {",
"Urine_Cr = 0;",
"Urine_Cr_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Urine Cr is 0 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Urine_Cr_param.value && Urine_Cr > 2000) {",
"Urine_Cr_param.value = \"\";",
"clrResults();",
"Urine_Cr = 0;",
"doCalc = false;",
"alert(\"The maximum value for Urine Cr is 2000 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Plasma_Cr_param.value && Plasma_Cr < 0) {",
"Plasma_Cr = 0;",
"Plasma_Cr_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Plasma Cr is 0 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Plasma_Cr_param.value && Plasma_Cr > 20) {",
"Plasma_Cr_param.value = \"\";",
"clrResults();",
"Plasma_Cr = 0;",
"doCalc = false;",
"alert(\"The maximum value for Plasma Cr is 20 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.FractExcMg_form){",
"",
"FE_Mg_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f7_50_7970=null;
var title_f7_50_7971="Blistering distal dactylitis 2";
var content_f7_50_7971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Blistering distal dactylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7971=[""].join("\n");
var outline_f7_50_7971=null;
var title_f7_50_7972="Atypical nevus 1";
var content_f7_50_7972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Clinically atypical nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFPAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1J1zGQVGAeDUe3YMg8GrIOcJjOe/aoZYdpK5PtWB6CJoJGMaAAOM5K561FcxjbuU4frj0FJDGUVtv3ieT7UkxV0+YncMCjdAlroVYTGxy7YZf1qZTkYz05qtOmxSABn+VOtGL4yenTPepT6GjV9TViBmjAY4A+6KVVBJA4OMfjUVvlZATgY5we9WSNzBl6+grRGTGTIQQGwM1Gn3MFTknhs8Yp1w3zA7CQeuTSQbgMbgRSvqNbCvG6MV3HDrnrwRVGXHlELkMDWsdssJBzhT+RqhNsDBgMrQ0OLMiR2MaxrwwbO6tK33SIm7GehHrVS+hy25CM9eOlS29ysYCOq5PRqyj7r1NmrrQtOSo2EAkHj1FKQWfcuFPpRbzAZLKD2yetOm3CVmY8HgY9avcgjaQMS2DvHp3qBnJXzFbP94CppgqHKPh+x9/est5ZLSVnkUEMeQO1S3bcuCuW5XICsx3Buh9KWaTPJJDjHtVVrgbHOVMb9B6Gld82TSFlwCB70XRdiG/kldeCQQeWJ5+tRwXCSRlp5PLuIuVc/xU2fejOCNzkDb6YNUpygLefhkAyMjg1D0dzaKurE16izIZJJA6x9WX9Dj0pfMzCiSDBHzI47isuW6MEilcCEjO0Dhfb6VppKs0SRgKsZ5B69fSpST1Ro04pADHlXU8n7w9DWokheEyqBuHb1rIkRIssuTz6cGpbC72/K+Bk8d6pOzszKauro0kZSysSQp/i9+xqeGbaQJOGHGe2apK5LSLIgCk8CpOAFaXlCcHHY9qpGLRYmZSSxOA3Xb61ZRhIhxk4GQKzyc7ejM2c4p8TNlAjKpJxyf51SepLjdFpmKOrKQAevelHysDjKHOKp3DkROp2qw44OefUU+GRZICWwHAxgfzovrYlx0uTEck44NOb5ABkFT1HpUUMm9cEjj1p7MhVsFgD2zkE1S8iWIZApODx2p0EpdWGR1OPrWe0uHIbqDjrRZ3Ijco3PzE+vPapuNx0NOSQ7F3sTjge1IG6ZOV9u1QGcOqqQBg8kVY37wDkE9DVbkvQlG1Qv3iuexxSlt/3gFb+8O/1qJ8vyPuioUYhuCcii4krluViuOOnG7tSZJXerHd6CoWLhMMcilgkIPy/lSb1Cw7csgOVVWGcsowT9aUEgnA7UKAXII/XFGBGc9fbNCQ7j0II56+godMBuMtSAo4BTg45wacTlV3ADHoKaJISjeYdoO4DlTTUQcjGR61MG8xuSwb19qZJkOSoOKlpItMVGCgqcH0p0n3sJnp+NQFuh6/0qTzcAMDhgetFwsNMpHHJxT45Aw2liozjpmo5trjPJ984qONSyjGRjtUNtOw7Kxa2Ffu8rQX34yeV46YqJLgocjkrxz6UjSoW5GM+nUVV0FmLNHx5gOSOoNPg+5gjdnmmrtxlTuyO/FOUEJu7ZxQD2sSImX2AZJ7UmCrbXHA5x7UR/M4Yk/WpJI2LZIy2O3SqS0IGqELFX9OCO9QtFtGQc+9SqNw7Y68USMzD5iMDpntSY7lRg5XC9algcyRBgGDLw2aAwU5OCKbZzlZHdG53EEeopR0Y3qiXOBnnj2xRT5HUhmiXC579jRV3JSIbeYxsqvwhPB9K0bkwgna4Y4GGHQms+TY9urIeAcN7Gqzl+gBIz0pc1h8tzWtWBmCjDexqS9giWUMu3djkVj2zuJsDKkdzWqpBh3rkup+Ye1OMrolxszPvog3zKuB0p9pb7IdwU4B5PrVlsEbZOQeaIGZIXhPBDdDQkrhzOwSoN2IycDkZ6ikLZAwSCOD7VNLGVKugGRwaLmNZE82IYyOfrVCuQzJIsat1DDiiM8AdHPVakjJlgwpAdOoNRFpJH3lcsvcUh+RK6BckNz2A6fSoSyyBiDgYwB/Soll2MWJyCec1Vu2I/eI3BPQdT70uYqMbkYLLOInBAwTn1qK4TMYIBBzwe1SCYysWccLxwac7j7NtYjCtx7ms3Zm+zCxYSl0cqsp45PWpVlcN5TZ3K3U9xVV1jkiBQYnByAPSmtN5nMnysn8OeTQnYGrl26jYlJDhTyNxPDe1ULhXMe5x+5JzkHkCnNKdu8ZKr0z2z7VUM42ujqxU/dbNN2Y4poryOYZCoQbT/Ceh96gE7IzLu4IyQPStCRkNuN5yRwKy7+18ho3d1TIyUD5OPaspRcdTaMk9GWIrgDhpCMDCc9ao6hKuyS3ZQqtx8p61XkuE2Lxl1HyDoDTbqSK+sYpEaRLiL+EDo3of8ar4kaqNncjj3vClpLIHjbkDqRjoc1aiDIpjYgAJnIOCfeqUTM8iu+A7n5wDj6gGoryaOZ38uQbx8vl9ePSpXumjV3Y1F1LyVaO6DsjLmFwePxqK0LyK8qrjnJIPSs2CKR2ywzCTjP92tO3f7NOnIaPOMe1RJ825MoqO25qRTkfu5wwJ4z2q0JGAZZBnAwf8arjy5I3XerMMbJAcceh+lNhmKExuCXHGPb+tbK60ZzPXYt3ExCM0PIHOcdKSKdQ/wC9IXOCD1qrJI0YQqGdMHOOKpRy4y6joecnnFTKdmOMLo2rzzF3K2ASoZR3NPDsCpTGNu76+tZ0V4SixHDIAdpA5wexqZZtsacnI7E9u4p3T1RDi1oX5ZEDApnY3OD1BommEYCcGTkhgflYVTuWkaIbB8oGN3vUdvcAoqTAbc5U45U+n0p81mQoaXCZjKm5ASV+YjFZiX0cN62WESNhju6j/wCtWlP1DbcuBjIzyawNSjLukbxxsJMgMeQM/wBaznvc2pxT0Z1cE48oAHJzu4H61oQEAYByTXFeHZLhg1ru3PCOQx+ZgOv9K6WymzweuOM9K0hO61Ma1LldjWY4GMEY/WkJ3RhgTnPX0qukuVGCWJ61KJSQeBtH6Vqc9rEo2OhBQ7+xFRE+U5GehwaApHOcEnvUN3KpjUAAY7+tSxrct25BknXcCow2PepJMBRn5gecVjWk0n2lmww3KMd+laO9jGvUYNEZJoHGzJCxH3QFB6ADFSgFuVJyOq+tVywABLA89KlWTA3Z4/KmmIkkcLg449BxTGbfjHJPQH1qKSVXH+12ApMqwO/ipbuNKxHINrDAOOjfWlclR146ZoVlXOfmHvTZpC0QGSUU9D2pW6lrUdC4ZcDqPWpfuqcnp2rBado50ZT8jHkf3fetVLmOQDBLH2pRkmVKNhzrnleMdTTlI3AYyT3FIUdu4HsTT1jKLk5GeRmlbUVyVcAYxtwOfepInUK27O49jUW7aM52/wBae+HxgYI7+tWQPYbRnqD3FEcm5doIHfPU/Smtny856cYqp86lSAQOp96HKwJXL7Hj5cDjJI7VGuSDkjn161LDIjW+xh8xOS2aYyIMYcevTmn5iITGVBxljWeVlikOxQYmOcnqD6VpucEY69aQBXJ7k84FRKN9ilKxXjckbjnnr7UUskeyXBOB7UU02huw+GItHHnpICBjsfenxELFvBxIh2sDVWK5aJmjBzGTkH0qYOApYgZPc96E0JolliZNjKAQ36+1SW5KsWUkBvlNMhkZ4tn8A5B9KlCZXcG5z0qlrqiX2J2jIcMwymeGHao5o/m3Z5J65oZyw2McfjT4zlCMA1diNh1tMgR1lBYnp9fWlOWHzNtGahkhAw4JA9/WozLkFPU0N2GlcnmjkTbNxk8fL3FQNJlAqEjrzTmLKQH7cACojESjbWPmAZ2+oqb9ikhHGQC2B2+tVZVV0DrkFWw/0qRpSVK4DAcggYxUE6eUc5yCPmA9Khs0ihm5EGGB2E4Df41VvX8mRIyuEbnPpSXQYhVViyL0I6GqdzIZECbWEsSgtnuD0qG2bxiXQ+y4RGbah6sOv1ov97kybh5yjB/2qqLcb4ovtDEbeOByVqx88dm4YEEENk9cVS1E1ZlW3md18uQ7QT1NVZrwQSmFlLYbCkdMUzUB5bMuTsdd4C9V9DUMP+mWzRXMyrPEv7okcP7A/wBKSvsbqK+LoW/tUccyh28xcg5HY+/tVC8c3l7cDKvITjcDkfhVSDFtdnz1kZQPuLwSfrVq0vEtYE86JTuGTjjHOaH7+jG48usdTNWeOImG6MiGM/KR/Knb/JbzeRuwUx39iKZrEBEhJBBJBjYHIYHpVSK4SJXMw3qpz5Z5BNZr3Xys6LKUeZFya5kEhjYositvdQMY9xUswDXcEsEMJ2DlQceaPc0EvLDbm1YTxImVLKNy56qfWo4G3MzBCQvygH+EmrZCfY0obVVs3Ys0bNlwDyvPYCs+aSYxCNAHCDcSo5U981IHaZI42kK4Py5PX1xVE3EkYdpUIZ8hJU6MnoaUldEwTT11Nywm8zLgKc/O4HbtVmOZD5m9W83PyMD09KxrWdYxF5QyWX5vrWgB5kgMjZDDdx/DTi3YicdR4vjmVJQeRy47GiNt7FiCAWAI6DmodVtQJVktnLQuPvHoG9PaktZIjFLFcSYlAOw9w3UVLTbswsrXiWmlEBwDjIyM9RUiykRp8wbcxJ29foaqvILq0VQo83GfxHb6VVt2YmMb9vPHP3T/AIVGzFy3WpsS3Bg5GQeAwz2pLeSOYTFc7SfunqfXFVppiZAm1V/hYAdj3qM5jKIzknkgoO3vVtkqKt5lySZlwc7lXPOeoP8AWsS7i8yzRo5DtYnO7qDmtHz13oQrLuwrd+e/4YqLyFFm7mSMP5hQKew68fnUS1Lh7pRtYpPOW4S4KzqpRyB95SO/1rdsrjfBGxAUgfNg8H396yB8mHiJV8VfsFwxjHVuAPf+lRGXQdVJ6nRWsokGCW6YOO1TLlEB6jJA5rMtGwwy2O3tWgM7fm4Xrg+ldkZXR581Zk8bHYfc9DTHUEEEcHtTFkAOVI29MGpedu8EjnAPvVbkbBHaiErKhGDx9D71O5ZDsyCp5ODkGi3O5JEVS4Ix07+tRJIGXy5MKM8H3o2C7e47DBQ3Tt70yViOBknuanGUDCVDuGM8/lTCFlOHO1j37VLXYE9RluC3Xgf3gKl8shcsvy+9MMckQH3seo9KshbeURi23iQfeL9zRFW0YNlWWJGGQoANVngRdyOm70OTkVawwJEgG3tg8U45cADtTauUnYpraI8ZJUkk4OegFWY1eB/LIO0jGcVatWXDRn7rdMnAzSTIxB+XaV7jvRypK6BzvoyI9cEjaOnrSxufMKD7nUZ7UiyQdJAS/bBxT5VDYeNNqgZPOcmp9AJcLnY6Dno2cGkAKNjpinQATKAFy5OBzSyo6ggDheSAOR9au3UjyGEE54wDSRopGHzz0I7GnQyKyep6gHvQCc8AADsKkd7CGM9F+96URDjJ60/O5PRh0OacAsingiUdcdG/+vRYLiEKUZQpLkgqc1XCsuCQQPbtUzN8tNX5hgNhz0FJghsimSIj5R3wByfcmimxKCy71BCnvRRbmHexUMbIqlkIHQnHFSRRkghzxnkelX1ZGAHG0jBHaq8qqsh2HJHH1FK1iua4sC7Cyj7v8qsPGYwjhslutNgyQQ3XGM1FdO0a4A4/u1pFWVzN6stNwuSOeoJpr5TDKfeqMFw0yksPmq9GA0ZJbqcYqk7iasSx4kIJOc9ahljRi3IBFOA8s8Z296axXdjdxTYkNhCszbj8w44/nTLt1WNVJKuuQzjuKWRRncGxIBnHTNVXdXUs3TODUPTQ0WupY0+dBbyW+I8uMh3OMCqEe0MRICyHgUiJmYRkHnlWHUUsyh0YqxyO/pU7mmzKFwoBcDjn5QDw1NDLuYyK4BUYY9VYcc+1XFWOSNzIMOo4IPGazJZlEm8OFizhgwyKlJI1WuhVv99vKys4KnG73p63UUsY3zEKq/JnpjNVjPA1yrl2KBGB781nRKwmMEmEbJKSZ4P+z71mpNS0N1G+5eLRR3sQjVnjkPyMxxx3GfSq2tNBaoVuFwrHI2now7H69jVZpmtopbe4gZomYfP12e3tSySRXdo8BYPJGv7rPPy9xn+VVe6sXytNPoKL4agkUWzEv3I+7N6LV2xtElcwXMZ2qhVvUHtXMWUiDUIdrPGQRvcDt64rftrhLlplLlJHBVZGbg/X0NEJX1YVocukdjPu4zAsluWxGp3KCcgEds1DcBL2KS5gPEWAVHUrjr+FPuFa4tWLwyAoSrPnILegFZ+l3EttdFI49zEBVUc8/TvnpSktbPY1he11ui7p90EGAS+7J46kVJG4kl8+EFS+Vxn731qjdxLb3ReONljY7th52+oqSPGVkDncTyFNTdr3WNxT95dTRCfKGOHEgII3ZKn1FIqskG+Fy65wwPX8qiiupXu5JkiQwt8pU9APY+vvU1snnCXyWwCOe+R2rRK+xm21uQRRHAkjYqgbp3Na0EhBAI3b+hPUGsiCZo5494ViCUwPXsa072OFIVkjYhH6p/dOOv0qYK2qFPezHyQboZgJAysTgbjlfcj07VQ8lCgZyc9G796kt3yDC7xI4PLc5596hv1mUiSN96scbwNv4U5pNXHBtO1zThCIwjjdXZT8pHIIIyPxokzbyxF1bYzZYD5cew/nWNDI0SbgQcclc859f/rVe+3wSWqsWbzAwJDqTuHck+tJNWJcGn3LLzwMSLd44yzAKx5PORj6+/vSw4k3wzFg38Ac/eA47e9YVyfnAReQSVYHOR6VYtZHXdIpy64KN3Rv8KjmuU6VluaOSJArFlx94nH+c1PFbh5Aqk4cDygR+h9DUd26T3COm7EiqMOvAfHIJp9vci1vC674pcEKpPPTkg1SjrZmbvbQltrULbmR+TvKhe3Hc1LbAA5IHPoM1ThuJEtTE25UB34xypz1qW3uDJAgfZneQNnr7+1JRStYlxlrc1g4Bk3A7lTcrAfKTUkEwYbiCT39qhdWkRNhc4PCgZx60zOyYuecdRWj02OeyaNaEhiNuCCPWp5AygKQQFHAI/Ws20mLTMQSFx1x37VdSTagAJUYwee3pVxaaMJJpliEtt+VtmTyc44ps0e18DleoJHWkhKuOW2ntxmnkkLucEr6+lW1dEbMb5hICEfKOnt9ach3Pg8A9ajYMFDZ+U0iy4+mfxqPUoshCGYeZn36044JyyZOOCDio1KSknLFhyfpSc54O5R0IFUIk8xwhVjlfeiFd2Wj4wPu5zUR5zwSf5U4ZB9AvcnvSGLKw64I9s8fhT1kPG7cyd+aYZTK2HAIHt1NJKrMCEYZHbsfpRcdiCZgHXjhujY6VZiPlkZHy+qnrVWZNvyn7x54qzbzvGhjZV2nHXqfas46Mt7aExLbjIgCgngA1NxIEaJnEnQjHeq6FWyFU7y2ODgY9qZMTEpfJOOrD+tXci1y65VmJkAWTP3l6596ikRwQSRj19aSCYyxDjO3J6VNC23ORuTuM8VW5OqIwQ3qD70SEqMpn8KMCRiE69cdKdyARyM8EUmMYASDk49ad5bqNxznqDSIc5XIxj0qVcsow4DDuTjNJK4mQscjd1z1opuQzfPgehHB/H1opD2HrH8wOMd6c4hLA/Nz1ApVLbQSMjuKfHErjjIXscdK0sK5WQ7CSOlDqJCfmO6rtrCsjyhl3HHaqciCNwd49x6UnoNashFvJEwDYB+97EVoMoblX/dycrnse4qF5SVPnHDbcL7imkCNQUk8yMjJA6qaasgd2SzMYSfmVuMYHNVS2RkMOaZ5ishUrxng5pomVWAK8Hp6GhyGoiXMr4CsCwXpjtVGRvOc/wAMgHOO9W5C4X5Tg7sAZrOvFbzPlfGPusOOayn3NoJE0cxK7XLq68pgZ596WG6XI8xFJAPynvms4XMkQKSk5zn2Jpsuph2ijnwAOhVeRUxmluaOm30JrljGvmFd8PVgDjH4VmtebA8LBGVxwuMnFWpZPtClZiRt4Ujis65t54JVlHlho8MNw5eiTe6NIJbMdbK1wxAVIgOinjNVpFeaO4SPHmwEsmOp705buXzxPcL5hdjk42jPoBVG4nkh1Fbq2IJPBU9D7VF1Y1jF8xftLkXMBmysbGMhtx4kXuDWJc2aeYpicIztuUjt/hVxcNKZYPnglJJVRxGe4I7YrMv/AJUUlwWHR8ZOe/FVe61Lgmn7pdiWUv8AvNrzD77KuCwHr61LPdH+zEWVIGiJ/g4JGehqrpN7LLbMmMyIDjccHBp4VTpUS3CfJnAb+6fQiqvpoS007SIYbpvM8pdgtjgqiEt5fPPXvVDVkktbm2uYsrHOWKMpx39asZkwSkZ4GC44AApupxJe2qRJcAhOMdAh9z70nrGxcfdkmaOnaksflLMkaRsMO2zd7cntn1qa705EM0oXbGW+Ux/w/wD1q5KKaYW4iZnJj52HpXQaTNOLYwSsAkvPlsuSeOx7U4yUlZinTcHzRY27tJrVisi/uN2G2nIJpIXNtGfKYhW4wGq5a3LC3kQ8xyfu3DDPy/4g85qJoE+zxmDf9oiZlc5BVsdx7+1S1bVD5r6SC1HlFnmhL/ddcnaevatFsLGqSR4JJDZwcZ7n3qpZy745vPY+Y4ChmYfkaYJ3dWiChcDDAjqemfrTWi0M5Xb1IzdPC+CiuEJwDxkdvqKtf2oLmGO2uYwgyxZkjwOR/SorhI/KdWDFigwTxtOe/tVWwLwLIJp3QIeF5IY+3pUpuLsVaMle2ojQyxKWwNw5GO3196iwzREjIA+8Kvic7A00ZDSjGMdey4/rTLmALI8kbLHArBGPcEjnIpOPVFqfRle4LIizHAHABHc49KuxM8lmuCdp5UDHymqiorM2CrqDt34OMd2A71OUNqsgjYOkpwpUYzjk/QVKVtRyaasaDM8sUfmZLGVT/vYGAafJZb4p3BjWa3+dyTuy2eQp/Gs/zxsUvlyDn/8AX64qxAcW5eNJZQuWcuAEUE4+taXuYtNbDVyT+8DAnp7+v1q7ZqkWDGp77j/hVK3dJpMIzvuByOpH096ljmZJCBtbsSv8VQnbUcrvQ2LSYt5SuxUZwxH1qU7fMfAbZngmqaEAKRhSDk+9WjJhF53EHj2rVXtqckt9CcRtyQcBBkjpx61L5jNtJPr0PH1qsLoxIfKIYsR1Gc/X2qBrjBY4yp6kdv8A61DaiRytm3auG+9nH+zyatDcM7Q2PcY/OsS0m/hB5Pp/StBJd6BT1JyD3JrSEroxnCzLBbnBwAe1VZZBF8x6ds1KHZV4O7vio7oh4xsADdMD1pSCO42K5Y/KApz0BHAq3G5mJ3SAYPzH39vas63t/m2s6ocZG7oT6Z7VYil+QJgbR26Z/Gs1LuaOK6F6Jowp2/MR78ZoL78ggZ9qqruH8OE68VNFIQe3PHTNVzdCHEkAz0ytOf52Bc7mH8qcOo6NS7VOPLJJ64PUVVhXGtICMBQFznB5xUUhTBKk8VLkK2HX5T27ikeLaQw5Q9DjrUspMWycPIyn1zj8KdKz/Ke2MdKqyNsnQpjMgIx7jmrVtMsoCSgcLgYOPxpxfRhbqTLGrBTFlJOm3sT7U13YNhs8dAf50OGQ4IHHT/GpBJuj2uN/pVEEYILEnjntUjt5i/OcMOh9RVdImaT5OAOqHk1IeF5ByOKSfcdiKQlWPOMfxHp9KlglBJ5BI7+hqvcRmYEY+Rjk8+lFrEYwQSVKDI7g1KvcqysXpInxuYEDucd6KgiumQbVOEz0I60VV0RZlhWK9x6H3qYk7GUNtz0qpBIsrANyDxVtFK43DcR2rRaky0GQ3AtmchQZGGF54FNucrklV5+Yj606WNWfecdMmqs0jOgweV6e/tUS0GtRJW/dbC2VzlcjlaSKUMgBIAHBAqP/AF0e9HCsPvA02E+W2+VP3eOSOozUp6mltCVxCsod2ZQc4IHX61BGiTkIxO49OcD606RxIhCrlT+tREt9mJ8xQU4CqORVFJEMUqR3ht5mDHON2expuqxeRINgyOnFZ8pimEkpk23akBY8Z3ikkvJEIjvQyjgAgZI9qz5raM35He6ItUlDQo6EBh8rgjr71jCdYrhHB3EDJB6fhWpfPCWaSGRyucZIydvfIqhKsCurBT5LHj1FZzjfVG9Pawst6ZQFUYXtntTboyxwqJHJR8lQTnb+NU7iI+auw4BO1h6Uv2phbmCQqQDlH5LflUpu+pfIlaxYgk3xPE7hwCSCaZJbq8RdEYgEBscfme5qMTCPcsR3I6fMzDknHSrkaGOOIuSY2XcBnPPv6Volfch6bGSltPZXMhjLPjlwo4I7U1QLu4CIqhSCdxb7p9K17ASiJ5F87ywCw/u5z3qnPD5NxldoVufl7H0+tCVlfoVz3dnuZckLRyLtBWQdauQEmwV4x5qklZYxyR71ZuYUNphZYVlJ+4QQw96o2QltC0uwugYblDYz9DQlysblzrzCG0Xc+JQYZAD1P5D3olslCpKinBOAD6jpx3HuanjKMny/vCx3OW7d+lX0mcTEXEUaLJjdODuBX0/z0qkkyHOSOalsHi2TNGQHOAwPG7uKe/mGNDwyngD+4a2p4LcwvJB8wf5XYE7Wx0OOxqrYuglMdyhZGyiY/hNQ42fqaKrzK76FWBjJKpRysqjGw8mT6Cr25hck+U0TPw6MMfMOhoa1SJxMjmMK21srlkPripVYlpjO0XmL0U5y3utUlbRkSknqis0W5xCziPGSGxn5uuPpUCXBLp5iK8q8ZJ5K+lX2ZZJEWQ7zGN3yHBPFRSJAEilkEgIJ3N3z/d9qHG2wlLoyOF2EoLAyI6lPm54Ppn0qe5t2METklT0XncR6HHbNZM18u5zKGWMH5FJzj2NaFpqEany5nClwdpJxnj17UJxehUlJapFSa5aJR53+tRgUJGCv4D1qGKdpdxx+/J3ZIySa1b660/ULE74fLvV4BjUqgHqevHt6msGCJxMAoJbP3c4qJNp23NIWad1ZmlDMBbABXDqcg56c8/h3qdWMxTdwAQvPGc9foKoxy5ceYdqkk9OQO/6VPNJGilYd4CnCM4+bBxye3A4/GknoKS1JL4CKcxSSKATkMnPsKc9sbuOMKEV142rLxwMliDwAeuKryBJZnfljgnJ4GBUarL54MJACjd1yR7mk3qC231LC77RgcSAPypIxmnht8j7AQDyB6VNbpNPdB7o+ZJIc7z396dL5SMxQ+WpfPB6H2oUfuJctfMtwTkRgE7mZfmUj39frUn2h5FCqdqjq3+ArPt2DJsOfOYhkPsfard0iK4KOqO+WAJyCc4z7Z96tXsZSirk+4pD833VPQEn/ADmopZnSYRRtkYwCcDjrVCO8fYwd8pnn6/yqSVhczrtaNGflAW+7jg7vrWUndaFKFnqX7a68tWCspA5+U5rc84NzHyQoJ5yK4xLtrebZJjoQFXHPvmtzT7h2ZFxuUdvX3NOE+hFal1NxJ8jkA46eppyybcseWPHI+77CqVzO0U5VtpKIPqPbFDzAwhkJOeeOtbOdjlUDTtgsok3novX0qNw0J3Y3eje1Lp7p5bFlJBx8ucVYC8ZIyCeg/nT5bq5LdmJAzBVYMfxqwojkOcfNz90Y5+lVwm1to6VO6Bu5UfqaFcljkPJXcMdj/jUiZbhQRnr9KiTC9AMetTq4YHev4g1SJY5mCJtJDDPQc1BvyxVQQB0z1xVkRK6AqzBScZYcVA6bTlWB+lNphFooXSuzfLnaDkHuDT7XcHIJ2g+9X3iDqGxhu4NOEEf2cZxz3B5HtUcjvcvnViRHxHtZSVHTI6UwsScA59COKiVniIG9sYxkdxUikPwMKxPBx1q+a5Nhi8NnJDD04xUxyB8/Xr16j1qNwyEkqQT6jtT0YbQD83cDtQgY7ClSOM9TTpkbyo3LDDDAIPI+opFYZHQ/TuP8aUsA4JGRVEkDxEgZb5h0x3oqebCZKklM8N3/AB96KhopNlK0hkRSHByvWtRZiyKMAMOM+tMwwkbOevT1qW5jClfLGCVB49a1SstCZO7EyjxM7AGTpjOKqzAKRgc9eKsIUdM8A5yc0bDKw2qT2pNXFsZsieWTJj5T19qkSUAsUx8yc8ZFWSrFWUjgjH5VVWMW8u8L5kZ/hPFRa2xoncqx7yhiUgBTnntVa8DRcxq2G6gnoatSzILhcxlR0ZTVm5YOjBdoDD5t3P5U0tDRSs0c1JCWTzerKeQO341BqOpxxhIihYnrk8fX8qtzwKZXj3uARnao7/4Vh3iIk485Q6ryVzWMm0ddNKT1EAj2sVO0MeoPFVpd/nyW4y+RkDPQj0qOf7RMR5cYeNeVAHGKmtIhGolcu+ODgYA9ADU3Wx0NWVy9FBC6oY3UiZQTJL/C3cCq2p26i6UK3IA3PjB/Cq9wBaT+XLnZKofaDnaff3q3lxHE1yEm3J8uT29D7000/dZi04vmTKM8csKOvCqPzJrQt7yKWMW9wwSFVGDj5mNMKB4mbJd1XII5wO2fpUjFbdkmMKyHIZ4T0b3FNJxFKSkrPcglhzCWWXHzfKxPygeuKgkkV32ljJMR87kdcdKuXU0c6lgjxbyTsPAA7YqOGGNLSVjmOXOY5M98fdI9D607CT01HnaDGjtGyyJuV1Odv19xVWezWVyiySeXnGQP1qK0DP8AdbLk8J61dRgvkCQSRCToQcBh7H0oVpCacXoZTQtbneucqefQUbgzLh355+XgKfUDpWtDGG8xZABk7WXP61j3SC2u/LkYsg+ZCOjD1xUS930NIy5tOpahW4dy7sgZQSTnHmD6d6ZewT2zsjRPHv2syMM4B/i4qYyEBIzI7wp91mwSuf6U8qZf9WwMoHyKp3bx3+lVa60J5mmUXmm89Nku7bn95IvDj0I9P1qdHiDbuBuwSccIf8KZJGsjxP8AMJDx7L+fSoDHv80AuSCFyw4z3zRdlaMZd3DO+yNmyzcqOp+lSRStCvzqrwvgsCMkHvxRFbeVLglcjqQf1HvUrBF85XHIAYZ756/zpK+5TatZGZdJateGNXZbdsbn6tHnuPVc1FfxvYySRE7mTo2Mbl7Ee1Pu4wjEHPyg8gdVPTNSx3MUixSXESyCLKNDkgyIRyM9iODmpsmy02rdUVLG/YuiSwqcZO5SVJ+p9Patm4NvdJG1vE8MiqdylMbcdOe/1NZ4sJkhaS2bzIQdhAIJQnoDUlsZklJkeTzCMbnpptaMU7P3okUi4IzkFeTmiIyOFj3Yjz09frVq5VYV23GEZh1IyfwxSBIjGGiYvN/GuCMH2pctmHOrE0UayZBLMRyFA/M1YRVWOPcdpwfujrz0I/wqCK5XylVY9rdyvVvqahup84MRBIwoAHaqdlqZ2bdi4tyUjU/MYgeScZDeg/pVeOTeQ8n3ZGIw7YBxzjPaqS3jhsNhEBwuOcN64qC7mkMQV8F252rztHr9TU82hpGGpZvpihSVQoZmJCqc4rSsNWW/t3trs/OCHBGOuMEt+nTrWDPbPJbQzZbIYxqSO45x9T1qCNTuDA8DnA4I9ealScJaGjpxlG3VHRTi3WS0maTzEfiRR94js2Pz4pt7GsCu3nq27BVXGH7enAPoDWY7bLcmNxhgFeMr8yjsQTQtzJIykphpGAVmb5c46nPf61UrMzUWupdgQs42sMk4Axya27BhBMqSS/NHkvz1PbH0/pWQsTRwlus3VSDkKO5z/Kqsd60b4U8/3j2PpWaXs9wkvaKyOpkuhIVK4VlyDu4P+TU1rcqrhjGcjgDrg1zNtJgvP5gJHG0c5rWsJJLolbYMGCnOemO4J9Kq7buYyppI3oZw77sfMeK0IwAcltvqB1NZERkhVDu4cAqQMfgfSrUEzBsE556VpGXc5Zx7GquXbr9PWpY5FI2vGCOxHBFVopA2O3GKnbBAKnJFbehg0TeUeGU5Hpjmm7/mU+pxTFnK4VgCoPpkj6Uy5USoMfKwHBH9aTel0CXctFifpTgvGD19KhsH82JPvFiM8VZUcfKQM9j1pp3VxPQRQwPJ49zU0TBTtdchuQCcZzUQ2/xhvxppOTn06U72C1xXU91whPbnH400oCQMcHvVggshkiYDH3u3NMBDcEYPqP8ACkwuIm9iFfqOPrT3RVJxtRh26ilKDgIwc9eBg0KcnaVwSMGmFxMFc5UqD2P86SQgEgkY7cdadtkjAVxlCeB/h6U0lT8p5BPBPY0xDZGOBtGcjnnk0U4bUYqSCPVe9FFgvYuTIwmLZzk9vWn+ZG0LDLGXOcY6/Smxg71ww3HtUYDQTlWHzg81dybEbpsbIGd3b0pocqhUsQT3HepJH8uUHNIyrtUyfcYnFT6DASKsGxgGJ5yD0rPu5PLHzDI6Y9KnfdGeW+XtxUN/teJXB3MeGovoXFamPeXJV+eQOMHqKcrsysu8YA3DJ6/Sq1zDumAZiATycdqfcp/ooSPBKcqR1rFN6tnUkrJEVwy5ChyqnowHfuK5q/d2ZwzEkN8q45/Gtf7e8T+VMBlu7jiq4lR7sspEcoBVWwDk+/tUSfNsdNNOGtirDO9kp2xkKy7iHGSp/wAKlkmfcXtWUbkw0bDdnPdT2qrcSmG4CztvDsR5h9fWrdvlJEkSNWhU7Sd2Vz9KI66FTXUbOUmaLzdowMtx1NLlVbZMMhvmiLfdI/nRJ/qSUk2yIemef/1VmJLNCpF0p27vkcdsdh7UpO2pKjzaFqRyLk+QBGHPIThfw9qnvdzwqsTsWUZBK4EZ/qKhWYTzpGwKQDnCcgZ71LJ8sDJIzuwAYOnP51a1TJlo0VI5nwCVzIR6E7f8KFnWSFxcK29vuKgyR9ankljjgWKTHl4yJVGWAPvT9S0+O1tI7iMvC5IIJPBGP5e9Ci+gcyvqUZY3tikiEhCu4jPKgdQat3LxxiExhiJY/uN91v8APUVQlkXALh1YDcwI+8KhklEbiLe7QPjYBztPYAnv61N0tCuVu1zV0e5jNzMsi4HBjGSckdqoXrQTJPsBWVJC0ec4KHqB+P51Pp7SJDNJKqSeYCqxA45PGSKrXHnhCj708s5K8bfxp392zJS9+6IraYAhoFJIwCrHlTWj9o+yySLsCTD5ty9S3rn0x2qhbD7NOAr/ACMdzZHBarEtwjq64B8w7lOcGNu4z6GlDRFTV35EM5aORphjazEFSep/yal02UyGQABfLAYh+h7ZzWVHIxyrHoeAen1q/bTFZ43hbbIeM9BnH8qSepUo6WJrrc0rtAgDcsoBwD64z/KqaSzRzQTwSK/mA/KM5A6Mp9eKr3ks029uQVODjovrUOnpMk2E3BmyFB7fSiT10HGNlqWNUHmGEQs0pIwUfqpB4Ge5I5pLeLeDJlgwOSMf55pLiKWWXcCz5GSwGOn9RVlZQwXzZNp6sccZ96N3cd7KyJLW4kimLrGD8vyqF3DB9vUU6KX902V3g8rI7Y47YH6VTlcxujoGxngEEKfbIqlPeiG4BCFSwwee/sB09KfNbcnk5noX5rkoWjf7jcDceBjpz/hVeOaZJTtRg0WWII6cjr7VmvfofknLeVjHynlfYVpWE2yeIvLuiyUjJA+VenzKPu/T8aF72zL5eVbEzXkF1LI0afZ3PIRWyAPSojOyHemWQAg4GD9DVJWe1ndFQlA+xie+DxzTpJo4zId+6NuHcHnHqPcUndhypbbCTXqRjcI1XHJGNxx/dxTFvBNlxtjVuRGi5rOuIfLupElbZtJXd2A9fx61D5mwrGC6R5ByBy4zUJ9zbkXQ6aLzR5UYw8ka7nVRnA65P59PWpLZWKPJvIRUyByM5OB+NZ9rILo+Z5kscYX5wuQdv+0Tx/jUz3OfuRknyeFU7cjPX3znnNaO1rmLT2FmnjhkQMuJG42jJZV9T6fU095YI7XDPG+xyFXk7uO3496oX0gMW0vvfncd2Qcdjjk46ZrOguJpJAzKRICFAA6D0+lGw0rmvLd+Yp2yfvBjcCCefQegArRgiiktJA5AkkYBTnngf/XrEVQLl1wjurfMQcqPp6mtiC4TyIzIgkdARg8BM87vc9sGoWr1KktFYhSZ0kaMttlHDA9D9K1LDUpo42WM7V+623msy7MbgSs4ErpuCjkkevtRau8aRMFRg+CQvr71m+aD8irKaOystStpYSsxxnCrj1/wq1A5WYqWBK85HcVztvGUZWUqQ6g9MsuexHQVro4WED5t6nj0I/n1q7t77o4pwS2NuKQAkkgZrTgk3oA4yemPauQtZT5qDe24H7pHBrpLOTODxu/unqfpWtKdzmq07F0KwIDAlexxRIp2kDBx2pqDMZLFlI6D1qWK4IIyAVHGDWjMCvZh4iW345O0ocYq+rs+G4Hr60OYpY/3cYRl/M0QbSAQ6j2Y4pJcug27ku7GFbBFLLHGf9QxIx91utNkUqoOxhx1PPNR7mz1P4U2yUgjV1Pfj061OF3Luwc+mKRmWQAg896FDBjg/gDSSG3cUduCD71M5EmS4IkHfHB+tMUEnJJ3+vvTS2Vw2d1WiRVIZipJUehqrcnZnZkr0z71ZZsgBiGUcDsaacsGJfcuO65//VQ9RooJMTzn5vQ0VN5Xzjcc5Hy44x/9eipSZd0aPJ6Ebu1NRjJLvfkk4JNEyOh8xcgKeeKhRt02W4Rzk4q27EWui7eGNogoUBgcf5NVJMCEcnKnoelSTEBcHHsfaoZTgqyDI6ZPQ0NiSFV+csq/MO54FQTRnyQcrsY+tO5Ocfe6j3qGRGJww3HqQO1K5SWpRuEAV8nDDp704PG0KiZF2qMHHBNNuvmUtkEj0NU7sAwAhjgjOD0zU3szeMblTUI7e6jYuCWUkLGnBA9c1jzxTWqqHG6IcjjJH4+lXEZ4ZFdd7sTggY6VKWZUdZcgEcq3AA9KzspanXFuGm6Mv/j6yqBBvIAB7GqkEstqZLchh5bbip6VJMAknnwFkMbZUjuRyAfT61PdPlzdFGV3XcMch6hd+pq+3QpSuvmAxFMNzk8/rU9xfm6xa3kX+knASUfxj0I/rT4reCeLeqg7eQFYA5+npUV5BJf43xBWQYZl4/Oq1QtG9ehXsriWynmXglTtZc5/KryAXH71VMbjqVBOfc+lJDAsGk3CuVkd2BQAfMpHfNSaWGkjlFnMEnRfnjZvvDocf4UQVnysznJSu0Vki8yOUFHdzwGxwPXFJGqrE5SWRl+4iOentVx5iV/eEmWMYXHKcfSoLCOG6jvGki87em9EU4KP3bjsKvl10J5tG2Z1tdr9qj3oWjOVfqMjuPqOtRFo980THdsJCuBncM8EVKYjcxNtLc4O7+8R0I96gDsmHdwGQ9B1cGsvU2Vr6F21aRBHGjLGycqd3Bz2J7VIhXcssZwSCsiI2cjv9M+tMikhkTAUKVOVIPUdwf8AGoLxnSAC1LRJu3M2OvoMVotEZtXdie6gS3v4po3QLOwUQBt20ds9s0y5t0Xf5kRRZPuhT9w/T0PvWXCQsb7pgZAcgAcmri3iSOokTYzg5xk7v8BU3UiuVxK9zDtC5OFxgFejf/X9aZGN42xP+8CkjtgjtVyOKW4a4SECSJVBRgeD/nmoSVgEXmx8sC6uvY5xzUSVtWXzaWEYGZt0Zfc4G7PJFTIjRYkDkIcgkHB6c1aDpuLo6o4X7/UE+ue2ar3UGLdZF5cA7lzyB1z71py9TPm6FfcgbMnmIVH/ACz4LH3B4A6VHM7NaxXPJTPl/NySep47fjTpSTb+ZlHEhyxZeQR/OqG5XWQAYZhjd0GP51PkWl1EmvGVZYDJhcA47HvTIpTNYsghRQp3NO4+bA7Ln69BUNwUnvpZXUkpgFPulwABx6EfrUc8UgdGjbc455XIIPTj0pX5WaJXRI6Sx7LixGxAdu6Rc4OO2etP0xy+6JyE/vSlP4s8f5FFgHeb99tQgHc7nJGBnAH1q1BahJI5CQAx5DNnBHOT9T0pruhN9GPu2ELSWqM0qMq4L4yuO2en1rPRXVw4X1GwD86n1KZHM7KdxZgEkztMZ6njuD0J+lUUvWRjuDMTxkdc/wCNEmrhBOxf1q3CQW7Jku8KNJ6k8j+lZ1pGJZxFIsjdcbOWzjtV26vWaAdBsQx+WB0+Ynr2qglzLDLtiVV24ZlYcj8e1DSvccG+Vpk8rNbFUdAUJB2SE7uOhIH8qt2o3pN5qnLBQZM5IJbknsBgdKrQzW00atCpDZPmKDgt6YPXpWiki4EMcZEeAZo+ABj7vX05zmqihTloZF3EAXnRWETsQjYK1Fan7PKjyOkjHooOT+NWr7UlkDLPJFcqSeQCB09fbsBiqyW/mIqBWYHnjk9etJrld0VGXMrMdaSHzSCVXuMHvn0/pV+4jf7MsnmZ7kbhkY9V/lVa3s1G4yqQR0YjOfbHrV6Y/Z1hnmXcrjBH8WBwD/8Ar61Nik9bIpQS3EU0kL71hlIJB/iPb5q6SwtShKyhQHXdhTwOcMV+nNZ5aF2X7BJNdKybWaZABnuNnYVNphkjnX52BTOFJ/kfQ0pK2hMm5K60OjgQQLIAGkiBG13bH6d6ieQxhTvKnqjDkVJc3GfKknCtFICS/Aw2Oh9O2Kqz22zO35fWNefwHvRNW2MIa7lwmXHmlsupy7A55rftpy0aOTww6+tc3YMISyuWRc4AbBx9RW1p0qgtGMBewBpRetzOrHSxt28qjgYJxwSf6VbRnl4wGHXBHSs+MofnjKK/909DVyCY+X3V/wCntXQmcUokyugJzuXHAI5x+FKB8/ysCuevrSALIx7OeAx7n3ph3DG896GJFyNiBhXP0FO+SThl2n1FQI+CN/OBjI61bU25QMqMCepU8CmtSXoQLhHIPI6A1ZjJA7Z6gZ/SoZ40MeYnZiOxH9ahjYjkg+1Cdh2ui2TtOdvzd1oXDpzkOvQ1CkpfKjjHHTrUbMrP8x24HWhyQuUsIBICAdr44HrTI3GcEBh7nAqpMzI6hmBbPBXnNO34yepHUUlMfKSTkYHy4Jzk0UxZYySVBDL/AAtyD9DRVXuNaGvEWKOjcZO41XkhEUgwcqehqSMhWRy2SwIIPrQwMpOBj6dq0tdGezIpECR5OS1RKThkZh5bc/SleN0fDDJPQ1FImMMT8wOPpWbuUiNJNxkjyAw5DVHI+6LP3Sx5PtUbrtfe2Tk/jTkUSbeflGetRFvY0styJjakON6s+3hjxzVKC4PlmDy1YE8ZFXr4NImCgCr02iqKrnIBw/QBeopt6mkbWMq7gcXDNGn7xTn0H5d6juY57iITlZOesx6Z9APSr8i72dHkbzdvyHHB+p7VnzxyoqGIlkkOWj3fKD9O1ZPQ6Yu9ik0CSFVZj5gJyB0Ye1QtFLbxk27iSEg5Q8kfStmKNZ7dVQ7pMEI5GCD3FZsEYaby2YifGBjgMPWi1rFqd7mbarJHOkkOEKn7pGfzHetOWQyHBQRsvB2g859f8KrB8MUckqG2lkxk0lwrWoVYnYRuQd3Uc1UNEOerF8mSeUA7twOCoGSaoQpKt88cbDzQcgq3B/GtJ5YQHjRnRUXG9G+ZpOxJ9PpVObct1BM2GJfYzZwOeO3pSmklcUG9UON5snMd6rJIP7vynNSxvBK0lxFK8c65yIjjC9M8cn3FUZk3I8d3PsljbCq65b8/Sqk4V2XzyEZejJ1P4UuZrcfInsadvI8VxcLsUDByehORjIHaqAiUqc5JzjnvUkEcglEm9mORkuc5+pqS+3SNI53Fj989vrRurhsysoCPjDtzgKBkn/GpVurSRWSWSQTkgxqR1I7eg/yKqyZmUhGZREu4bR0HQmqJMSfdkYoR8xVcE/jSUrDcb7kzS3CM3lQb9wJVlXHHtSRRu6IwDY+7yOh9KVbzZalHRSz/AHZCTuXn+H3PrUsN2bZDG0IkSUYWWTnbg/wr0B7ZpaPqO7XQ0IzGn72JpF3JsZTwPw/GqN24Z/KQhjyWx3P+NaBltjFCdoYqSDGudxHY46fl6VTaDZduVbeigcsQTjpzjgc1ctrGa63KiySoinG8beKngeWdQVQ+d/sjoB39vekfcgeJgCm7p6HpmnRxTQxs6O0ULjBBbqP61MLrQuTTVyIvmQoQIznJRehPoKzJmUPsjiYNuyTtyQR/Ktd7MT3EcUQdWUBlCj731pt0rOxAMZYkKQnB/Idqck7BGSuZkeWlIJVWI3eVnPA68+v1rUtbZfJCTF0Th43QBtvse+PpVWK3JeRVVWRWG9tvT/gXXFXVZ4ZIxASWwdvT5R14B/lTSvqxSl0RGkCCbaEBY9SeTj1A+lPlVZIJl2qhx8oxyff61FbXJaQzkwfLlgV4PHbHqf1ps+oQRyOWikQu/wAvzZCj0Hv6ZqlZE+82UL54pJlZo2SKNQJSSTz9fQn+GseW8Q3LqBIYzwyr8vHar+pSWuZWWWVULDdE/wDF78de5qPTdPFyTcJNHs3YHOQ34f0o5bl3SRR1eQiGJoJGeJVABK4yfp/Wn6dLG0oFyWVOnyrnII7/AJVtS2Itt8UqrhwGG05Az2/CqF9ZRtDF5BeOSEEzbj8p54K/gelSrp6lNprRkUCyb5JbcQ4BzgnKqD71IbyTybmLJ8pyGZguWJ7c+59amQI8EcSxr8nR1GPfJPeownkbtzE7uqKeDzkA/wA6bVnoPdamVa2sryb3KxRg/Nnkg+n1Nb1q01uEnSNfk5IVv4emGPYn0pDd20kSM8h8oH94pQqVP+z2b8xirBSNRHHI4kV/mUIOo+vTNDWmhN9dS3BeR3UGWtzECMZz39ae9jHLZyzO52hguzGGPuKjSII6skSmIYHzNlvbk1atIzLlR8rkEjc3f/DFTrLRhfl+ErW0AztCKkeMk5zgetWJ4lCEIT2PzHA+uapmUwSGNgFbsQOfwqbT7uGSQ213MUhIwWbJBx0yKjR+6zRp/EWbq5AIjMpmgGBgcDpjIFT6dqZ+1xNNHGYgwBQORuHoT1/GiWwsXmb7Js9Y1kOXc+uBwB9arrp5IYxooKnDFX7ntRLmT0EuRqzNq+jgkhWWKVGuGOTGB8qr2BOOD9M1csM74kkBR+u7PBGOv51lww3EKeXPFIy87srkLS2jm3m8xWO0nANS2r3aIcNLJnV2sobgjBHUehrShDEhjnPt3rJtFDOHBJVvbAH/ANerqbo3B5+U8kGtVocM12NHChFIVsdDuFCy5+UkEA9PSly80WeQoHQc4qKJVU9c1bMUXGjDMfLOB2UnmnIjIcYKH3qM8jjH9Kmt3+cnIYL/AAnoafUkk3NgDdwOcdqR1+XKcrnJHpUp2k7kG0EdM5NQFjFKExzjP1FWxIRR0Knb6YoK/Ky9c9utSuibcqevIHpTeVUZAHpmlYLkAjWIH5AD6jigR5YMi89OlSlvmHzAn0xQyFkLJxjquaSiO7Kd1EwHycD0NFPZ8ZopOKZabSNNAsiq4/KrBIf5EABI6CoLQKULHOAetTJGzHMUgDDmuhbGMirI247eTj9KgMZyecj0PerE6kEnGGPUYqNZAMEjNQUtNiB4+Oe9NtZfJkyBg9amkdSuM4NUGcLJ1pNW1KWqJZo2IZ0O0HsD0rPuVMa7tvPpj731q6GyCw5B7VHtD/cYlv7tS1cuLsZgRjKPMXYM8gVWnVDNtLMkO7r6GtbyVyVYbTjl2/h+lUpoZAAzMTHncM9z64qGnY2jNXKAuntTIYDsbsXxgD/Gs6+ja4la4YgsfmzGOR7/AP1q1pbMXSMvG8A4z61nyI0cQgbfGB8ysoyahp7PY2g1utzOluJYCCuxnI2uQvX/AANKbiR0MLYVAMAAfKp9B71ZnjQXCtBkjaAUwNx/xNVIYPNvYxHvTc2ZFPGAKHdPQ191q7CWA2sURkZSWO4jqcZ/lVfUDPdkkRkbRgKowkY6jHvRcXhmnnYlDvJjw69F6D6VOZ2a3jVjmOPjYON3uB/M0XUtEFpRs3uCW0N7HFNvLOAfM5wVx3x+dRfZtspQRo0n97o2Px4pIELIZI2C+UQc5wOTxVoziS4eS5/eFlDFkHQ9M4pqzRLunpsR2aOpwZsxp8x+XP6d6o6nIzeY+45kGGyAAPoB0q7LErySGN1+RRIF6gjPSsu9lWfJfJA7fdCihuysEVeVylZzlL5DIqtGFwQeRim38RhuiGAUPk4HAU+mKs2cDNdxp8sm4MgHQNkVdZUnQpOUBUcvtwWPQfSpjHmVi5y5ZGZa7jLEZYjk/dOM4x7f41fW3jL72eIGRS24yDaP95jwD7CmW8SsxZEKlcny/wCLj1Pp71HI7XDIAFUR8gdAc0LTcUtXoOjdDauu1lZ8HcSecf41a04GGBzFHG8mRuibOXPXHtjioVARw+87h8xK85PYL6CrsKo1oFyCVxwnDMx68/41S8iJvQj1OFIpbsD5XLoUUDOQRnr2HNY91I8cayQkBA3zqBnafQ9/pXV38ZN7HucFBEueOh29fxrlbiVYLh2Me9TwyE4DD/PelUXLqKi+ZWEjnZo2SESMvUgnAP8AvVMXLoiCTzUiJbcoCLk/woe+PfpUMm9HRsK0DDfEc/Lj6dyKmu1jVI3bdJAzZLAgfN2JHpVR13KlZbFaW7miEZBYd0APB5rOluw8qPGT83LDGcc9RT71k8wAEzM3oOAc1m3Mj2wRo4ZI43YjzccEe1J6MtJNGhFcrulDttUxkBiOmSMZPT/OKmVor2FQkwxkKd3DEdN2O3zHj2rNKmVWIkI3RBkDEEu2eAwHHUmrelQvHPGs5C7mMLHAz8wyOPqMU12E1ZXEksvO/csVZlyu8dcVAyRW8flwr1+UlhtwO54/KtlHUuEgDF0ZSoHIOeo/OqN/KYJGLooJ+Yvjd+Htj9aLWVxp8zsQ6dJJyrNtjJO0OcLgelEkytJIMb40GQRwT7kVEl0XOcCJAM+aSQ23+WT7VRspZPNZ5GMgc5PHX60aNC1T2NGC9jjVWEJdwTlwex7kd/pUl3qQELR24ChhhiwA3d8gdR+dVbyH7O5kjA2n+Ec4GPX1qtdaaGiMyTb+5K9FH17/AIUJtaMuUYtXQybz3hiEYYxZONz8Z7nHrVrSQ0AYvG7buVGMfninWcYk8qIlWCAvnbtC+5z1q9KCLVXWU7wd2RxuB6Z/D0pPQFqbcKhiRKoTKAFR0X8PbFQBkmsLyR3VG8xVV3Pz9CcgelZa34C/ZwR8xBdwOW/+tWnLYKbOGQERJIT8+MgjHp+lF77E25dzNjv/ALQ3kXqHeowGHb0Oe9OYExZKHjqe4qOW0kSUTxDjOBtBAH/6609NlBRUKFowSH3DOc8c/SsZLmdmdCfKroNLuUwYp0YgkENjBH5da2oQWkdsIgYZCscZ9vU8VgXdtLDI0ERbaDkerDt+lTWImeMr828DG49sU1O3usmUE/eTOjtb1lk8qfeDg7fm4A6ceop0xPmlASBkYKdqqIjSW0Ely5I6K5OMt/jVoOoIx8xPGcdh3qJttGNknobNtOQxVpTIeApPGK1FkKiMkZ3HB56ViWQSVDjJ8s9Qeua3bKJZWG4nI6KPX1JrWm20clSyLNsXTlDwKuzIkkYdOGH8Pc0xFbyj5cZYL3HYUsJxIO6nt3FbWsrHNe7uNRlBQSdeasIo/gHfvVe4iAlG0nYDnJH6VPb4+U5+U8c0kJkybgMYH1xzRIqk4YDd2NO+90I596a8TA/xflWltCBDMyFd7FgvQHt7UCRj7jJ47U4hR83Ujg/41GpUEgjjOQaNhjzEHQsV2HoDnr+FRsWj5HOO4pzjIyB16jNMBweG2+9AivM4lbcq4PeipXRHDYIDjv6iipaZomXoHMTHH3ejD2qRz5ZDIQVNRsMtIxHGM4qKQqFJUZzywFapk2ux005MiHgkdeaaDvxgADPUVBIw2lWQ89D6UsRKIWxlc9B2pXNOXQnKqy5Uc4rKuAySMyqCrDByOn0rQSXGQOB0qEqCrAjPNEtUStCGwjM0YDHbng0s0QQEFWDA8YNW7JNrMFyXAyCKfNsIYR5z33UlHQly1M1UM4xIcHcOW9PWo7gRbWSMl8HAduOPWrtxZzpEkoUCNxlSxrMnyMfezkdfWjbc0jqQTwo5P7wRlcZAPJ9xWPckRSMjkk4yhGPm/Grlz5xkIU55+XHas+dZCcTMrL3zxtrCpJHXTj3ZBCoJL4C4G7K87eew9aW5V1t/m/10vzbu4X3qa2sljLsJCwTlSejfWqt1FPC6m4icbvmDMPvA+lTqka6OWhTjs4ZJGSWZo2cfeAyC3+HvT2UQRN5gAcMAGB4Y+mRVyZFlRWKDHf3/AAqAQKsP7wqEHAHc80LR6Dcr7lS0DpfeXIFjQ8srnAH196tXqhWkc8OCMKoyuP60JbMuXQEmL59x5Dc+lF28rLKCnz4D7gMCPPsOPoaewpO70KCyAMgX50dSCgzwT/8AXqs9rK0TO3J/i7lD7iriRyxQSzwvuijUGR27tntVuKKBlE8YjiumQMkMbMVbqCGB70kubRjcuXVGGYzEDhyXAGGx0q60rOFllYKyHcTsyD2GaZsbyskZjztyexpzwFRjd3APbB9DTjowlZ7l+2lR3ml/eRGVMF5PvDnkYHY0jxRI0jLGmVTeods+WM/eH94n07UyDdGYyIfOcghVwT8o71SXJMgZMqoIZQxGAfXFaSfcxUddCCO5jlklZiwZlGwJ359qu2ihIoyxaINkg7uB2OfSq1jBGsqmNXZslQR8vHp61agvLdhFHsdygbOGyqemAamK6sufZFi9U7osOdmxQASQc46n2rE1EMJG3tHJkfdIwVHrirNzICytGSgYFSASwPOR78VDOWR2ZpFLHB+dcqx75py1IguUxFuCWa3kcpuO6N2ONrf561BmZJJEkJRzxIvvVnXYwIhOUQfNvZRyEx2zVaCaHKLdAO4+ZWycOP4Q3ccf0qORxN1NS2RCYgp3ea4PXCNyq98nsas3N4fsksSQBLd2VSc7iB1wx6Z+nSn+bbFWSFi0Tjc8MmAwI6EHHPP50AxLCZ4wqhU2yHPLsR6dq0jZKyIkm3dkdnaohkMYVg4OQf4APXPQc1VvJTaak6yFpQ4CM6EHBxnOfUcc1YVo38wWiMsiYAk3HDE9dxPb+dVvIMzGVpGcbiGO7qf7w74qZbaFx39407V+V8/GWYKSPT1HtVPUpnnlGxgSfuc8A56Adqjt3Zj5LgeYv3Se49qlt4GguZI3CuM5AP8ASkpX0Bxsxt7YvFZJMrs6zZQggfKR2/PNZ1pDKv7sqdwPGOTXTXLxHTo4Ej2bOcg5PPXPtWb9jFrGlyrhEI5fJ3Z/z6U2rPQE7rUr26S5eGAZ9ffnoPU+1SzW81vdSWqPtVhlQDk9eV+tVWunlvlj04hSp+Qq2SWHOcnHNWdPkN7C/GJE+bd3460mk9Ck3uW7WymkO1hiTdtJ/wDrVcuptsTxCKNTnDOeHPt7D6U9raW4jLQRDagCqRww9j65J61mTSzTvmZiXj4BbnBHak3yqwl7zuMWLbLkINw65q5LOziJHZtqDC5649PpUC5lXzA2WJ+Y44q44Mk5DRpF6IFJCn05rOOmhq2nuTWl5BCZFubeWWRhhfnwqHscDr9OlatxILq1lmjSOHccmONdoH0A6fjWQkLCRS3OOFA9fU+1SCF44nDSEIRnbu6/hVub2I5Ve4u8M8eHfzOzdlNXSrOizMhjPQMDkk+9Vbe3DxhIzmcnJJPGPatCzaOKcRTMUwcFmTDfhWN77lSdtiW3jmKsCwIYdxnHuKlCzW7ptmMhHrVqzJaQdGGcMo43D19q07aFJZAsUvyseC3QGhRuc8qltyHSYXaVZJFCIvKID1Pqfp2rqLXCZYbSO4xVWygSNtkh4B+Yf4Voi3EXzA5X171104cqOGrNNlsHhXDbh39vwqC4QqxwB+FKq8llPHcDpUpkQx7Gz0xuFVJ6GK3EhZmVCx5Hr6VYMTOmYVHvj/Cq0YweP1qeIt/C5Vh3FKL7gxEG3g9KlU4bIzimsxb72Sf72MVXd2VyOvvmm3YW5JMQATg1RWZjIw7Eir5YGL5vve1KscbRr8pJHfHT/Gi1yk7bjEbcQWPIqR4yUJMeVHqagkTafkJx3pUMicqDgdfemn0E/IjZUHIbafrminkRsCeFzRSsNMv3ACzYB3IfvYPWq8iFCQgGD09qnJUR7Qq5PQ55qANtl25GatsaIJDgFW5+lLhoweO2an8oOSMjHX0pEwwwecdDmkVzEAJY/IvB61KI9o7le9ORF3oCcc0+YK2fLbg9R6U0iGyMBbeZSGVlYdV6USLuycgmmlVCr8uBnk560+aN7VlcjdGehNNEsZMd+OXb0zwB9KzbmFxNjJI7A1pyPG8e4Hae4qvMwk8vZng53dyaUrMqDaMiaJGBFureaPvMT0rMltWcBXXK9W44rXvPlcyRNgtyarwCYnOTyc72/pWEopux0xk0rmYJHikTbGvlqf8AV4wMelWLjfcIZJ5VZh/yzzkfhVgwiaTazBV7MehHqag2KnTaijgYGc0kmi3JMijEC5SYld3KsDVNzHAzLZlZwwKsXXlfof61cugyp5LwMsxOdzHgr9KqXlrNAoYZZOmRxn1xRLTboEVd7jgEKHzPvYwMcAfhWfeo0dyQ8hkVgPl6Bh7+uK1rkmSKIxD5EU/w4A/xqldTPN5W8BmjwFfGPwpSdyoN3uY8o3SsZMKmT8gPb2/xpYXPl7Ax8sHdx69ia0ru4KxGRIEcSMRukH3jnsO9VoVeN97oiY4O7+M1NtTbmutSG5lZlCqFIx90LhRVYkqqln3bVKDB4x6Vb1RisSmMrGq8gYx2659fpVZbvzLBBOCyKm2JQOE9j/nrVNq+oktEx5mQ20W47ABgkMST9fT8KW4CQzwTQOyvt3Da2Sp9z7+lURI0JZJUcNjrjBH+FNjkBAR2BiBz5fbP1pxmno9xun1RbkaOVkaZPmZnLOvGe53ep9h68mqpAREdcKFbBU8sR/u1FPO4nRSGYoCFVeFQeg9qjVzEXZ3KK2VJTBJPUYY9Pr9abauCi0iw00axo80QUEHIB+ZvdvT6U3z0kVpGBdR1KfxHsAKoWzR+fGLkRJE+dpZuDnPOeoUd/WqV3PJM0htyQI23PPvwhGewH8OPTmnHuKSWxT1vUVhSeK3K+Sw2t3I/2f8A9VP0q0N7Yws8uyX/AFSRbc+Y2eAT/Ceep4rH1qb7UwVQrMcDCLgBf8+tdFbRxtKoXzLXTpiFUSHezOfu7f7wB43cDmtFG+5jKdmrGfLHOrSxlF86MlXRl6Y6moFWZZdsoOGO7a3O7/gXQVb86d79hiRrlD/CTvJXggnt0Ipmp24ilP2eRRE6BjFu3KAefTBI9qy5EtUdKqPZj7F5vNdIUtFEbDeC2VYDPUnrVi7vY5pFkijEY2j5cHr3BPcVl28REbvcHhHB5YcHHGRWhbLDMQ6b5JvvFQuFQZ6kd/rTTb0E7biCM3EZkI2uAShH6k+1WLO5t9yxvGBIOPmJ/pTrqcLKySpj5eAgyBkcc1jxzSiXzjIY35UMpqZaO417ysbl3fQ2smQjEgduv/2P0rMvL20crh5jN/CGAAwfeqCNLDcR+XKrsvTC8Enr9fxrXgml2yI0MStIRligOz6D+Gr3ISsZiQOJdkqKoHTP3m75x1q/b/6Mh8lX3t97P3cen41BdRl7jMUKq2cYB+ZiPU0izzICXDbVwxAHSs5aM2hrGxsx6onnRhUaMlB8qNhi319fWobf9/PtcqzOeWz09TWOzC7lZ5y2CNqjAGPatPTSkJ3dcdCTjvzk96G+YFHlNV9OlhZtoUofm3Dhfb86RGUrHLgsd3zbjy1TT3krWQWCbzLeTI2g/wCqLdQcjgnFJaXNpKkcO6VJ1AwSOGPfn6UOCb0ITdrsmjuolTLbcscbV649+9W/JQ2zSNPtZRuA2BlJPYY6Vzr4t59hOFJ+Ujow+tTRTSM/l7zsz0Tg1CqW0aNHS6pmmhk2OeWf74K9BjjmrEbm8ULKhMnqBVYLKYtyriEfKzFgB+NWbaVREqNKzFuFTb0/GoaE+5btXe3lXymUc/xDIOOta1rdAszFdrNww7GqFnHmRI22Bn5B7n/CtCWLypBlGypOdvzUJNGE2m7M2LS43ZLEeYOcDtWrbScA5Fc3aSpIjLGqpg855J+pratywjVk6dOe9dFObZxVYGqFXblCAf7p70zc6tgDg9eKhWQED5gGqdG4G8dfWtHqY7FgxrOgYfeFN2vGw5yR+tCAryvNStIJI9vRl5ApcorgHUq3mqxJ6Y6VEdhI8wEDP8NSqC43ZwP501wRkfdPbPenYEEmcAJgKehxTFlK5U/maakhGRtyB1BFO3bkGRzRfsPYdnIJHWhk+XdG2P8AZFCKXcbVJpSijJLkMOxqtyWMjkCqQyhx/tCikbBwDgfyoo1Au24RXG7oeMmq1ygWVTnkGpMjdlgQT0xVe4RkBfORnknqKm6tY0itSUBxjzMbD0IqZgAfmiKcZFZ6ToW2qxY9WI6CryzgHLOWwMZ9qqLQSTHgloy2FB6cCgbYkV0XcejZpA6mTMbHa360shCtlGwvenchkMiKUzHkHOSpHSopZi5QSDJxgU4PnONyjnr3pXwzoQMAYPHepTuV6kMqhTuTBAHKtQgTaJARlcDZT5Oc78Z64/xqrIm18xsdvXHoaNtRrUQ24R2dkDkjO3t9aqywEtyM5GcetW45SkmRwRnmkkkjmdDENhAIPv70WTQ02jLaH5Svz5HU44ApGjTy32nZJ1GTgEVfLF02Mdqg9u9RTQMzFkAI6jPJqbdi1LuUQxkRY7gKBuJ3n7x9Tmo2X9wzSIwR8Ebur89h2q75QWJyRvYjGCMgVmX0Ty7ndzu4wQent7Cpem5pGzZSkuGDPGpYxt1XPWkdA7b9ocAZA7KPSlltZHVGU7WzuJPf2Ap8SNGN3UE4IrFXv5G7tbQYkCGN96ZbO1EU4GevPoMd6qTTb7hJBJuEI2o5XIH0H9Kuv5ThpASqjvnp/jWdIxYx5+aFD0ZsKw9MDHrWl0tggrvUr3dxLPJIWSLZn7icKvHQD9aIpI7eSNjwoUYD/MQ2ewHf3PSnQGILlI8jJLE8YHYCnW8EM6Orh/Md+Co5wB90fWpTbZcrLToMlMVxOCyFi5ZXRm5K4BB3euc1k32nvbXGxogxBzzzn61ZMbGY7lKoGwATnODVy7jYs8ixBY+oC/dA9Kl+8UnyOy2MxF2XPmyhpoUYblYcbcHqRzgegqK5sQYUufLMaNJtKswLc9G29doq3eufJ8+GPIUgNgcA+v1rNjmZJcq6PM/3jMNwAP8AnoK0i1fULNq6M+fEV1cBh+/I2LJKNpAOM4XpyOlLdmKUoJ0uZ51jDExMuI19z/CfUU2S6P2popbbejP8xZfnJ9cEjGOcelZd3Misz2/yh/4WJIPv7n61pGViZRbHaTYxXl3cSXMqF2jZkDNncwIGCT16/pVnUbW7YM822PA+fLg+Wo4AUDvx0GaZp2Te2zXCJgRlQm3OAOR+PWrlytrewvJbkQurkkTn/WAcbVbHH0HGauLVjOUXdFPUrhrywF5K5jlKrFc/NliwGEbA4AcdfcH1qkiSxwJvkHTGwnOOPXp+FW3kijuXkESSpKpE42bA0fHyqOg29QfUUy/hjhYQNcJcI6eZC2CAy9if9r1HYiolZ7FQTjoyFE3xec6k4Ozryy+/49Kt3otoYmiNyxjHUCMkv9SfTtmmaftlCiYAbBud8/f9AvYVZuobVihlzGOQGC9cUkrK6LbvozM0+S7mke3s5i6tyASBhRzyT0FWIkZy3mRnefmPGAfcU5lRyqsweziUACEbcDOc9Oue5zWtBNGFENsPlIBkw2QxPQDPPuaXxKwfC7mPq1lLC4a0KtGQG3IcZJFVLBWdny8guBz8q5z9a6r935bLIY5BEoLqx2nB7r9KoT2otLgyW0rtGOjAAGk01qVFp6FOKORGKSqxDkFcevua31WRVju9h2Sfundk+Rh024rLhn5KxMw988kVaBcI0au3lNyVDcE+uPWkp6DcOgya1SGUtCFZz0yvX1GKbPA/7uRXdwDwhxgDvnHSrEkaLHHIhw5GZPb2FVNYDWUxa2nZ4gBg5xz1xU3t6FLUurcR3Vy5ESwKF/1aghc4xnnkn61TLSWNxKjFd0i9sEg/Xt+FJa30rkHYvnHLMz88+tSxSxyOslzCFiTKuE4LepJpydwiuUkBSW2aOUZ4+VQOQfrTreB40IyCQQcHuKSIyW5PlBfKfkAkHj61qM8T2imFTlOWbPGfas5Lm9S3Ll9GNO5jiU4/DAqaGBmOIuSepA5FUlmZx8xbaTw3vWlbXTRQsnHlnlgBgN9ahNPcmV0tCa2t/s2MtgO3XOeO9XPPUyMLQTdcLk8H605RHebWjlXCJyrDG0DsPWiwgWWTLb1PoPSm9NEYOSesjW09fNG6QRhuhAHJrYgUIMKSWIxj2rPgURqqoQWPHA/SrkJIbax2j1xk10U1Y4pu7LULFWw/y+1XAS3Kg/nWVJIAR8xPbJFXbU4IYcmrTu7GUlpcvRttUEE5HWnCRHHzZHfNRlt4B6+uKqysF3FOo7GnJ2Iirl2KQoxHBB/SnuwJ+b5mPQdqybe5dZcsAQOCKurIrcJgmojNMqULE7lgQM5HpimSA9V+VhTlyvJJ/CkmcBMrlj3q7EkIkKEEtj2FTpKr8N0PSs2RWkbAbaueQKskGBFbaCp6HPSkpMpxJj7Hg+ooqFHZ8ndnPeiq0ZNrGwU+XO04XqepqpdptjOWLFhyPT61cLMxGcL71TukkDZP8XehlRMf54C4TBD8MSKvWjNIvJ2v2I6U/Y5ARwAgPXHNWIIAp2dPQ+tRGOppKasLANjHzFJ4xx61MqI0QO47geV7fhTMSI3Qcdx0p/mgvGU4fJyOgH41qrdTJ6kLR7GIZQD2Hc0gTgHaeOue9XWnDoMofMHGcZwarklGLYbkd6LJCuV2UCReMhugqKZWxuI4HWp/N2sxGeR2GcVWlmcriOGRsc89KTaGmU71gkYZmAHSqVtO0pPGMHHI5zVieKa4yCVhj9F5JpYrLylUou1R0HrWTu3obKyWpIisy7+4pxjBTcvGevtU6ruiAJ+UnilEbDPK4PWtUjNspFAF25IUnqelQtGAuTgfUVfdQSN8gYLwFC8VE0IMbHdgg5KnvQ0NSKDws5+cBxj0qvJGBEBt557dSauSqVzt6mopY3kkwOT0Axn9Kho0UjGuUVYgCmcNk/8A6ulZMqFpMscqR+f+fauluIwyOqnKhuc81mT2wVwW+6OcVzSTT8jppzRSht2UMEOCzcAn6Yq2kcqyrIkih4zuX5sMT7e9S2pmWKW2UIsG/wA0sF+YkDj5vSopomw4X5t/GK0S5dUKUruxTQBppJSIyWbbkjOPUjtj3q1cIVUojxnIJwQcj/PrVW4jKxnPCIMAZ5/+vTr52jZkVZI4wNu1zk9O/wDhSjK243G7VjLkPkxzRsNy9iDwD3I9ayLyOGELJBKMgBlGCCG9B/jW2WZXjeNtxjOVDrwD1xj0+tZjOn2ty67jnc5K9M9wOnWpZ0wMKSGa5kkkkyVH+sdui59fUn86qmyWOFbk+cZS+IsjEZwOQB1J5HsK1nib7QFU5hduGHPGemauXlurToHDOFURptxgDPt6+lXDYc3qjAsyJIJoyDtOBnHKc5q5Gvl26iZhGDwrN0OKtXHlQgoYzJND/AyjYPqByTnseKjvpHRN0jAzMuA7AErjtjse1HL3E3fYoyxz3EsjM4k2Dc7t8oUdOPUVUEkDW6xzHZDuOx15kRu5Pop7j8aju7ySaVFcjanKrtwoP071GwVZxIC0id2Pdsc1SsS0yWGWdJifmiVSA2CCD36+n0qWa6+SJCuAN3XjIY/55q7YSldOkyoRGBjw/wDGG5CgdcDGaoz2bzzM9vG8iN6nJ6d6LitqOjm3XcXlIFOcsAcI2OckD6VbDG6iWNFG05kZVAVT6s39B9Ko20RjA+YBxlSD2B4rTtoQnmRyBTIF24Z9oH+NSn0ZUktxlud10vmDzMZYLnsO5NV798TfuPOPcliSD9O9aFkVS+DSfOqJtO0cc9ql1BJCxEhdY5GOCRvIyOMY7479hVJaE3s7GNAzSb5AoDR4z+NakNwJEC4Ifpj0qqoSCZVIXyjwR0yO546VGHXdnawB+6PT6VElbVGsXfRmg/MbAkjuT9KguikzFmYsGwNwGf8A9Want1MtsZN5V0w3Iz+dCII5N0zYc/MOOB70osOpRktdqoVydpyUB+ckdyDVhbgXLAbVGW+Zvb0qO6BZ5HtWPnSNkuRkkf0pbS2MbguRvzkgVMnbYtLqzSUrb3Lwo37sNlNw5NS7kHDNgk/d64p0tv5onLFmKrw2OlU0UGdVdnUYySvXFS3YSSkaCRrLvJ3Ow/hVeFFOihKqsgc5PBBHFTNM8kMdtboFi3cBfvH6mtOG0DlYUdZGIwSBhV9vek482xm58q1JbG2PlqwQ/N1Y9K2YIkULHGvXqe5NU7O2kWAeUxIU4w3+NaMKuFG+Fs9ypBrWEdDhqTuyRo3jAPQ9qsBSIgW445zUQXLA7JB+IzVkIH+90z0bmtbGLkQugZS2SMetSwyMq8Z4FSvCSRtX8aFtgz4Y4U9SKXK1qLmTRJbylkBHJ56d6gkbMhHJOO/ery2yKu1SMjoTxio2gw4YOpJ9qJRdgi0QwZYksMH1FW4SmcMoB9qQwDbuEo3Z6YpVjfcCTkCkotCbTJlZm4Vvlp8yDggkEdfem5XBwMZoORjdnFbW0MyCKJfNYuMj0JodhkowwKlfZyVBHpmkdlkHzLx65pco73IC4BAwM57UVE/y52nIoqb2Ltc6RiRt7HHHvQ2GAGMt3z0xSuA0hXeAoHenRMFOQuewBrYyIGjDJwDgdST1/CnPHsCMO479qkeM7CdwJ/u+lPneM2i7Qxk2c4HT3otYL3IDLhArjOT1qF8OxY8AHHpToWjVGEy71deD3BqIQ5m3rgKf4alspKxOgOcxtyByPalYgsTnJ6exqNw6gMykL2xx+VPXZuJBbaeqmnclivGBnd8p6bcdabJbMwJjHAGTz0p6yP553KGJ9aklU7MAkkn7q/4VWjJvYzzESGyAVHUg1E6kQL0KqTx6VelfoAuCDgZ6/jVdwPmwOv41LRaY21VcMDyM8Co5ICHwFLN1IHamrhW56Z6VYMpAAhUIO5zTTVgd7leSPyhlwN5H41VfJb5flBOavuyCNncO8jdGzwKy55vJc78ckDn1ok0hxuyR4x52wYPORULqxJWAlSSQWHBYVYjBZg/DBTng/wA6iyMc8A9D/Wp0K1KssATK7SOMdqo3EA5ZRkgcZrb3ll2KECnlzjhvSqtwm5CqqACeOP8APFTKKaHGbRl28RK/NgN16UskSEksSEzjJHf1rQSINGQRgjgVTuFIUggsQMAVNrItSuzAvImWcsrFtjfLIo6c1Hcs4mJly24k7jySe9bN5LNNDBHKwEEbZS3RcKp7n3J96rusQaSR23XDcgY+VKwcddDojPTUxbhNow24MeeO/wBaq3lvJ5GX8sK3937xxWtcMJFVQrlj0VQWZj6k9hUT2whhJk3ea2AqjhB/vetCVzVTtYw438jSLmWTbtEixIjHk9ztHbjqTVS5vHzi0YqvYHqPxrTvLaN7oKy7oxywAwAf89Kx9RSNI9kisrbyFIBJP4epppyiaQSbv3M+S6MMkhVpDJIuCX/ve59qS8uZooY0tZMxyhWlVlBXcOAV/Cl3wxOwKu8qqR5ci/d9z6n2qkbsxFT5CXCEHKEE4zxke4pxlZ6mko3V0JOYp03fN55PRh8zev4U1bZgyBwW3fdHQA+p9a17W4Bs3WK0aWOUbGkIGc9QM9SepIqGdJY2WFTvaQBivfGeBjsfYVUlbUhO7sVtUdUhiWJ93yckDkEcHH889avaXqFz9nltwAVmUeb8vLBemazpGQkZ4IyPQtW3bgR2cjQh9rYWSVlBKn/PQfjTi29hSglvqZ2sgQoZMhnYcgHp7k1ZBuJ7Cxt5TGI5Iw8BSMZYnopNULxBIMl9oVwS55UHr171ZtXE1pApYH97nf6fhVOzJSaYtnKlo7pdxtlWIIzhlPpihryNFCMxRNuBg5Iz/IGrGuIslvHPGHF0pxKHOcjtWZC8MsciTQmQyEEvxkH2Pas3eLsbJcy5i9aNbSA7hja3DuflI/z6Vdjt43AaBOmcydc+nHb6VjwrEjokNsZc/wAUknC/gMZrYjuGtowuT5jHA4wAOwA9aSaJkn0IFcWk0byR+ZGeDzjH/wCqte6t4DYxhdrxSHMb4+dG9D/sn3rFdvPuGXaFPTHapockbPzB6ZqVOzsyuS6TuSNashZ48bM4x2z7UscYV8MuCOfmGeavQmRIgrKCOuccijBabdg7Cc4H8VTKPVDUn1GTM7uVRsJjkD+tTmYNbpB5KLEDyVA3t9W9Pao2kJdiFO3sBzip4Vy2fu4HJPapcmLpqTKoYEpEI1A4UGt7SYv3Rd+oHyjsKzbWPzCB61v2MYjQKwLegrSkryOSvPSxoWka7sKAyuO/FO27RjJPtTbdQJArsFA5z/SpnZM/Ipx7muu2hwN6kcSHeSe/apx17ZpgOEyOucGpFO8cD8TUg9SVGIXrkmpAuVqNVGOCDmp41KkFgcVViRSu8cHnpSMpbAbkDpihW2uSBUpy3I4ApWuF7DIlU9B+BqxtyhPft7VWHzSZ7/zpfNYdjihJIHqAPGOpz6c0c7sE96UN8oEZCnuT3psjqVJH3umAKqwBMWX7qjb61XU5Bz1FEjsg649qq/aGMhDcVMmkUkTXKbNvOGPNFISr8sSTRUtXGnY6qIrsYkAydMdeKRBhuePX2qOWVVzgDDcEimrMWkBPTOcVrczsW5HLOenljg46mo5ivlx5OV2kYH1prRMshYtwRnNRjMhAAODwKGxJEIDHeFOB1we9PjUjG3HXAJ6U5oSkm1zz3oiDBl3jjNRYpu5OITEDn5gQefQ+1QMgkYKBtPrnrU7sUXAyRmq8zkfcYsuc1bJQJknoWVepHUVOLh1iKx43dfM7/SqxAXoc+3rTGJzkZ57dqm47XHn5ozlfm68f1qpISdyoevI9c1ejulC7JAcDovYn3qsQhYYJzjLY9aHqNaEeNypgZ78daNwVSjbmx0HQA0CQxkOOCOOPSkZN2HHfnB70DY2RgSMrnsOaz5bZDMTJln6rk9K0WiV1Ib5X4x6GoDDtznr3zSauOLSGGEx/IwOQAevrSBI/KfIZ2wcKOAPqaszMHKsR/CF/EVXKMvzElSD0FVoK/chUEKACfbjrQIyykgEkkAcdacn3u5A4Gewq0uPJCcDOT+Pahaik7FIRkNnGMHnNVJwVbfjJB9M1qBdpcMQGyAGPQe9U5YmO4np1yR1pSWgRepkSRqTjGcnkk/1ohhtHcNcykgcBdhwo+nepNmyT5unYkZxUc0eGJyT79c/jXOu9joGaiYwqG1DKowGPQn0rKktSZsSEBuhz2rVk4UpghhztxVaRdylmO0gE4B5H/wBcmqdpMuDsY6EvcrEu0WwYcf3scnJ71jam7l7i4gkxHOdpPRj3wPpjqK1b5xDM3lMrgDiXJI54IAx+tYc8zAyJO/314yOSPQnsKhtWszspwe6MJrRhcJJtUKc5bPGaI4yFYYYfNtUr3Hvjr9Kk8syDYxz6AH9aUZiBQnIfrk+nrWcXZnVLVEsTCzhk8p2Ow7WjfqHP04qvB81x5twCscf3yrYCj6+pNJORNtVURQOhUYA9MDtVi2EtsTLGyGXIZCQG246EdvzFaNq5la2+5UnVbqVHy/mOC0kjDG4+w7DtVm3OHBwrBiFJ5IA9fc0tvZyY8wwkyucOxbJb6Cpr+EQ7PKDb8beo7j270XtqO1/dM2SFHmeSZ32HhVwOD/If/XrT022SbTbzBxJCY5lI9M7W/LINVliF1EBLn5V4XoPzrQsgsaBgdpdTA6gcBGHBH44obuxNWVhbsRPMqi3EQPDqhPPHXn161iyWfkzlQflzjAroJo3jj+cDzCOMHkD396oBGkmwcKF5xjJNKWoQdivEr2yAvE5mIxHjHT1zTVv/ADIRDHGyg/K0u35m/wA+tWZQxDBEBDdMc1Zt7FjayyxoUEaqXMpAOT2Ud6XN2G0t2VLJDyDyRxgirc6qiRMoYM4O4nv9KktYRIrMAADwR6VbvY1aKPygWwoU5Pf1qLXTY72ZUtJHC4VwD3x6VfjGXVuiE9f/AK1UIYfmxwT7d6vQkjbuGAD0HelGQSWug8S+QxKnAJx0q5bYkx5gQ49qgeAyhgAAvpnpU0CPCVGMEc5NJszdreZ0VjHC0anywrAY3ZrRS3RXLJJuA6HtmszTSZTgrya1UIXAJAA6CuunZq55lS6Yu08MMYFSxZJyw6VCZsNnGT6mpkcOSSeSOtaXVzNjkGFYgEkH060K3pnJ60oIEZAJLGmKxHsaYkTK204AqxHJhW3ZP0qDbxk9aUNmP39KWqFuXEmGAAgH86czZY7sVRiLbjmrG8qcHApp3E0OTDMRuIxUqSLES7qrnt7VV3qsgKmiTJB5wDQgsKzhm+Xv6U0glSyjJHvUYi2n5cmlDdUzgH0qfUr0GSbn6nB96jEOXUkk+9TKCR+8b5fTvUygN8qqAPWhRuDlYhARSSqkjtk0VOUV0+btxRV2JubNxC6lWIwrdqYsRR/m6mrBctgMeAep7D0qbyTtDjv0+lPlTFzWGgBojluFHfv9KrNuCgqvfOR1q2q4E/AO0Zz6VChMq7QcYHGaGJMa0mNm7spX8fWkLfvo/myARzSahsKRvEPujDD196pG7yq85Cn06VLdikrmrM6h3G3ODwagaQHGMYPoMYNM8zeA7End3JpxP7srx6+9Nu4rWEcDzOMH+dJHzgHOf503dkgMT7e1EqsGPPHr6VPmBHdIFClcEnqOuKZEp5JIGfXvU7FVZXYl/UU1FyTtBx1x6UW1KvoNIBiBJHU9qdGFx8w6D1p0a7kZG+Vh0+vpTVHykcbsc1diWEwCEsdpYj8B/wDXqF8MgU8t2xU68YGBnGAcdKgnUlzu5B5pMEVXO3pncp5p6tHt5JB9BzRKpTII+tQROVDAgDf2IqE7F2uiZgrElflP90c5qJ3CjBGD6mnwO0TnKgnoR0yKglLTuxlBI6Dnr/gKbloLlJMZiD5JY+vP406dZJY97EkDjcxwBTIEYhdh+YdAOpp5Z4X+6u5eQDzimn3Ja1KNzAVTLFSSeMZ5qmAqPhwST2BwPxrbW482VjIgMjHl26IO5AqlJAkkjEIGYn5RUSjfWJcZdGUZAH5PI6HnrVGeJHXywwRX4JI4AraurWaNfm2/KdpA6jHtVKXaGwUDtjd+NDXc0hLsc1qFmYwTATgMRublj/hWBqFj8iB2G5/mAJPA967yZHliDCPOCSxBwfoBWTdqiQny4wrswJc/fwBwB2APWuecOp2Uqz2ORis5rXY07QQQ4JDycsw9lHP51n3EO8Yj6MSU9fxrpk0O4uWE8Qyd20b25Y+gHc1OdJMKt91XUncR1DZ6fWos5LY6vaxT31Of0zTiY1DbSxO0A9fwq/Mi2YKSRRiPGFLk/wAxWrFaW4kx85OPnbPTPQ1DqNjNEhjk2yI6jHuD3X1FXGLSuZOpzOzM+wltbmd2ebzVXAYpxxnp6jjIH5mnajHZ+ddG3ixEZcRn0weM+vFZS2wtSwVSF3Hvyp7ilE0kjhBz79Kr2q5bNGnsmndMl1aAPe7kdUJwCwPy5xUClN/DDJ/hxt/Si8D+YN0ZYNwoPUj60JaMyM2/PlkZPqKly1ujSK0s2WroySsXQkSdemMn0+tZ1ux81lcnkEZNbbGJojHvwGwERhjj1J9apXNntIddwIOOe/vRJdUTBrZjrMNksMhkHycYwassJNwY/PuHKgcD8aLWJgytknI5rUigYoCV3Ln7hPBqd9iZSsynsEUAjKDPUkdvr60t5GHXA9BxjA/+vWkysINsQGzvxyPao5UY7pM/MuO38qHpoZqQ2K0VrdWKbZOhYnH5Co1tmV+c49cVOsbI+XwwI6sec+mKvIPMQKF6jBApJJkObRTjt2EikHFaaQMwHnEFT6jmpra2cunnDoDj3q35DKeFwK1hTOeVa5HYxlS5BwqjgelW1YupVlH170RRqvHTuachHYcetbxVkc8pXZG+BgAYNSxoVj5xj1pNgJyOfrT5/uAZ6DpQo9RN9BA/JwakCkYdsAGsd55DOqghK0oJWKDetCkm7DcWiyrbjwSSaeUMWCTn2zUUJTozhR3NBdASFyR6mnoQTLJgEn8KeWDJubqOM1T3hWyRkCrG5XiyCB7U0waIZpFXkU+G7jYjcM47VXmUyDnpVeKBvMyT8veobaehaSa1NdXSRDjgnoajKBTyTUUUYJ3biCO1WO2HzntWm5m9NiNB8+c7s1OpcZwMD1qu24KWBHXgUsUpUcZ560LQT1JJHP3VOSaKhd8sfSihsaR0itnHHy/rVhpmSEbTgnjr2pqFC+Qu0d+9JLgbsAH8KeyI3I0m4k64IpNxbkjkdqbED5o43e1XJRB5Bx8sh6jFJalPQpSkEZztB6ZrOnj2zDac/Toa0pSSVVDnb04qFoxvHGD71LSZcXYtQwjcFIwMADPrT5x8+H2hgMfKcg0s4G1Oucde1LlJEVVTBH3sd61srWM79SjcAB9y9B1+lPDllVB09fUVJNANm8Nz6YqtGwDlT+vasXoy1qickDATB9u1LsJIwzFjwKXbmMMeADx/hR5u0Mg43fxAc49qpEkcmY5dhIzjnB6UhkC5ZRkkc1Fdv5ZXLLkDgLzUUVwJCM8eoo5rMrlurmkjL5Y8tAT13NVdsvyOh6mgOUX5Pu91NWJXEp6BeAMDnNVe5GxmyAyFxjk4AFRPHggOvTjg96vxquSMNknHHpTJIwshUc+maz5epSl0Knl4XL/KDz7062h82YRs2zdwpJGPxqdAjt8wzjjk8VEECtjGTn86pBca9vsDbSflPOOmPao/K3H37CrYfDMcE57DgCopgFw0ZGfQHpRZCuymUO7aww2cAelRPuRgCOhq/Kx2AqoAPcck+2fSq4QyA9gKlrsUn3GXMrysT8zF/vEfpVJ4DsHXOcZ9/StAiRUYxMQvcA1GrKw2n73ceo9qe+407bGVNFMhDQfI/UE96oPGGQPsG0Hcctnmt4eXI7q4JXtzVe5hRZNqj/WZK4HXHX/Gs5RutDWM7MwpAUcMquZW6nOP0p0b+ftVhnsoxirqRkzEzBvl5HY/iai8gP8AePQdV7gVkk+htdFSS3EcMvllUki+cMRy2awp7l45iIpChzzg5BNb1yuWKltoI9ScfWsuWJY1cBlDHrgcj1A9KHKz0N6VuplC3MrOysrSEncuOT71SaNkLY+8eq+lahiCH5AwA7AU1beT77xkqTnJ6HFZuzOpSsZT+ZuDsmeOPar1tAwXd5RLOvypnHXufX6Vci3iNzCiuV/iKg498VFmbGx1IHrjGKE0lqDdxwR4YS0qxupJXJGSD3APYVAsZuEySTgfJjpitKCDz1G8tsxgKen4CtNLSPIVcAgemePSrV5GDqKPqY1rZyCIkbiOwrWhXyolEgkAxkbeRWhBAQAOBjqfWrMaAKYzGHX+6apQsc061zCAXLbInx7elSMiPAuUwc8MO1XZbVhJtjDAGpFh8uAKwyM498VFmDqIzZvnOVAAHXPetPT41cRhUAPds1F9mjlcEAjHY1etbcx5H3QPWrpxblcipNctiwyEKCBnutTAce/pTACSBkc96duCPjPtmutI42xrsEPKg0DB/hGKHRTgcnPqKTZGg+4rMR36Cp2GSfJswwCEd/Wqlzcwxn5nUe2c5oMMZblFP15pgSNGyEUfQUcxUUUzG9wymNGC7sl2GOPQCtiHEiYI2sKrQEtks2B1qWKUAsVHHbNJWRUm2GAsmGANPcqT8q49qiuX3MGUbT6URn5am+tifMnWNT984HtRhApCk49Kr5w2WbFSJMgOAAB396pWCzJljIUFjxSHaMEdqfncR6CmyHBximTckfBXchwfSmLcMq7W4pkb8H1pkwHUHJob6oLdCUtnoMk0wn5sfyqJHYdeKUt6cU73DYWRH6rn6UUkqMyA7zuPpRUtO+g00dWkoUMoGSTgGpRgpluueTTJCCQSQeOAB0prTqpXOOenPWqJtfYCDHtZSM5zgUskmR8vGeSaSc/NuyvvjpUfYDkA8ikBIoycYwOuaWQABcH2pkfJ2nn29aWcNw6YHOMU+gD5XykeSTt6inRyhAG28Z6HvSJkA7R04NRbflAOSDTuBJNM0oO0AYGQB2H1qpIqspJOWzUsiAY3A0xTl+R1rOWu5S0Ggqx+Y7T2HrU2G3A9QB1HSmMqh/nwD6jtS5YE9QaFoDI7iLzHR1JyOvrmqdrAy3UvzEsQDg9OprQZRvQ7lYdx6fX1p9jtLSuUGHfp6ADA5p8qbuHNZDFGccDafSlPy9T8vY1YVNshVhweTx1okh2pnqo6j0qrEXGR7Y5MsMjqabLL5rrhfnHYDgD0FK5OwAAc96fbjcxQoCSMDHBPNLfQPMpqgBwCPXPp7VLEOTlisZ+UGiWIJLxhl6gjt6ilkULGikZJyT9KSVhvUbHkSHaec4z1p86ykFZGyCMhegqMY2jGfTNKjBGG88nk45wapPQTRAY3xhc464zihlVQuBtHXb6/Wp9xaVz3YZ4H9KZ+7dgvy7u3PNGgalZ0ycrjJ6L6fWqs0OOQOD3rRMJZSQRtHbHJqGRW8pgUBHY55z60rXKTMyTG7GcMOR9abIVl8hmZgySAAemeD/OllVtx+RumAR1NIkJZoywKgHls8kjpxWXU10sRXFviRjhiR1yOarSQMiE8qeuK1HBZ2JJLdAT3on+Vkcncccf/AF6bigU2jCe3ZkYOfLHdQPmNVIrJyJPuqSwO1xyR2rfnUlPO754x2qON8h0CbA/VjySe2T6Vm6avY2VV2Mee1DbhsQsevGPyFEcRlPyR/MFMfPOfw7Vv3MEAgPlPmQke+PU1Te1I2CMcDlm71Tg0xKrdHMGwFoMxks4O5lB5A9/eriM7mMSnciDnA6/U960rm1YTEoCT3J6n60iWMrR/IcY9PSseRp2ibOspK7IbfynDlolU4+XA+8ff0qxBCrR8bc98DpSLbuoCqWznJ9KvRRrGmMh/ocCtYJ9TCc+xVkR/lWMYJPOe/vVpYzgZGTU0S7sn5V7bfWkVv3qrk9a1UUtWYOVxvl8/NgfjTZYOAW49MVNv8uRiB82ePagfcJ6knrVcqZN2iBIwPu8Dv60r8A7eTnvUrEDlRiq5k4IYcUtFoF2xVZsgdgae33s96QcIOg4zRy3SqQMlaRSuP1pjkEgYyBTH+X73J9KYW3HnpQ2JIQMuSCcCnO6lTtA9KZLhcADGagL/ADfKAPWovbQtK5PGgZTx81OhXMgUVBBMwBPOamjbDFmpLcbuieUFc4UYHeq4YhuM4oLc4XJFKfu/NxQ9dhLQUkEetAhDuAgOfaoi4RsYqzDM2Mg4HtTST3BtolAKOcndj1prMJGwzBcUh+ZznpUDgIT2+tN6CWpLGF3YB4oLkH5V4qqZOakV2xkUkxtDncOT7VFvIxnP4092VvvcN2I6iqU8kiffG8eqj+Ypt21Ei+k4xgEGis62VmBcfdPaihSbQnFHew3G+Pbj6kUy42uUVV6ccUy2t2SHcGIjz606Q4iJ6KO3rTbdtRrfQaD5ZzkcHp1pWnEknX61FHggF+hNEm0vhBtAqNSrFsFSh4Jcnseg9aGYBRjOaZGmU3qcsPwppIJIwasmxOJC3BA2L6d/rUvLRjyyAQTVePBjJJwRwMd6RQWcKo46EZxmi4rEiBdx3n/gVIYcgkk5HPtUnyYDAHg8g84HtSMQf8KbQiPCEYJxnvimnk9QM8ZqQBdp4wc8mkWPcVCjDHnmpsMRgQu08MOM09YjENoGVA6io9waVMg9e3pUysNzZAyehpoGgeQMmWYAg8AdanD4QR8Ae5qpKAB9TwKFdhjvjgjNNOwnG5K6hCRjPr2zUTjI4BJA5YHHHapjcDcc4KkY6VWG5mIhzu6gE9fUUm7bCSZYVlaPeVORweeppj9fRT3I5qNN54OcNwf8Kur5aQxm4+7tGQB1prUGrFIIiJLnk44I9feq0TE8AqT396tSMqOHi+RTxk80gjjVZGT5n3ZJxjNKw+hE7MkwcEA+uOKjmiLuhBOCuQR+oq1GyA7XGVoZRkbDgtwCOOabjcVyON2iKpIwXI4k9veo3jDZwwx044p2wpIDIx4zyOcdjSSwmNj824cH8PWkgsV3gVQjA7tv5ipJ0UuSpyvb0NSbUdCyrtA65OaW3XehDAcds0W7A2UZUZlDhQcfKfaoiv7zYU4Jzk8VfniMRDYyrcdev1qkXUShTng8f4VL0KTuIbd2jYEBUzg88moxAqAhsFgRkDuDT3l8q4dAxUA8AjIP4U7krnAzntTVh6ortEVmUxgBc9KScgkqVwRUhYxyg4yAc496Y2HLFuuc5NAyBwCAM/NUmEj5UnIGMD+tNPLEL+dOGHRg33hQtwYm3epIIBHOPWjYCiEjFSmIKq7SQ5GQO1NZkVQCWZ/0FVbuTcb5ZGcMAvqahZNrEhvoKlZyGyec1FvzKcDHFJpMFcaG65yfbNTROm3DIT6c9KhwCw96SVlL/JnAoWgNXLDlG4XcPaqVwyoOPyqwMZwGbJqrcqShUMM9c4olsEdyJLjecNmrglwoweP1rPt7Zlfc7g59qvyRxhvkYn6iohzW1LlYQsD0yajDgP8AN0p4BEZI7dai2nJOKolCzEv8xOTVQE+YFP5VaRtjA4z7GquoKwmBBBYjNTLuaR7EnmbH2gYqZm+QDPNY8LXL3hEmCo6HNaeMMNwpRdwlGxaiIGCaY78kk0wSsEwMYFNyzLlqtshIr3L4YNU1pcMykZwKjmC7NzDpUtnEvk8jBNQk+Y00sTq5PAPSlO1gc81ANyse4FWVKtAcj5u1XuZvQhKhfc09FOM1GqnOecU7zCvIpLQGSsoHzMp5qPKb84PHQUiyl2JfqKRzuYnofar3J2JABtIwB7CioVkKHpk0VSsLU//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7972=[""].join("\n");
var outline_f7_50_7972=null;
var title_f7_50_7973="Pyrimethamine: Pediatric drug information";
var content_f7_50_7973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyrimethamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"    see \"Pyrimethamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/12/9413?source=see_link\">",
"    see \"Pyrimethamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Daraprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Daraprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Treatment, congenital toxoplasmosis: Initial: 2 mg/kg/day once daily for 2 days, then 1 mg/kg/day once daily given with sulfadiazine for the first 6 months; next 6 months: 1 mg/kg/day 3 times/week (eg, MWF) with sulfadiazine; oral leucovorin 10 mg 3 times/week  should be administered throughout the entire course to prevent hematologic toxicity (CDC, 2009; McAuley, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"      see \"Pyrimethamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"     <b>",
"      Toxoplasmosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment, congenital: Infants: Initial: 2 mg/kg/dose once daily for 2 days, then 1 mg/kg/day once daily given with sulfadiazine for the first 6 months; next 6 months: 1 mg/kg/day 3 times/week (eg, MWF) with sulfadiazine; oral leucovorin 10 mg 3 times/week should be administered throughout entire course to prevent hematologic toxicity (CDC, 2009; McAuley, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment, acquired infection (HIV-positive/exposed patients): Infants and Children: 2 mg/kg/day (maximum: 50 mg/day) once daily for 3 days followed by 1 mg/kg/dose (maximum: 25 mg/dose)  once daily for at least 6 weeks given with sulfadiazine and leucovorin 10-25 mg daily; followed by chronic suppressive therapy (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment, acquired infection (non-HIV patients): Children: 2 mg/kg/day for 2 days, followed by 1 mg/kg/day (maximum: 25 mg/day ) once daily for 4 weeks given with sulfadiazine; oral leucovorin 10-25 mg with each pyrimethamine dose should be administered to prevent hematologic toxicity.",
"     <b>",
"      Note:",
"     </b>",
"     If sulfadiazine is not tolerated, clindamycin may also be used (McAuley, 2008;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's recommendation: Children: 1 mg/kg/day divided into 2 equal daily doses for 2-4 days, then may decrease dose to 0.5 mg/kg/day divided into 2 doses for 4 weeks  given with sulfadiazine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis for first episode of",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     : Infants and Children &ge;1 month of age (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     In combination with dapsone: 1 mg/kg/day of pyrimethamine once daily (maximum: 25 mg/day) with dapsone plus oral leucovorin 5 mg every 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     In combination with atovaquone: 1 mg/kg/day or 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     of pyrimethamine once daily (maximum: 25 mg/day)  with atovaquone  plus oral leucovorin 5 mg every 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis for recurrence of",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     : Infants &ge;1 month and Children: 1 mg/kg/day or 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily  (maximum: 25 mg/day) given with sulfadiazine, clindamycin, or atovaquone, plus oral leucovorin 5 mg every 3 days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults:",
"     <b>",
"      Toxoplasmosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 50-75 mg/day for 1-3 weeks depending on patient's tolerance and response, then may reduce dose by 50% and continue for 4-5 weeks; use in conjunction with a sulfonamide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis and treatment in HIV-positive patients (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis for first episode of",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     : 50 mg or 75 mg once weekly with dapsone, plus oral leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis to prevent recurrence of",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     : 25-50 mg once daily in combination with sulfadiazine or clindamycin, plus oral leucovorin calcium; atovaquone plus oral leucovorin has also been used in combination with pyrimethamine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment of",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     encephalitis: 200 mg as a single dose, followed by 50 mg (&lt;60 kg patients) or 75 mg (&ge;60 kg patients) daily, plus sulfadiazine and leucovorin calcium",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daraprim&reg;: 25 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with meals to minimize vomiting",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used in combination with sulfadiazine for treatment of toxoplasmosis [FDA approved in pediatric patients (age not specified) and adults]; used in combination with dapsone as primary or secondary prophylaxis for",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     in HIV-infected patients; pyrimethamine has been used for chemoprophylaxis of malaria, however, due to severe adverse reactions and reports of resistance to pyrimethamine, other antimalarial agents are now generally preferred",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Daraprim&reg; may be confused with Dantrium&reg;, Daranide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (large doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, atrophic glossitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, megaloblastic anemia,  pancytopenia, pulmonary eosinophilia,  thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrimethamine, chloroguanide, or any component; megaloblastic anemia; resistant malaria and patients with seizure disorders",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal or hepatic function and in patients with possible folate deficiency",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May diminish the therapeutic effect of Pyrimethamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. If administered during pregnancy (ie, for toxoplasmosis), supplementation of folate is strongly recommended. Pregnancy should be avoided during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC including platelet counts twice weekly; liver and renal function",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits parasitic dihydrofolate reductase resulting in inhibition of tetrahydrofolic acid synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 2.9 L/kg; appears in breast milk; distributed to the kidneys, lung, liver, and spleen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 87%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 111 hours (range: 54-148 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Pyrimethamine and metabolites are excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/12/9413?source=see_link\">",
"      see \"Pyrimethamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if rash, sore throat, pallor, or glossitis occurs. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leucovorin is required to reverse symptoms of or to prevent hematologic problems due to pyrimethamine-induced folic acid deficiency; dose may vary. Upon discontinuation of pyrimethamine, leucovorin should be continued for another week  (due to long half-life of pyrimethamine). Combination therapy of pyrimethamine and sulfadiazine and possibly atovaquone also provide prophylaxis against PCP.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F216072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Simple Syrup, NF and methylcellulose 1%. Crush forty 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     500 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 500 mL. Label \"shake well\" and \"refrigerate\". Stable for 91 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7973/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7973/abstract-text/19357635 /pubmed\" id=\"19357635 \" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McAuley JB, \"Toxoplasmosis in Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2008, 27(2):161-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7973/abstract-text/18227714/pubmed\" id=\"18227714\" target=\"_blank\">",
"        18227714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2006 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 27th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2006, 545.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;Guidelines for the Treatment of Malaria,&rdquo; 2010, World Health Organization, Geneva. Available at file://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12754 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7973=[""].join("\n");
var outline_f7_50_7973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216093\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216094\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049610\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444903\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049604\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216067\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216052\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049613\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049612\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216134\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216132\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049617\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049603\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216123\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216061\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216063\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216078\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049609\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049602\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049616\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049608\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049618\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216072\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12754\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12754|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=related_link\">",
"      Pyrimethamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/12/9413?source=related_link\">",
"      Pyrimethamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_50_7974="Molluscum penis 2";
var content_f7_50_7974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient has a \"giant\" molluscum lesion on the shaft of his penis as well as other scattered smaller lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7974=[""].join("\n");
var outline_f7_50_7974=null;
var title_f7_50_7975="Vinblastine: Pediatric drug information";
var content_f7_50_7975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vinblastine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"    see \"Vinblastine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/60/17349?source=see_link\">",
"    see \"Vinblastine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16369039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vinblastine Sulphate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Mitotic Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"      see \"Vinblastine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vinblastine may be administered at intervals of every 7 days or greater and only after leukocyte count has returned to at least 4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; maintenance therapy should be titrated according to leukocyte count",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hodgkin's disease: 2.5-6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once every 1-2 weeks for 3-6 weeks; maximum weekly dose: 12.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Histiocytosis X: 0.4 mg/kg once every 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Germ cell tumor: 0.2 mg/kg on days 1 and 2 of cycle every 3 weeks times 4 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3.7-18.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day every 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Children and Adults: Direct serum bilirubin concentration &gt;3 mg/dL: Reduce dose 50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sulfate: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"     <b>",
"      Do not administer intrathecally, death may occur",
"     </b>",
"     ; do not administer I.M. or SubQ since the drug is very irritating; may be administered IVP directly into the vein or through a Y-site of a freely running I.V. over a 1-minute period at a concentration for administration of 1 mg/mL; I.V. continuous infusion: Prolonged administration times and/or increased administration volumes may run the risk of vein irritation and extravasation. Assure proper needle or catheter placement prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, bleomycin, cisplatin, cyclophosphamide, doxorubicin, doxorubicin liposome, droperidol, etoposide phosphate, filgrastim, fludarabine, fluorouracil, gemcitabine, granisetron, heparin, leucovorin calcium, melphalan, methotrexate, metoclopramide, mitomycin, ondansetron, paclitaxel, pemetrexed, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, furosemide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, doxorubicin, droperidol, fluorouracil, leucovorin calcium, methotrexate, metoclopramide, mitomycin, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doxorubicin, heparin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); 1 mg/mL solution prepared with preserved NS injection is stable for 28 days when refrigerated and protected from light.",
"     <b>",
"      Note:",
"     </b>",
"     Vinblastine must be dispensed in overwrap which bears the statement &ldquo;Do not remove covering until the moment of injection. Fatal if given intrathecally. For I.V. use only.&rdquo;",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of Hodgkin's disease; advanced testicular germinal-cell cancers; non-Hodgkin's lymphoma, histiocytosis X (Letterer-Siwe disease), choriocarcinoma, breast cancer, mycosis fungoides, and Kaposi&rsquo;s sarcoma [FDA approved in pediatrics (age not specified) and adults]. Has been used for the treatment of bladder cancer, melanoma, and nonsmall cell lung cancer (NSCLC)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       VinBLAStine may be confused with vinCRIStine, vinorelbine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Must be dispensed in overwrap which bears the statement",
"       <b>",
"        \"Do not remove covering until the moment of injection. Fatal if given intrathecally. For I.V. use only.\"",
"       </b>",
"       Syringes should be labeled:",
"       <b>",
"        \"Fatal if given intrathecally. For I.V. use only.\"",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F234149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Common:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression, leukopenia/granulocytopenia (nadir: 5-10 days; recovery: 7-14 days; dose-limiting toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain, jaw pain, tumor pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Less common:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina, cerebrovascular accident, coronary ischemia, ECG abnormalities, limb ischemia, MI, myocardial ischemia, Raynaud's phenomenon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, headache, neurotoxicity (duration: &gt;24 hours), seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis, photosensitivity (rare), rash, skin blistering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Aspermia, hyperuricemia, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, gastrointestinal bleeding, hemorrhagic enterocolitis, ileus, metallic taste, nausea (mild), paralytic ileus, rectal bleeding, stomatitis, toxic megacolon, vomiting (mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, thrombocytopenia (recovery within a few days), thrombotic thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Cellulitis (with extravasation), irritation, phlebitis (with extravasation), radiation recall",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Deep tendon reflex loss, myalgia, paresthesia, peripheral neuritis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Auditory damage, deafness, vestibular damage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hemolytic uremic syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, pharyngitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vinblastine or any component; severe granulocytopenia; presence of bacterial infection.",
"     <b>",
"      I.T. administration is contraindicated (may result in death).",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with ischemic heart disease. Acute shortness of breath and severe bronchospasm have been reported in association with concurrent administration of mitomycin; may occur within minutes to several hours following vinblastine administration or up to 14 days following a dose of mitomycin; use caution in patients with pre-existing pulmonary disease. Leukopenia is common; granulocytopenia may be severe with higher doses; leukopenia may be more pronounced in cachectic patients and patients with skin ulceration. Thrombocytopenia and anemia may occur rarely. Dosage modification required in patients with impaired liver function or neurotoxicity (may rarely cause reversible disabling neurotoxicity); dosage should be reduced in patients with recent exposure to radiation therapy or chemotherapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Itraconazole and erythromycin may decrease the metabolism of vinblastine via CYP3A4 inhibition, and itraconazole may increase the effects of vinblastine via P-glycoprotein effects; severe myelosuppression and neurotoxicity may occur. Should be administered by individuals experienced in the administration of vinblastine",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; vinblastine can cause fetal toxicity when administered to pregnant women; for I.V. use only;",
"     <b>",
"      intrathecal administration may result in death",
"     </b>",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Must be dispensed in overwrap which bears the statement:",
"     <b>",
"      \"Do not remove covering until the moment of injection. Fatal if given intrathecally. For I.V. use only.\"",
"     </b>",
"     Vinblastine is a moderate vesicant; avoid extravasation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Assure proper needle or catheter placement prior to administration. Should be administered by individuals experienced in the administration of vinblastine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Injection (solution) contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of vinblastine products containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of VinBLAStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of VinBLAStine. Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Consider vinca alkaloid dose adjustment.  Specific dose adjustment guidelines are not currently available.  Monitor response to vinca alkaloid therapy, including development of vinca alkaloid toxicities (e.g., gastrointestinal toxicity, neurotoxicity).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of VinBLAStine. Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: VinBLAStine may increase the serum concentration of Tolterodine.  Management: Reduce tolterodine dose to 1 mg twice daily (regular release formulation) or 2 mg daily (extended release formulation) (adult doses) and monitor for increased levels/effects of tolterodine with initiation of vinblastine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6753821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated resorption and teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant during vinblastine treatment. Aspermia has been reported in males who have received treatment with vinblastine.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, serum uric acid, hepatic function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to microtubular protein of the mitotic spindle causing metaphase arrest; may interfere with nucleic acid synthesis by blocking glutamic acid utilization",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Poor penetration into CSF; rapidly distributed into body tissues; V",
"     <sub>",
"      dss",
"     </sub>",
"     : 27.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via CYP3A4 to an active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 24.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Biliary excretion (95%), urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/60/17349?source=see_link\">",
"      see \"Vinblastine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stool softener and laxatives should be used for constipation prophylaxis. Report to physician any fever, chills, sore throat, bleeding, or bruising; avoid contact with the eyes since the drug is very irritating and corneal ulceration may result. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Women of childbearing potential should be advised to avoid becoming pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 4-10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 7-14",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Balis FM, Holcenberg JS and Bleyer WA, &ldquo;Clinical Pharmacokinetics of Commonly Used Anticancer Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(3):202-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7975/abstract-text/6189661/pubmed\" id=\"6189661\" target=\"_blank\">",
"        6189661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bashir H, Motl S, Metzger ML, et al, \"Itraconazole-Enhanced Chemotherapy Toxicity in a Patient With Hodgkin Lymphoma,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2006, 28(1):33-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7975/abstract-text/16394890/pubmed\" id=\"16394890\" target=\"_blank\">",
"        16394890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crom WR, Glynn-Barnhart AM, Rodman JH, et al, &ldquo;Pharmacokinetics of Anticancer Drugs in Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1987, 12(3):168-213.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7975/abstract-text/3555940/pubmed\" id=\"3555940\" target=\"_blank\">",
"        3555940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadner H, Grois N, Arico M, et al, \"A Randomized Trial of Treatment for Multisystem Langerhans' Cell Histiocytosis,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(5):728-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7975/abstract-text/11343051/pubmed\" id=\"11343051\" target=\"_blank\">",
"        11343051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tannock I, Ehrlichman C, Perrault D, et al, &ldquo;Failure of 5-Day Vinblastine Infusion in the Treatment of Patients With Advanced Refractory Breast Cancer,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1982, 66(9):1783-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7975/abstract-text/7116356/pubmed\" id=\"7116356\" target=\"_blank\">",
"        7116356",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yap HY, Blumenschein GR, Keating MJ, et al, &ldquo;Vinblastine Given as a Continuous 5-Day Infusion in the Treatment of Refractory Breast Cancer,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1980, 64(2-3):279-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/50/7975/abstract-text/7407762 /pubmed\" id=\"7407762 \" target=\"_blank\">",
"        7407762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12881 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7975=[""].join("\n");
var outline_f7_50_7975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708853\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369039\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050585\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050577\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234079\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234064\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050589\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234150\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050580\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050588\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234153\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234149\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050592\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050576\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050575\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234139\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234073\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234075\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6753821\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050584\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050574\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050591\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050582\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050593\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=related_link\">",
"      Vinblastine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/60/17349?source=related_link\">",
"      Vinblastine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_50_7976="Management of locally advanced cervical cancer";
var content_f7_50_7976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of locally advanced cervical cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7976/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7976/contributors\">",
"     Jennifer F De Los Santos, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7976/contributors\">",
"     J Michael Straughn, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7976/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7976/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7976/contributors\">",
"     Arno J Mundt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7976/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7976/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7976/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/50/7976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with locally advanced cervical cancer (stage IB2 to IVA) have a higher rate of recurrence and worse survival than those with early stage disease (stage IA to IB1). After surgery alone, the rate of relapse is at least 30 percent, and five-year survival rates range from 80 percent for stage IB disease to 30 percent for stage III disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to women with locally advanced cervical cancer is reviewed here. Because the predominant histology of cervical cancer is squamous cell carcinoma, specific issues related to other histologies and other topics relevant to cervical cancer in general are covered elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"       \"Management of early stage cervical cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"       \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=see_link\">",
"       \"Small cell neuroendocrine carcinoma of the cervix\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=see_link\">",
"       \"Invasive cervical adenocarcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF LOCALLY ADVANCED STAGE CERVICAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following staging, locally advanced cervical cancer is defined by the presence of any of the following findings (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link&amp;anchor=H5#H5\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\", section on 'Staging procedure'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confined to the cervix with a clinically visible tumor &gt;4 cm (stage IB2)",
"     </li>",
"     <li>",
"      Invades beyond uterus but not to pelvic wall or to lower third of vagina (stage II)",
"     </li>",
"     <li>",
"      Extends to the pelvic sidewall",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      involves the lower third of vagina,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      causes hydronephrosis or a nonfunctioning kidney (stage III)",
"     </li>",
"     <li>",
"      Invades the mucosa of the bladder or rectum, or extends beyond the true pelvis (stage IVA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20013012\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women with cervical cancer should undergo a lymph node evaluation. Although nodal involvement does not alter the FIGO stage (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ), it impacts treatment. For women with locally advanced disease (stages IB2 to IVA) for whom primary chemoradiation is planned, we obtain a positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/computed",
"    </span>",
"    tomography (CT) scan prior to treatment to evaluate the extent of disease with particular attention to lymph node metastases to provide information to design radiation fields. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with suspected para-aortic node involvement based on CT scan, some experts proceed with a lymphadenectomy or a CT-guided biopsy for pathologic confirmation of nodal status. At other centers, FDG-uptake in the para-aortic nodes is sufficient evidence of nodal involvement and further work-up is not performed. Regardless of whether pathologic confirmation is obtained, treatment is required if para-aortic node involvement is detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link&amp;anchor=H12#H12\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\", section on 'Surgical evaluation of lymph nodes'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H30045461\">",
"     'Treatment of para-aortic nodes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with renal insufficiency should undergo imaging to determine whether the etiology is urinary tract obstruction (which is diagnostic of stage III disease) or intrinsic renal disease. Some experts obtain upper urinary tract imaging for all patients with more than a microscopic tumor. In our practice, we obtain non-contrast CT if a woman presents with an elevated serum creatinine.",
"   </p>",
"   <p>",
"    Any urinary tract obstruction should be corrected prior to cancer treatment, especially in patients who are otherwise candidates for primary chemoradiation. In a retrospective study performed by the Gynecologic Oncology Group involving 539 women with stage III cervical cancer (44 percent who presented with hydronephrosis) treated with chemoradiation, women who received treatment for ureteral obstruction had a significantly longer progression-free survival (PFS) and median overall survival (OS) than those in whom obstruction was not treated (PFS: median 18 versus 10 months; OS median 34 versus 17 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/3\">",
"     3",
"    </a>",
"    ]. A discussion on the etiology of ureteral obstruction and its management is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=see_link\">",
"     \"Recovery of renal function after relief of urinary tract obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15242?source=see_link\">",
"     \"Placement and management of indwelling ureteral stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY CHEMORADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with locally advanced cervical cancer, we administer primary chemoradiation, although we acknowledge that the benefits of treatment are larger with earlier (stage IB to IIB) versus more advanced stage (stage III to IVA).",
"   </p>",
"   <p>",
"    We do not proceed with primary surgery in women with advanced cervical cancer because surgery is not likely to be curative and these patients usually require adjuvant treatment, which is associated with a high incidence of morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In a 2010 study of patients with stage IIB disease treated with primary surgery plus postoperative RT (n=34) or primary chemoradiation (n=25), the rate of serious (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    complications was doubled among those treated with primary",
"    <span class=\"nowrap\">",
"     surgery/RT",
"    </span>",
"    (26 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of chemoradiation for women with locally advanced cervical cancer rather than RT alone was demonstrated in a 2010 meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/7\">",
"     7",
"    </a>",
"    ]. Compared with primary RT, the use of chemoradiation resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the risk of death (hazard ratio [HR] 0.69, 95% CI 0.61-0.77), which translated into a 10 percent absolute improvement in survival. The survival benefit associated with chemoradiation significantly decreased with increasing stage. For women with stage IB to IIA, IIB, and III to IVA cervical cancer, the five-year survival benefit was 10, 7, and 3 percent, respectively (p=0.017).",
"     </li>",
"     <li>",
"      A reduction in the risk of recurrence (HR 0.66, 95% CI 0.59-0.73), which translated into a 13 percent absolute improvement in progression free survival. There was no association between stage and disease free survival reported.",
"     </li>",
"     <li>",
"      A reduction in the risk of local recurrence (odds ratio [OR] 0.59, 95% CI 0.50-0.69) and a trend towards a reduction in distant metastases (OR 0.81, 95% CI 0.65-1.01). This reduction was seen in trials using both platinum-based and non-platinum based regimens.",
"     </li>",
"     <li>",
"      Higher rates of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse events including gastrointestinal toxicity (OR 1.98, 95% CI 1.49-2.63).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24941777\">",
"    <span class=\"h2\">",
"     Chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and the combination of cisplatin plus 5-fluorouracil (5-FU) are used in combination with RT for the treatment of cervical cancer. Of these, we recommend weekly cisplatin (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    during RT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Single agent cisplatin administered with RT achieves similar outcomes to cisplatin plus 5-FU and has a better toxicity profile. This was demonstrated in a randomized trial of 155 women with stage IIB to IVA cervical cancer (without para-aortic node involvement) who were randomly assigned treatment with RT plus either cisplatin or cisplatin plus 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/8\">",
"     8",
"    </a>",
"    ]. At a median follow-up of 39 months, compared to cisplatin plus 5-FU, treatment with cisplatin resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of completion of chemoradiation (71 versus 60 percent, respectively)",
"     </li>",
"     <li>",
"      Less serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic toxicity (26 versus 43 percent)",
"     </li>",
"     <li>",
"      Similar complete response rate (91 percent in both arms) and overall survival rate at four years (67 and 70 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in combination with an alternative agent to 5-FU would improve survival outcomes is not clear. A phase III trial that enrolled 515 women compared cisplatin alone to cisplatin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    during concurrent RT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/10\">",
"     10",
"    </a>",
"    ]. Women randomized to combination chemotherapy also received two additional 21-day cycles of cisplatin plus gemcitabine after completion of RT. With a median follow-up of three years, the use of cisplatin plus gemcitabine resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in progression free survival compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      alone (HR for progression 0.68, 95% CI 0.49 to 0.95; three-year PFS 74 versus 65 percent)",
"     </li>",
"     <li>",
"      An improvement in overall survival (HR for death 0.68, 95% CI 0.49 to 0.95)",
"     </li>",
"     <li>",
"      But was associated with significantly more serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities (87 versus 46 percent) and rate of hospitalizations (30 versus 11)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not clear whether the benefits of the investigational treatment were due to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    during RT or following chemoradiation. Therefore, we continue to prescribe cisplatin alone during chemoradiation. (See",
"    <a class=\"local\" href=\"#H620051171\">",
"     'Role of systemic chemotherapy after chemoradiation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10523862\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most women, RT (in conjunction with chemotherapy) is delivered to the pelvis using external beam RT. Vaginal brachytherapy is also administered in an effort to maximize local control. Two issues that arise in the design of the RT field are the treatment of the para-aortic nodal region and timing of RT treatment. These are discussed below. Further discussion of RT techniques is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=see_link\">",
"     \"Overview of radiation therapy for gynecologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30045461\">",
"    <span class=\"h3\">",
"     Treatment of para-aortic nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with evidence of para-aortic node involvement have a poor prognosis with a five-year survival rate of approximately 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/11\">",
"     11",
"    </a>",
"    ]. Despite low quality data, it is routine practice to treat these patients with extended field RT. There are no trials that compare chemoradiation using extended field RT (to cover the para-aortic region) versus pelvic RT, but given their high risk of disease progression and death, we prefer to treat these women with extended field RT with concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . However, it is critical that women be counselled that such treatment is associated with a high risk of serious acute and late toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest study, the Gynecologic Oncology Group enrolled 95 women with histologically confirmed para-aortic node metastases and treated them with concomitant chemoradiation using extended field RT and reported the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three-year overall and PFS rates for the entire group were 39 and 34 percent, respectively.",
"     </li>",
"     <li>",
"      The rate of grade 3 or higher GI toxicity was 19 percent, likely due to a lower dose to the para-aortic region used in this study compared to the RTOG study.",
"     </li>",
"     <li>",
"      The rate of late morbidity at four years was 14 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that disease control can be attained in some women with locally advanced cervical cancer. However, treatment is associated with a high rate of acute and late toxicity.",
"   </p>",
"   <p>",
"    Given the lack of data that prophylactically extending the RT field in women without para-aortic node involvement improves outcomes, the acute and late toxicity risks of extended field RT cannot be justified. Therefore, we suggest not administering extended field RT for women without evidence of para-aortic node involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Importance of time to completion of chemoradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all women undergoing chemoradiation, treatment should be completed within eight weeks. Although older studies demonstrated the importance of the timely completion of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/16-18\">",
"     16-18",
"    </a>",
"    ], there are limited data on the importance of time to completion for women undergoing chemoradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In one series of 113 women with stage IB to IIIB disease, with a median follow-up of 26 months, time to completion of brachytherapy &gt;56 days was associated with a higher rate of disease progression within the pelvis (26 versus 9 percent, HR 2.8, 95% CI 1.2-16) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the time to completion of chemoradiation was not a significant factor for distant disease progression or disease-specific mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10523258\">",
"    <span class=\"h2\">",
"     Role of hysterectomy after chemoradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some surgeons perform a simple extrafascial hysterectomy following chemoradiation in select patients with disease characteristics that suggest a higher risk of relapse (eg, initially large cervical lesion &gt;7 cm, lower uterine segment involvement, or those with posttreatment residual disease). However, there is no evidence that doing so improves survival outcomes in this population, and we do not routinely perform hysterectomy following chemoradiation in our practice.",
"   </p>",
"   <p>",
"    There are few high quality data regarding this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The only randomized trial to evaluate this question was a small trial (n=61) of women with stage IB2 to II cervical cancer who had a complete clinical and radiologic response after primary treatment with chemotherapy plus RT and were assigned to hysterectomy or no hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/21\">",
"     21",
"    </a>",
"    ]. At three years follow-up, women who underwent hysterectomy had no significant difference in event-free survival (72 versus 89 percent) or overall survival (86 versus 97 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620051171\">",
"    <span class=\"h2\">",
"     Role of systemic chemotherapy after chemoradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest not administering systemic chemotherapy for women completing primary chemoradiation, as there is limited evidence of benefit to justify the additional toxicity risks. However, some data suggest that there is a role for additional treatment.",
"   </p>",
"   <p>",
"    In the previously described study (see",
"    <a class=\"local\" href=\"#H24941777\">",
"     'Chemotherapy regimen'",
"    </a>",
"    above), women who received two cycles of systemic intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    after chemoradiation had significant improvements in both progression-free and overall survival compared with women who received cisplatin alone-based chemoradiation and no further chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/10\">",
"     10",
"    </a>",
"    ]. However, as discussed above, it is not clear if the survival benefit was due to combination chemotherapy delivered with RT, following RT, or both. In addition, the Gynecologic Oncology Group ran a similar trial of gemcitabine followed by cisplatin with concomitant RT but this trial was stopped due to excessive grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/23\">",
"     23",
"    </a>",
"    ]. Given the concerns for toxicity and the unclear contribution of systemic treatment in this study, we await further results prior to administering further treatment after chemoradiation. The independent contribution of adjuvant chemotherapy to chemoradiation is being addressed in an international randomized study",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT01414608\">",
"     (the OUTBACK trial)",
"    </a>",
"    being sponsored by the Gynecologic Cancer Intergroup.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10523617\">",
"    <span class=\"h1\">",
"     NEOADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of neoadjuvant chemotherapy prior to definitive hysterectomy as an alternative to primary chemoradiation has not been studied. While two meta-analyses suggested a benefit to neoadjuvant chemotherapy plus surgery for women with locally advanced cervical cancer, the comparisons were to single modality treatment with primary surgery or radiation therapy (RT), which are no longer considered appropriate treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In parts of Europe, Asia, and South America where access to radiotherapy facilities is limited, neoadjuvant chemotherapy before surgery is administered for locally advanced cervical cancer. However, there are no data that show that the use of neoadjuvant chemotherapy followed by surgery is equally or more effective than primary chemoradiation. Therefore, in areas where chemoradiation can be performed, we prefer to administer chemoradiation rather than neoadjuvant chemotherapy.",
"   </p>",
"   <p>",
"    Two ongoing phase III trials will hopefully delineate the impact of neoadjuvant chemotherapy versus concomitant chemoradiation in women with advanced disease (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00039338\">",
"     EORTC 55994",
"    </a>",
"    and a",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00193739\">",
"     study",
"    </a>",
"    sponsored by the Department of Atomic Energy of India) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main goal of posttreatment surveillance is early detection of those recurrences that might be amenable to potentially curative therapy. The optimal surveillance strategy has not been established. Consensus-based guidelines for posttreatment surveillance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/42/17064?source=see_link&amp;anchor=H7#H7\">",
"     \"Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance\", section on 'Surveillance strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620051306\">",
"    <span class=\"h1\">",
"     QUALITY OF LIFE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer treatment may have a negative impact on quality of life, which can persist for years following treatment, particularly among women who were previously treated with radiation therapy (RT) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of early stage cervical cancer\", section on 'Quality of life issues in cervical cancer survivors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major prognostic factors affecting survival are stage, nodal status, tumor volume, depth of cervical stromal invasion, lymphovascular space invasion (LVSI), and to a lesser extent, histologic type and grade. A summary of survival rates by stage of disease according to the latest FIGO data is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef64747 \" href=\"UTD.htm?27/28/28108\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with locally advanced cervical cancer have a higher rate of recurrence and worse survival than those with early stage disease. After surgery alone, the rate of relapse is at least 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. According to statistics from the American Cancer Society, the five-year survival rate by stage is [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage IB &mdash; 80 percent",
"     </li>",
"     <li>",
"      Stage IIA &mdash; 63 percent",
"     </li>",
"     <li>",
"      Stage IIB &mdash; 58 percent",
"     </li>",
"     <li>",
"      Stage III &mdash; 30 percent",
"     </li>",
"     <li>",
"      Stage IVA &mdash; 16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6927280\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6927288\">",
"    <span class=\"h2\">",
"     Incidentally diagnosed cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare instances, women who undergo a simple hysterectomy for what was thought to be cervical intraepithelial neoplasia (or for another benign indication) have a final pathology result showing cervical cancer. For women in this situation, we suggest a radical parametrectomy and upper vaginectomy with lymph node evaluation rather than chemoradiation. Single institutional studies have shown that radical parametrectomy is feasible and results in recurrence rates between 0 to 11 percent and a five-year overall survival rate over 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjuvant chemoradiation may be a reasonable alternative to further surgery for women who are not candidates for radical pelvic surgery or those with disease that cannot be easily encompassed by a radical parametrectomy. However, a retrospective study involving 147 patients with occult invasive cervical cancer suggests patients treated with this approach have a higher rate of recurrence compared to those treated with radical parametrectomy (7 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, chemoradiation resulted in a 27 percent rate of late complications related to RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H546745501#H546745501\">",
"     \"Management of early stage cervical cancer\", section on 'Adjuvant therapy indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620052119\">",
"    <span class=\"h2\">",
"     Women who are poor candidates for primary chemoradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform a primary modified radical hysterectomy in select patients who are not candidates for chemoradiation. This includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with acute or chronic pelvic inflammatory disease in whom chemotherapy is a relative contraindication (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Women with a coexistent pelvic mass that is suggestive of a dual malignancy",
"     </li>",
"     <li>",
"      Women with anatomic alterations that make optimal RT difficult",
"     </li>",
"     <li>",
"      Women in whom compliance with RT would be difficult",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study, these criteria were used to select 95 women with stage IB cervical cancer for primary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7976/abstract/36\">",
"     36",
"    </a>",
"    ]. The five-year survival rate in this highly selected group was 91 percent.",
"   </p>",
"   <p>",
"    For women who are not surgical candidates, we suggest primary radiation therapy (RT) alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"       \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"       \"Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Locally advanced cervical cancer is defined as: disease confined to the cervix with a clinically visible tumor &gt;4 cm (stage IB2); disease that invades beyond the uterus, but involves less than the upper two-thirds of the vagina (stage II); disease that extends to the pelvic sidewall, involves the lower third of vagina,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      causes hydronephrosis or nonfunctioning kidney (stage III); or disease that extends to the rectum or bladder, or beyond the true pelvis (stage IVA). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of locally advanced stage cervical cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with locally advanced cervical cancer, we recommend primary chemoradiation rather than primary surgery or radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We acknowledge that there are greater benefits to treatment for women with earlier stage (stage IB to IIB) rather than later stage (stage III to IVA) disease. We suggest weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      during RT rather than combination chemotherapy (eg, cisplatin plus 5-FU) during RT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We perform a",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      in all patients with locally advanced cervical cancer in order to define the extent of disease and evaluate the pelvic and para-aortic lymph nodes. (See",
"      <a class=\"local\" href=\"#H20013012\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a positive",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan showing para-aortic node involvement, some experts perform a lymphadenectomy or CT-guided biopsy for pathologic confirmation. Other experts do not perform further evaluation if the",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan is positive. (See",
"      <a class=\"local\" href=\"#H20013012\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30045461\">",
"       'Treatment of para-aortic nodes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with suspected or pathologically confirmed para-aortic node involvement, we suggest primary chemoradiation with extended field RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, consideration of the risks of treatment should be discussed with patients. &nbsp;",
"     </li>",
"     <li>",
"      We suggest not administering extended field RT for women without evidence of para-aortic node involvement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who are poor candidates for primary chemoradiation include women with acute or chronic pelvic inflammatory disease, a coexisting pelvic mass, or women who are not candidates for optimal radiation therapy (due to anatomic considerations or concerns about compliance). (See",
"      <a class=\"local\" href=\"#H620052119\">",
"       'Women who are poor candidates for primary chemoradiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not performing a post-treatment hysterectomy following primary chemoradiation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some experts offer patients with an initially large cervical lesion (&gt;7 cm), lower uterine segment involvement, or a high posttreatment residual tumor volume a simple hysterectomy at the completion of treatment. (See",
"      <a class=\"local\" href=\"#H10523258\">",
"       'Role of hysterectomy after chemoradiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following primary treatment with curative intent, patients are monitored serially with history and physical examination and Pap smears. We reserve imaging only if a recurrence is suspected. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/1\">",
"      Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006; 65:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/2\">",
"      Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 38:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/3\">",
"      Rose PG, Ali S, Whitney CW, et al. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 117:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/4\">",
"      Yessaian A, Magistris A, Burger RA, Monk BJ. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol 2004; 94:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/5\">",
"      Yamashita H, Okuma K, Kawana K, et al. Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study. Am J Clin Oncol 2010; 33:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/6\">",
"      Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/7\">",
"      Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010; :CD008285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/8\">",
"      Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol 2008; 108:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/9\">",
"      Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 2004; 22:4657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/10\">",
"      Due&ntilde;as-Gonz&aacute;lez A, Zarb&aacute; JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011; 29:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/11\">",
"      Macdonald OK, Chen J, Dodson M, et al. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. Am J Clin Oncol 2009; 32:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/12\">",
"      Grigsby PW, Lu JD, Mutch DG, et al. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys 1998; 41:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/13\">",
"      Varia MA, Bundy BN, Deppe G, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1998; 42:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/14\">",
"      Small W Jr, Winter K, Levenback C, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys 2007; 68:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/15\">",
"      Grigsby PW, Heydon K, Mutch DG, et al. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2001; 51:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/16\">",
"      Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/17\">",
"      Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992; 25:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/18\">",
"      Chen SW, Liang JA, Yang SN, et al. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother Oncol 2003; 67:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/19\">",
"      Song S, Rudra S, Hasselle MD, et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 2013; 119:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/20\">",
"      Nugent EK, Case AS, Hoff JT, et al. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol 2010; 116:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/21\">",
"      Morice P, Rouanet P, Rey A, et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist 2012; 17:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/22\">",
"      Darus CJ, Callahan MB, Nguyen QN, et al. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer 2008; 18:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/23\">",
"      Rose PG, Degeest K, McMeekin S, Fusco N. A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 107:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/24\">",
"      Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003; 39:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/25\">",
"      Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2012; 12:CD007406.",
"     </a>",
"    </li>",
"    <li>",
"     Information on EORTC protocol 55994 available online at file://www.eortc.be/protoc/details.asp?protocol=55994 (Accessed on May 17, 2011).",
"    </li>",
"    <li>",
"     Information on trial NCT 00193739 available online at file://clinicaltrials.gov/ct2/show/NCT00193739 (Accessed on May 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/28\">",
"      Vistad I, Foss&aring; SD, Dahl AA. A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol 2006; 102:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/29\">",
"      Greimel ER, Winter R, Kapp KS, Haas J. Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 2009; 18:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/30\">",
"      Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003; 68:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/31\">",
"      Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     Cervical cancer: survival rates by stage file://www.cancer.org/Cancer/CervicalCancer/DetailedGuide/cervical-cancer-survival (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/33\">",
"      Leath CA 3rd, Straughn JM, Bhoola SM, et al. The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy. Gynecol Oncol 2004; 92:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/34\">",
"      Park JY, Kim DY, Kim JH, et al. Management of occult invasive cervical cancer found after simple hysterectomy. Ann Oncol 2010; 21:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/35\">",
"      Li J, Xu H, Chen Y, et al. Laparoscopic nerve-sparing radical parametrectomy for occult early-stage invasive cervical cancer after simple hysterectomy. Int J Gynecol Cancer 2012; 22:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7976/abstract/36\">",
"      Allen HH, Nisker JA, Anderson RJ. Primary surgical treatment in one hundred ninety-five cases of stage IB carcinoma of the cervix. Am J Obstet Gynecol 1982; 143:581.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3187 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3B792D9370-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7976=[""].join("\n");
var outline_f7_50_7976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF LOCALLY ADVANCED STAGE CERVICAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20013012\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY CHEMORADIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24941777\">",
"      Chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10523862\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30045461\">",
"      - Treatment of para-aortic nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Importance of time to completion of chemoradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10523258\">",
"      Role of hysterectomy after chemoradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620051171\">",
"      Role of systemic chemotherapy after chemoradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10523617\">",
"      NEOADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H620051306\">",
"      QUALITY OF LIFE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6927280\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6927288\">",
"      Incidentally diagnosed cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620052119\">",
"      Women who are poor candidates for primary chemoradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3187|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 1\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/28/28108\" title=\"table 2\">",
"      Cervical cancer survival",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=related_link\">",
"      Invasive cervical adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/42/17064?source=related_link\">",
"      Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=related_link\">",
"      Overview of radiation therapy for gynecologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=related_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=related_link\">",
"      Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15242?source=related_link\">",
"      Placement and management of indwelling ureteral stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=related_link\">",
"      Recovery of renal function after relief of urinary tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=related_link\">",
"      Small cell neuroendocrine carcinoma of the cervix",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_50_7977="Overview of fertility and pregnancy in cancer survivors";
var content_f7_50_7977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Overview of fertility and pregnancy in cancer survivors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7977/contributors\">",
"     Elyce H Cardonick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7977/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7977/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7977/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7977/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7977/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/50/7977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the strongest predictors of emotional well-being in cancer survivors, besides sexual function, appearance, and employability, is feeling healthy enough to be a good parent. Cancer survivors are often fearful that their history of cancer or its treatment will have an adverse impact on their offspring conceived after cancer treatment by placing them at risk for malignancy, congenital anomalies, or impaired growth and development. They are also concerned about the risks of cancer recurrence, infertility, miscarriage, and achieving a successful pregnancy outcome.",
"   </p>",
"   <p>",
"    Despite these concerns, surveys have reported that fewer than 60 percent of respondents had received information about fertility after cancer treatment, and even fewer had received information about potential risks to offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Others have reported that the rate of elective pregnancy termination among female cancer survivors was higher compared to sibling controls because of the fear that their prior cancer therapy would affect their children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/3\">",
"     3",
"    </a>",
"    ]. Patient education regarding future reproductive function is thus an important component of the care of individuals with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3690?source=see_link&amp;anchor=H19#H19\">",
"     \"Various rehabilitation issues in patients treated for cancer\", section on 'Infertility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss general issues regarding fertility and pregnancy in cancer survivors. Methods of fertility preservation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancies complicated by specific types of cancer are also discussed elsewhere in individual topic reviews, for example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=see_link\">",
"       \"Breast cancer during pregnancy and lactation: Epidemiology and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=see_link\">",
"       \"Breast cancer during pregnancy and lactation: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4759?source=see_link\">",
"       \"Management of ovarian cancer in pregnant women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6826?source=see_link\">",
"       \"Cervical cancer in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=see_link\">",
"       \"Management of classical Hodgkin lymphoma during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H28#H28\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Pregnancy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H23#H23\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Pregnant women'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic agents and radiation therapy can produce gonadal dysfunction in both men and women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=see_link&amp;anchor=H16#H16\">",
"     \"Pubertal development and gonadal function in survivors of childhood cancer\", section on 'Infertility'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"     \"Effects of cytotoxic agents on gonadal function in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Childhood Cancer Survivor Study compared the pregnancy rate in female and partners of male cancer survivors to the rate in a sibling cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The relative risk for female survivors of ever being pregnant was 0.81 (95% CI, 0.73-0.90) compared with female siblings; poor prognostic factors included",
"    <span class=\"nowrap\">",
"     hypothalamic/pituitary",
"    </span>",
"    radiation dose &ge;30 Gy, an",
"    <span class=\"nowrap\">",
"     ovarian/uterine",
"    </span>",
"    radiation dose &gt;5 Gy, a summed alkylating agent dose score of three or four, or treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/6\">",
"     6",
"    </a>",
"    ]. Males who were not surgically sterile were less likely to sire a pregnancy than siblings (HR 0.56, 95% CI, -0.49 to 0.63); poor prognostic factors included radiation therapy &gt;7.5 Gy to the testes, higher cumulative alkylating agent dose score, or treatment with cyclophosphamide or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Ovarian effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of ovarian function can occur after either chemotherapy or radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/8\">",
"     8",
"    </a>",
"    ]. The frequency of amenorrhea is dependent upon the type of agent (alkylating agents are particularly deleterious to the ovarian follicle pool), the cumulative dose, and the patient's age (risk of ovarian failure increases with age). The loss of ovarian function may be permanent or temporary. Temporary amenorrhea results from destruction of maturing follicles, whereas permanent amenorrhea is caused by depletion of viable primordial follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/9\">",
"     9",
"    </a>",
"    ]. Importantly, ovarian reserve can be decreased even in women with regular menstrual cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Ovarian failure related to radiation therapy and chemotherapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two FSH levels in the menopausal range (for the specific assay) measured at least one month apart and associated with",
"    <span class=\"nowrap\">",
"     amenorrhea/oligomenorrhea",
"    </span>",
"    and low estradiol levels is strongly suggestive of ovarian failure.",
"   </p>",
"   <p>",
"    Young women who have undergone unilateral oophorectomy generally do not have reduced fertility since young women have many primordial follicles per ovary; however, prior unilateral oophorectomy may impact fertility in older women, as they may develop diminished ovarian reserve sooner than women with two ovaries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Uterine effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that chemotherapy directly damages the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/14\">",
"     14",
"    </a>",
"    ]. On the other hand, exposure of the uterus to radiation can cause uterine damage, including restricted growth and impaired blood flow. Obstetrical consequences include an increased risk of miscarriage, midtrimester pregnancy loss, preterm birth, low birthweight, and placental accreta (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Radiation therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Methods of fertility preservation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spermatogenesis is much more likely to be disrupted than testosterone production because the germinal epithelium of the testis is more sensitive to damage from cytotoxic drugs than are the Sertoli and Leydig cells. The degree of damage to the germinal epithelium is influenced by the stage of sexual maturation of the testis. In general, the postpubertal testis appears to be more susceptible to damage than the prepubertal testis. The magnitude of the effect on sperm production is both drug-specific and dose-dependent. An elevated FSH (&gt;10",
"    <span class=\"nowrap\">",
"     U/L)",
"    </span>",
"    concentration after cytotoxic therapy suggests the presence of azoospermia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=see_link&amp;anchor=H16#H16\">",
"     \"Pubertal development and gonadal function in survivors of childhood cancer\", section on 'Infertility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of the reproductive implications of cancer treatment do not include baseline fertility data obtained before diagnosis. Therefore, it is not known whether the quality of sperm (count and motility) harvested from cancer patients before treatment is poor because of the disease process itself.",
"   </p>",
"   <p>",
"    Some types of surgery used to treat men with cancer may affect a man's future fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Men with testicular cancer may undergo orchiectomy. As long as one healthy testicle remains, the sperm count should be adequate after surgery; however, some men with testicular cancer have poor fertility because the remaining testicle is not truly normal. Men who have undergone surgery for prostate cancer or retroperitoneal lymph node dissection may not be able to produce semen or ejaculate, but sperm can be taken directly from the testicles and used to fertilize the partner's egg in vitro.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREGNANCY AND NEONATAL OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Congenital and chromosomal anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In studies including several thousand offspring, parents who have been treated for childhood cancer with chemotherapy, radiation therapy, or both are not at increased risk of having children with congenital anomalies, single gene disorders, or chromosomal syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/17-25\">",
"     17-25",
"    </a>",
"    ]. Some representative examples are illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An international study of over 25,000 survivors of childhood cancer in the United States and Denmark who gave birth to or fathered over 6000 children reported no significant difference in the incidence of genetic disease in children born to survivors and those born to sibling controls (3.7 and 4.1 percent, respectively, in the United States and 6.1 and 5.0 percent, respectively in Denmark) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from the Childhood Cancer Survivor Study showed no increase in heritable genetic changes affecting the risk of stillbirth, congenital anomalies, or neonatal death in the offspring of men exposed to gonadal irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/23,25\">",
"       23,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar study compared 2198 offspring born to 1062 cancer survivors to 4544 offspring of 2032 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/17\">",
"       17",
"      </a>",
"      ]. The controls were siblings of survivors matched as closely as possible with regard to full sibship, sex and date of birth. The incidence of genetic disease was approximately 3 percent in both groups of offspring. There were no statistically significant differences in the proportion of offspring with cytogenetic syndromes, single-gene defects, or simple malformations.",
"     </li>",
"     <li>",
"      A case control study using computerized record linkage determined the incidence of cancer in parents of children born with an anomaly versus a matched sample of parents of children without congenital anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/19\">",
"       19",
"      </a>",
"      ]. Over 170,000 mothers and fathers were included. The incidence of cancer was similar in the parents of anomalous and nonanomalous children. In addition, there was no association between congenital anomalies in offspring and any type of cancer treatment (eg, radiation therapy or chemotherapeutic treatment with an alkylating agent).",
"     </li>",
"     <li>",
"      The offspring of 1915 female survivors of childhood or adolescent cancer had a gender ratio (male:female) of 1.09:1.00 among their 4029 pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/3\">",
"       3",
"      </a>",
"      ]. This figure is consistent with that in the general population and not significantly different from that for offspring of female siblings of the female survivors. This finding argues against transmission of lethal X-linked mutations as a result of cancer treatment. Similar findings have been reported by others [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these generally reassuring studies, two studies observed an increased risk of congenital anomalies in offspring of cancer survivors. One of these involved survivors treated with radiation, the other involved offspring of male cancer survivors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series on pregnancy outcome that included 427 pregnancies of 20 weeks or more duration after treatment for Wilms' tumor found a trend toward an increased risk of congenital malformations in previously irradiated women (p = 0.054) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/28\">",
"       28",
"      </a>",
"      ]. Records were available for only 309 infants, 20 of whom had malformations. A small portion of women with Wilms&rsquo; tumor may also have uterine anomalies, which may contribute to the increased risk of stillbirth or neonatal death independent of the radiation risks [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Compared to the risk of congenital malformations in the general population (3.6 percent), the frequency of offspring with one or more congenital anomalies was significantly higher in women who had received flank irradiation, but there was no significant influence of radiation dose:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Risk of congenital anomalies in nonirradiated women &mdash;",
"      <span class=\"nowrap\">",
"       3/93",
"      </span>",
"      (3.2 percent)",
"     </li>",
"     <li>",
"      Risk in partners of irradiated males &mdash;",
"      <span class=\"nowrap\">",
"       2/61",
"      </span>",
"      (3.3 percent)",
"     </li>",
"     <li>",
"      Risk in females who received radiation doses from 0.01 to 25 Gy &mdash;",
"      <span class=\"nowrap\">",
"       8/76",
"      </span>",
"      (10.4 percent)",
"     </li>",
"     <li>",
"      Risk in females who received radiation doses above 25 Gy &mdash;",
"      <span class=\"nowrap\">",
"       6/60",
"      </span>",
"      (10 percent)",
"      <br/>",
"      <br/>",
"      Malposition of the fetus and early or threatened labor were more frequent among women who had received flank irradiation, and both were more frequent among women who received higher radiation therapy doses.",
"      <br/>",
"      <br/>",
"      Although this was the largest follow-up series of Wilms tumor patients, the sample size was small compared to other series that did not find an increased risk of congenital anomalies after parental radiation therapy. Moreover, three children in the irradiated group were born with cleft lip",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cleft palate, but no family histories were given to see if these children were already at risk regardless of maternal treatment. It is reassuring that most malformations were isolated and that three of the malformations in the irradiated group were ventricular septal defects (VSD), the most common congenital malformation (one also occurred in a control infant). The trends noted in this series need to be confirmed in larger studies of survivors of both Wilms' tumor and other malignancies before considering the offspring of these women at high risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A cohort study used data on liveborn singletons from nationwide registries in Denmark and Sweden to compare the risk of congenital anomalies in offspring of male cancer survivors with the risk in offspring of fathers with no history of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/30\">",
"     30",
"    </a>",
"    ]. Offspring of male cancer survivors had a slightly but statistically higher absolute rate of major congenital anomalies than offspring in the control group (RR 1.7, 95% CI 1.05-1.31; absolute rate 3.7 versus 3.2 percent).",
"    <br/>",
"    <br/>",
"    One explanation for these findings, which are discordant with almost all previous studies, is that offspring of cancer survivors were examined more closely because of their paternal history, resulting in ascertainment bias [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/31\">",
"     31",
"    </a>",
"    ]. Although data were available for only a small number of children, the rate of congenital anomalies among children of subfertile men was the same for those iatrogenically conceived with sperm cryopreserved before and after cancer treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pregnancy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy outcomes that are most often evaluated are rates of miscarriage, low birth",
"    <span class=\"nowrap\">",
"     weight/preterm",
"    </span>",
"    delivery, and stillbirth. Virtually all series are retrospective and therefore subject to recall bias. Underreporting is particularly an issue with early miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/32\">",
"     32",
"    </a>",
"    ]. A study that merged data from a hospital registry of cancer patients aged 15 to 35 years at diagnosis, and data from a birth registry, observed perinatal mortality, low birth weight, and preterm birth were higher among first births delivered to women after a cancer diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/33\">",
"     33",
"    </a>",
"    ]. There is no evidence of an increased risk of adverse outcome among female partners of male survivors of childhood cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data do not support an adverse effect of prior chemotherapy on the risk of miscarriage, fetal growth and development, fetal demise, or uterine function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/3,21,28,34,36\">",
"     3,21,28,34,36",
"    </a>",
"    ]. The Childhood Cancer Survivor Study compared pregnancy outcome (ie, live birth, miscarriage, birth weight) in five-year female cancer survivors who were less than 21 years old at diagnosis, with outcomes in their sibling controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/3\">",
"     3",
"    </a>",
"    ]. The most frequently used agents were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    . Over 1900 females reported 4029 pregnancies (63 percent live births, 1 percent stillbirths, 15 percent miscarriages, 17 percent abortions, and 3 percent unknown or in gestation). There were no significant differences in pregnancy outcome between patients who had received chemotherapy and controls. However, women who had undergone pelvic irradiation were significantly more likely to have infants weighing less than 2500 g at birth (see below). Study limitations included survey design with possible recall bias.",
"   </p>",
"   <p>",
"    The same investigators also compared pregnancy outcome in the partners of male survivors of childhood cancer to outcome in the partners of their male siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/34\">",
"     34",
"    </a>",
"    ]. Over 1200 male cancer survivors sired 2323 pregnancies (69 percent live births, 1 percent stillbirths, 13 percent miscarriages, 13 percent abortions, 5 percent unknown or in gestation). Although the percent of live births was higher than among female survivors (69 versus 63 percent, see above), it was significantly lower than in the partners of male siblings (69 versus 76 percent). This was due, in part, to a higher rate of pregnancy termination among the partners of male survivors compared to controls. The rate of miscarriage was similar in both cases and controls (13 versus 12.1 percent), as was the rate of stillbirth and birthweight distribution. Interestingly, this study showed a male:female sex ratio of 1.00:1.03, which is lower than that in female survivors and the general population. Possible explanations for this finding are chance and lower testosterone levels from exposure to chemotherapeutic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy in women who have received prior pelvic irradiation appears to be associated with complications such as miscarriage, preterm labor and delivery, low birth weight, impaired fetal growth, placenta accreta, and stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/3,21,23,28,40-48\">",
"     3,21,23,28,40-48",
"    </a>",
"    ]. However, studies reporting these findings did not consistently adjust for maternal factors that could contribute to these risks, such as maternal smoking, alcohol use, diabetes, hypertension, preeclampsia, and infection. The partners of men who received testicular radiation do not appear to be at increased risk of adverse pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/23,49\">",
"     23,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypotheses for these findings include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The uterine vasculature exposed to radiation therapy may not respond normally to cytotrophoblast invasion; that is, the small muscular arterioles may not convert to large capacitance vessels of low resistance. Small arterioles may also be directly injured with fibrin deposition, necrosis, or sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/40\">",
"       40",
"      </a>",
"      ]. The resulting decrease in fetoplacental blood flow may lead to impaired fetal growth and stillbirth or neonatal death.",
"     </li>",
"     <li>",
"      Decreased uterine elasticity or distensibility and volume from radiation induced myometrial changes, such as fibrosis, may lead to preterm labor and delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/50-52\">",
"       50-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiotherapy may injure the endometrium and prevent normal decidualization, resulting in disorders of placental attachment, such as placenta accreta or percreta [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of these effects depends on the total radiation dose, site irradiated, and the woman's age at the time of irradiation (the prepubertal uterus is particularly vulnerable) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/23,53-55\">",
"     23,53-55",
"    </a>",
"    ]. These hypotheses have been supported by evidence that radiation therapy results in anatomic changes in the pelvic vasculature that can lead to reduced fetoplacental perfusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, uterine size and response of the vasculature to exogenous hormones in 10 women with premature ovarian failure secondary to abdominal radiotherapy in childhood was compared to that of a control group of 22 women with other etiologies for premature ovarian failure and no prior radiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/53\">",
"       53",
"      </a>",
"      ]. Endometrial thickness, uterine length, and uterine artery pulsatility index were performed at baseline and after postmenopausal hormone therapy. Uterine length and endometrial thickness were lower in women exposed to abdominal radiotherapy despite a 28-day cycle of exogenous sex steroid replacement. Most had no detectable uterine blood flow. In contrast, there was a linear increase in endometrial thickness and blood flow in the nonirradiated group.",
"     </li>",
"     <li>",
"      A similar study also reported reduced uterine volume and impaired uterine blood flow in patients undergoing bone marrow transplantation after total body irradiation (this represents lower radiation exposure than with abdominal radiation) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/43\">",
"       43",
"      </a>",
"      ]. A significant, although subnormal, improvement in uterine volume and blood flow by Doppler study was noted after three cycles of physiologic hormone replacement.",
"     </li>",
"     <li>",
"      Irradiation induced changes in uterine vasculature and fibrosis may injure the endometrium and prevent normal decidualization. This may increase the incidence of placental attachment disorders, including placental accreta or placental percreta. It has also been hypothesized that radiation therapy may lead to diffuse thinning of the myometrium, increasing the risk of uterine rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large studies of survivors of Wilms' tumor have compared the pregnancy outcome of those who did or did not receive abdominal radiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/28,35,41\">",
"       28,35,41",
"      </a>",
"      ]. Women who received flank radiation therapy as part of the treatment for unilateral Wilms tumor were at increased risk of hypertension complicating pregnancy, fetal malposition, and premature labor, and the increase in risk correlated with higher doses of radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/35\">",
"       35",
"      </a>",
"      ]. It is unlikely that the adverse perinatal outcomes were secondary to radiation-induced germinal mutations, as pregnancies sired by irradiated male cancer survivors did not have an increased risk of these outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/23,41\">",
"       23,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Childhood Cancer Survivor Study, a large multicenter cohort of childhood cancer survivors including 2201 children of 1264 survivors and 1175 children of a comparison group of 601 female siblings, found that survivors' children were at higher risk of preterm birth than the siblings' children (21.1 versus 12.6 percent; OR 1.9, 95% CI 1.4-2.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/47\">",
"       47",
"      </a>",
"      ]. Compared with the children of survivors who did not receive any radiotherapy, the children of survivors treated with high-dose radiotherapy to the uterus (&gt;500 cGy) were at significantly increased risk of preterm birth (50.0 versus 19.6 percent), low birth weight (36.2 versus 7.6 percent), and small for gestational age (18.2 versus 7.8 percent). These risks were also noted at lower uterine radiotherapy doses (starting at 50 cGy for preterm birth and at 250 cGy for low birth weight). A study that used transvaginal sonography to measure uterine volume in 100 childhood cancer survivors evaluated outcomes based on location of radiation: none, uterine, and above or below the diaphragm [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/55\">",
"       55",
"      </a>",
"      ]. Among nulliparous patients, uterine radiation and younger age at exposure were significant risk factors for lower adult uterine volume. Uterine radiation was also associated with a significant increase in the rate of mid-trimester abortion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recommendations for monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women who have received radiation therapy to the pelvis or abdomen are at higher risk for impaired fetal growth, placental attachment disorders, and possibly preterm labor and delivery. Placental attachment can be evaluated with sonography in the late second trimester and third trimesters. Ancillary techniques that may be used if the diagnosis is uncertain include color Doppler ultrasound examination and magnetic resonance imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .) Serial sonograms every four to six weeks in the late second and third trimesters are useful for assessing fetal growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"     \"Diagnosis of fetal growth restriction\"",
"    </a>",
"    .) Weekly nonstress tests may be useful for women with a history of abdominal radiation before menarche, as they may have an increased risk for stillbirth or neonatal death. There are no reliable modalities for prediction and prevention of preterm labor and delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link\">",
"     \"Prevention of spontaneous preterm birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cancer risk in offspring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The offspring of cancer survivors are not at increased risk for cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], unless the tumor suffered by the parent was a component of an inherited syndrome, such as retinoblastoma (see below). As an example, one series evaluated the risk of cancer among 5847 offspring of 14,652 survivors of cancer in childhood or adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/56\">",
"     56",
"    </a>",
"    ]. There were 17 retinoblastomas and 27 neoplasms other than retinoblastoma, of which 22 were considered sporadic cancers. This yielded a standardized incidence ratio of 1.3 (95 percent confidence interval, 0.8 to 2.0), which was not significantly higher than the cancer risk in the general population matched for age. However, in this series there appeared to be a slightly increased risk of cancer in children of survivors who were diagnosed when less than 10 years old.",
"   </p>",
"   <p>",
"    Another large series identified seven cases of cancer among 2308 offspring (0.30 percent) of 2283 case survivors and 11 cases among 4719 offspring (0.23 percent) of 3604 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/57\">",
"     57",
"    </a>",
"    ]. Again, no excess risk of cancer in offspring of cancer survivors was observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Inherited cancer susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain individuals may be at a higher risk of developing cancer by virtue of their family history of an inherited predisposition to develop malignancy. Retinoblastoma, and the various cancers associated with the Li-Fraumeni syndrome are among the best described of these inherited conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of retinoblastoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other malignancies that are less well recognized as having a familial component (eg, brain tumors and acute leukemia) may also aggregate in the relatives of some families. An underlying genetic predisposition for such tumors is suggested in these families, and pedigree analysis of the survivors' family should be elicited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=see_link&amp;anchor=H22#H22\">",
"     \"Risk factors for brain tumors\", section on 'Genetic factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35354?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Familial leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with heritable cancers should be counseled about risk of the disease in their offspring. A genetics counselor can discuss options for prenatal diagnosis or preimplantation genetic diagnosis, if this is desired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cancer recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the possible exception of gestational trophoblastic disease, pregnancy does not affect the risk of recurrence of any type of cancer, although the diagnosis may be delayed because of the pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .) In particular, recurrence of melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/58,59\">",
"     58,59",
"    </a>",
"    ] and breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/60-62\">",
"     60-62",
"    </a>",
"    ] appear to be unaffected by a subsequent pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=see_link\">",
"     \"Breast cancer during pregnancy and lactation: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RISK OF COMPROMISED CARDIAC FUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiation induced cardiotoxity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of cardiac injury directly resulting from radiation includes acute pericarditis during therapy (rarely associated with treatment of juxta pericardial cancer), delayed pericarditis that can present abruptly or as chronic pericardial effusion or constriction; pancarditis, which includes pericardial and myocardial fibrosis with or without endocardial fibroelastosis; cardiomyopathy in the absence of significant pericardial disease; coronary artery disease, and functional valve injury and conduction defects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic valvular disease, predominantly mitral and aortic insufficiency, typically occurs 11.5 years later and becomes symptomatic 16 years post mediastinal radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/64\">",
"     64",
"    </a>",
"    ]. Radiation induced cardiomyopathy is more common if radiation therapy is given with simultaneous or sequential anthracycline chemotherapy. It is not clear if irradiation causes structural alterations in the valves, but myocardial fibrosis adjacent to valve rings can lead to distortion and functional impairment. Rhythm changes can occur secondary to ischemic fibrosis affecting the conduction system.",
"   </p>",
"   <p>",
"    Women with a history of prior thoracic radiation therapy should undergo a baseline echocardiogram and electrocardiogram prior to pregnancy to detect subclinical radiation-induced cardiac sequelae. Consultation with a cardiologist is advised if the echocardiogram is abnormal or an arrhythmia is noted. There should be open communication between the patient's oncologist and obstetrician during the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chemotherapy induced cardiotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients receiving certain chemotherapeutic agents are at increased risk of developing cardiovascular complications even if they have normal hearts, and the risk is greater if there is a known history of heart disease. Among the serious clinical cardiac complications that have been reported are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arrhythmias (usually acute)",
"     </li>",
"     <li>",
"      Dilated cardiomyopathy (acute and chronic)",
"     </li>",
"     <li>",
"      Coronary artery vasospasm resulting in angina or myocardial infarction (acute)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The anthracyclines (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ) are the class of drugs most commonly associated with long-term cardiovascular complications in oncology patients, although many other agents have the potential for cardiotoxicity (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ). In general, the risk of anthracycline-related cardiomyopathy is dose dependent, and can occur many years after administration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. A series of 37 women who received doxorubicin for childhood cancer and subsequently had 72 pregnancies described generally favorable pregnancy outcomes with sustained myocardial function; however, myocardial function deteriorated in the eight women with a lower than normal left ventricular ejection fraction before pregnancy (fractional shortening &lt;30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/65\">",
"     65",
"    </a>",
"    ]. In a multivariate analysis, female sex and a higher cumulative dose of doxorubicin were associated with depressed contractility, and there was an interaction between these two variables [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7977/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    treatment and pregnancy stress cardiac reserve, thus highlighting the importance of careful follow-up of cardiac function during pregnancy and postpartum in patients previously treated with doxorubicin. In patients with a history of exposure to cardiotoxic drugs, cardiac evaluation should be performed prior to pregnancy and may include electrocardiogram, echocardiogram, radionucleotide angiocardiogram, and 24 hour Holter electrocardiogram monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of women with acquired heart disease (including cardiomyopathy), pregnancy risk assessment, and treatment of heart failure in pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link&amp;anchor=H8#H8\">",
"     \"Acquired heart disease and pregnancy\", section on 'Assessing risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link&amp;anchor=H14#H14\">",
"     \"Acquired heart disease and pregnancy\", section on 'Cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18546?source=see_link\">",
"       \"Patient information: Preserving fertility after cancer treatment in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/57/11154?source=see_link\">",
"       \"Patient information: Preserving fertility after cancer treatment in men (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=see_link\">",
"       \"Patient information: Preserving fertility after cancer treatment in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytotoxic agents and radiation therapy can produce gonadal dysfunction in both men and women.",
"     </li>",
"     <li>",
"      Parents who have been treated for childhood cancer with chemotherapy, radiation therapy, or both are not at increased risk of having children with congenital or chromosomal anomalies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Congenital and chromosomal anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The available data do not support an adverse effect of prior chemotherapy on the risk of miscarriage, fetal demise, or birth weight. Pregnancy in women who have received prior pelvic irradiation appears to be associated with complications such as miscarriage, preterm labor and delivery, low birth weight, and placenta accreta. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pregnancy complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The offspring of cancer survivors are not at increased risk for cancer, unless the tumor suffered by the parent was a component of an inherited syndrome, such as retinoblastoma. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cancer risk in offspring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the possible exception of gestational trophoblastic disease, pregnancy does not affect the risk of recurrence of any type of cancer. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cancer recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that women with a history of prior thoracic radiation therapy or who received anthracyclines (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ) undergo cardiac evaluation prior to pregnancy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Risk of compromised cardiac function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/1\">",
"      Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer 1999; 86:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/2\">",
"      Zebrack BJ, Casillas J, Nohr L, et al. Fertility issues for young adult survivors of childhood cancer. Psychooncology 2004; 13:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/3\">",
"      Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 2002; 187:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/4\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005; 83:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/5\">",
"      Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2010; 28:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/6\">",
"      Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2009; 27:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/7\">",
"      Green DM, Nolan VG, Kawashima T, et al. Decreased fertility among female childhood cancer survivors who received 22-27 Gy hypothalamic/pituitary irradiation: a report from the Childhood Cancer Survivor Study. Fertil Steril 2011; 95:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/8\">",
"      Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980; 93:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/9\">",
"      Falcone T, Attaran M, Bedaiwy MA, Goldberg JM. Ovarian function preservation in the cancer patient. Fertil Steril 2004; 81:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/10\">",
"      Larsen EC, M&uuml;ller J, Schmiegelow K, et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003; 88:5307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/11\">",
"      Bath LE, Wallace WH, Shaw MP, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-M&uuml;llerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003; 18:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/12\">",
"      Barton SE, Missmer SA, Berry KF, Ginsburg ES. Female cancer survivors are low responders and have reduced success compared with other patients undergoing assisted reproductive technologies. Fertil Steril 2012; 97:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/13\">",
"      Lass A. The fertility potential of women with a single ovary. Hum Reprod Update 1999; 5:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/14\">",
"      Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005; :64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/15\">",
"      Foss&aring; SD. Long-term sequelae after cancer therapy--survivorship after treatment for testicular cancer. Acta Oncol 2004; 43:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/16\">",
"      Nonomura N, Nishimura K, Takaha N, et al. Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy. Int J Urol 2002; 9:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/17\">",
"      Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet 1998; 62:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/18\">",
"      Li FP, Fine W, Jaffe N, et al. Offspring of patients treated for cancer in childhood. J Natl Cancer Inst 1979; 62:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/19\">",
"      Dodds L, Marrett LD, Tomkins DJ, et al. Case-control study of congenital anomalies in children of cancer patients. BMJ 1993; 307:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/20\">",
"      Green DM, Fiorello A, Zevon MA, et al. Birth defects and childhood cancer in offspring of survivors of childhood cancer. Arch Pediatr Adolesc Med 1997; 151:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/21\">",
"      Chiarelli AM, Marrett LD, Darlington GA. Pregnancy outcomes in females after treatment for childhood cancer. Epidemiology 2000; 11:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/22\">",
"      Kenney LB, Nicholson HS, Brasseux C, et al. Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia. A Childrens Cancer Group/National Institutes of Health Report. Cancer 1996; 78:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/23\">",
"      Signorello LB, Mulvihill JJ, Green DM, et al. Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. Lancet 2010; 376:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/24\">",
"      Winther JF, Olsen JH, Wu H, et al. Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol 2012; 30:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/25\">",
"      Signorello LB, Mulvihill JJ, Green DM, et al. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol 2012; 30:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/26\">",
"      Boice JD Jr, Tawn EJ, Winther JF, et al. Genetic effects of radiotherapy for childhood cancer. Health Phys 2003; 85:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/27\">",
"      Winther JF, Boice JD Jr, Thomsen BL, et al. Sex ratio among offspring of childhood cancer survivors treated with radiotherapy. Br J Cancer 2003; 88:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/28\">",
"      Green DM, Peabody EM, Nan B, et al. Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2002; 20:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/29\">",
"      Nicholson HS, Blask AN, Markle BM, et al. Uterine anomalies in Wilms' tumor survivors. Cancer 1996; 78:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/30\">",
"      St&aring;hl O, Boyd HA, Giwercman A, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst 2011; 103:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/31\">",
"      Signorello LB, Friedman DL, Boice JD Jr. Congenital abnormalities: a legacy of cancer treatment? J Natl Cancer Inst 2011; 103:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/32\">",
"      Wilcox AJ, Horney LF. Accuracy of spontaneous abortion recall. Am J Epidemiol 1984; 120:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/33\">",
"      Magelssen H, Melve KK, Skjaerven R, Foss&aring; SD. Parenthood probability and pregnancy outcome in patients with a cancer diagnosis during adolescence and young adulthood. Hum Reprod 2008; 23:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/34\">",
"      Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of partners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003; 21:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/35\">",
"      Green DM, Lange JM, Peabody EM, et al. Pregnancy outcome after treatment for Wilms tumor: a report from the national Wilms tumor long-term follow-up study. J Clin Oncol 2010; 28:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/36\">",
"      Reulen RC, Zeegers MP, Wallace WH, et al. Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 2009; 18:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/37\">",
"      Chow EJ, Kamineni A, Daling JR, et al. Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. Arch Pediatr Adolesc Med 2009; 163:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/38\">",
"      James WH. Occupations associated with low offspring sex ratios. Am J Ind Med 1994; 25:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/39\">",
"      Egeland GM, Sweeney MH, Fingerhut MA, et al. Total serum testosterone and gonadotropins in workers exposed to dioxin. Am J Epidemiol 1994; 139:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/40\">",
"      Hawkins MM, Smith RA. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer 1989; 43:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/41\">",
"      Li FP, Gimbrere K, Gelber RD, et al. Outcome of pregnancy in survivors of Wilms' tumor. JAMA 1987; 257:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/42\">",
"      Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87:3045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/43\">",
"      Holm K, Nysom K, Brocks V, et al. Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. Bone Marrow Transplant 1999; 23:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/44\">",
"      Pridjian G, Rich NE, Montag AG. Pregnancy hemoperitoneum and placenta percreta in a patient with previous pelvic irradiation and ovarian failure. Am J Obstet Gynecol 1990; 162:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/45\">",
"      Norwitz ER, Stern HM, Grier H, Lee-Parritz A. Placenta percreta and uterine rupture associated with prior whole body radiation therapy. Obstet Gynecol 2001; 98:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/46\">",
"      Winther JF, Boice JD Jr, Svendsen AL, et al. Spontaneous abortion in a Danish population-based cohort of childhood cancer survivors. J Clin Oncol 2008; 26:4340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/47\">",
"      Signorello LB, Cohen SS, Bosetti C, et al. Female survivors of childhood cancer: preterm birth and low birth weight among their children. J Natl Cancer Inst 2006; 98:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/48\">",
"      Lie Fong S, van den Heuvel-Eibrink MM, Eijkemans MJ, et al. Pregnancy outcome in female childhood cancer survivors. Hum Reprod 2010; 25:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/49\">",
"      Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 2009; 73:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/50\">",
"      Critchley HO, Bath LE, Wallace WH. Radiation damage to the uterus -- review of the effects of treatment of childhood cancer. Hum Fertil (Camb) 2002; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/51\">",
"      Smith RA, Hawkins MM. Pregnancies after childhood cancer. Br J Obstet Gynaecol 1989; 96:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/52\">",
"      Watanabe T, Matsubara S, Saito Y, et al. Pregnant woman with an extremely small uterus due to pelvic irradiation in childhood. J Obstet Gynaecol Res 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/53\">",
"      Critchley HO, Wallace WH, Shalet SM, et al. Abdominal irradiation in childhood; the potential for pregnancy. Br J Obstet Gynaecol 1992; 99:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/54\">",
"      Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol 1999; 106:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/55\">",
"      Larsen EC, Schmiegelow K, Rechnitzer C, et al. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta Obstet Gynecol Scand 2004; 83:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/56\">",
"      Sankila R, Olsen JH, Anderson H, et al. Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med 1998; 338:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/57\">",
"      Mulvihill JJ, Myers MH, Connelly RR, et al. Cancer in offspring of long-term survivors of childhood and adolescent cancer. Lancet 1987; 2:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/58\">",
"      Reintgen DS, McCarty KS Jr, Vollmer R, et al. Malignant melanoma and pregnancy. Cancer 1985; 55:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/59\">",
"      Grin CM, Driscoll MS, Grant-Kels JM. The relationship of pregnancy, hormones, and melanoma. Semin Cutan Med Surg 1998; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     Peters, MV. The effect of pregnancy in breast cancer. In: Prognostic factors in breast cancer, Forrest, APM, Kunkler, PB, (Eds), Williams and Wilkins, Baltimore 1968. p.65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/61\">",
"      Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 1999; 85:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/62\">",
"      Danforth DN Jr. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology (Williston Park) 1991; 5:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/63\">",
"      Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/64\">",
"      Carlson RG, Mayfield WR, Normann S, Alexander JA. Radiation-associated valvular disease. Chest 1991; 99:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/65\">",
"      Bar J, Davidi O, Goshen Y, et al. Pregnancy outcome in women treated with doxorubicin for childhood cancer. Am J Obstet Gynecol 2003; 189:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/66\">",
"      Katz A, Goldenberg I, Maoz C, et al. Peripartum cardiomyopathy occurring in a patient previously treated with doxorubicin. Am J Med Sci 1997; 314:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/67\">",
"      Davis LE, Brown CE. Peripartum heart failure in a patient treated previously with doxorubicin. Obstet Gynecol 1988; 71:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7977/abstract/68\">",
"      Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332:1738.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4801 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.4-DD5E041DAF-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7977=[""].join("\n");
var outline_f7_50_7977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Ovarian effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Uterine effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREGNANCY AND NEONATAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Congenital and chromosomal anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recommendations for monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cancer risk in offspring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Inherited cancer susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cancer recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RISK OF COMPROMISED CARDIAC FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiation induced cardiotoxity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chemotherapy induced cardiotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6826?source=related_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=related_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=related_link\">",
"      Management of classical Hodgkin lymphoma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4759?source=related_link\">",
"      Management of ovarian cancer in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18546?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/57/11154?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=related_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=related_link\">",
"      Pubertal development and gonadal function in survivors of childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3690?source=related_link\">",
"      Various rehabilitation issues in patients treated for cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_50_7978="Clinical manifestations and diagnosis of Paget disease of bone";
var content_f7_50_7978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Paget disease of bone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7978/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7978/contributors\">",
"     Margaret Seton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7978/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7978/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7978/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/50/7978/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/50/7978/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/50/7978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16031870\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paget disease of bone, also known historically as osteitis deformans, is a focal disorder of bone metabolism that occurs in the aging skeleton; it is characterized by an accelerated rate of bone remodeling, resulting in overgrowth of bone at a single or multiple sites and impaired integrity of affected bone. Commonly affected areas include the skull, spine, pelvis, and long bones of the lower extremity.",
"   </p>",
"   <p>",
"    The majority of patients with Paget disease of bone are asymptomatic. The diagnosis in such patients is usually made incidentally following a routine chemistry screen showing an elevated serum concentration of alkaline phosphatase of bone origin or an imaging study obtained for some other reason that shows pagetic changes in bone.",
"   </p>",
"   <p>",
"    The two main clinical manifestations of Paget disease are pain due to the pagetic lesion in bone itself or from secondary consequences of bone overgrowth and deformities in affected areas, such as osteoarthritis or nerve impingement. Fractures, bone tumors, neurologic disease, and abnormalities in calcium and phosphate balance can also occur. In addition, because of the vascularity of pagetic bone, excessive bleeding may occur during orthopaedic surgery.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and diagnosis of Paget disease of the bone will be reviewed here. The treatment of this disorder is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10602?source=see_link\">",
"     \"Treatment of Paget disease of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16031877\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paget disease of the bone (PDB) is a fairly common finding in aging bone, with estimates ranging from 2.3",
"1ff8",
" to 9 percent in older patients within affected populations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]; it is often asymptomatic. Its onset is typically after age 55, with a slight predominance in men. It is common in England, Scotland, Central Europe, and Greece, as well as in countries and cities settled by European immigrants, such as those in Australia, Canada, and the United States. Even within these countries, there are geographical clusters of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/1,3-7\">",
"     1,3-7",
"    </a>",
"    ]. Paget disease is rarely reported in the Scandinavian countries and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/1,8-11\">",
"     1,8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PDB is an ancient disease, claimed to be identified in a Neanderthal skull, with scattered reports of skeletal remains throughout history demonstrating this disorganized pattern of bone overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/12\">",
"     12",
"    </a>",
"    ]. The recognition of both geographic and familial clusters of the disease led to a search for both environmental and genetic causes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/3,13-16\">",
"     3,13-16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16031884\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The best initial estimates of prevalence came from two autopsy series in Europe performed during the mid-20",
"    <sup>",
"     th",
"    </sup>",
"    century on patients over the age of 40, in whom the prevalence was 3 to 3.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]. In one series, only 7 of 24 patients recognized as having Paget disease had been diagnosed during their lifetimes (29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/17\">",
"     17",
"    </a>",
"    ]. The prevalence may rise to as high as 9 percent in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/2\">",
"     2",
"    </a>",
"    ]. Over the last quarter century, the prevalence of Paget disease appears to have diminished (except in regions of Italy) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/18\">",
"     18",
"    </a>",
"    ]. The extent of skeletal involvement is diminishing, and cases of symptomatic disease are less frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/15,19-22\">",
"     15,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the estimates generated by epidemiological studies have relied upon the distribution of skeletal lesions, deriving prevalence estimates from reports of pagetic bone detected on screening abdominal radiographs (a &ldquo;KUB&rdquo; view). Paget disease can affect almost any bone in the body but has a predilection for the skull, spine, pelvis, and long bones of the lower extremity. Thus, abdominal radiographs tend to capture the proximal femurs, pelvis, and lumbar spine (common sites of Paget disease) but miss patients with monostotic disease of the skull, upper spine, or distal extremity. Other epidemiological studies have relied on elevations of serum alkaline phosphatase from bone as a marker for disease.",
"   </p>",
"   <p>",
"    Several issues are likely to have led to an underestimation of the prevalence of Paget disease, including the facts that it is often asymptomatic, that screening abdominal radiographs are no longer routine with hospital admission, and that the diminished skeletal extent of Paget disease has made it less likely to be incidentally detected.",
"   </p>",
"   <p>",
"    PDB does not occur in children. A disorder called juvenile Paget disease (or hyperphosphatasia) appears unrelated to PDB in adults. This condition in children is an autosomal recessive bone dysplasia. Most reported cases are caused by a germline mutation in the gene for osteoprotegerin (OPG), the decoy receptor for receptor activator for nuclear factor &kappa;B ligand (RANKL), leading to a deficiency of OPG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\", section on 'Other skeletal syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16031884\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paget disease of bone (PDB), which is characterized by an accelerated rate of bone remodeling, resulting in overgrowth of bone at selected sites and impaired integrity of affected bone, is believed to be a disease of the osteoclast. Evidence for the pivotal role of the osteoclast in PDB includes abnormalities in the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoclast phenotype:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The osteoclasts in pagetic bone demonstrate an unusual appearance, with a disproportionate number of osteoclasts with too many nucleoli.",
"     </li>",
"     <li>",
"      Intranuclear inclusion bodies may be noted in the nuclei of pagetic osteoclasts but not in the nuclei of osteoblasts or in osteoclasts from unaffected bone of the same patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoclast physiology:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Osteoclasts from patients with PDB show a hypersensitivity to vitamin D [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiresorptive agents used to treat PDB suppress osteoclastic activity and restore bone remodeling towards normal levels. Treatment with bisphosphonates can result in clinical remission of disease in many patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both genetic and environmental causes are thought to contribute to the pathogenesis of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/26\">",
"     26",
"    </a>",
"    ]. While it is clear that genetic mutations underlie susceptibility, a marked decrease in prevalence that has been shown in Britain and New Zealand also supports a role for environmental determinants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no consistent correlates found between the occurrence of Paget disease and varied environmental exposures, including milk ingestion, dog ownership, urban versus rural living, exposure to measles, heavy metals, or family size. A positive family history may be elicited in 12 to 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/13,27\">",
"     13,27",
"    </a>",
"    ]. Persons with familial Paget disease may differ from those with sporadic Paget disease by having an earlier onset, more skeletal involvement, deformity, and fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/27-33\">",
"     27-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16031891\">",
"    <span class=\"h2\">",
"     Genetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors influence the development of Paget disease of bone (PDB), and inheritance appears to be autosomal dominant with variable penetrance. There are at least seven genetic loci now mapped that are associated with PDB; the best documented of these is the P392L mutation in the ubiquitin associated (UBA) domain of SQSTM1 (PDB3 Gene map locus 5q35) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Some genetic determinants associated with PDB may affect the bone marrow microenvironment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major focus of study has been the pathways involving receptor activator for nuclear factor &kappa;B ligand (RANKL) and macrophage colony-stimulating factor (mCSF), which",
"1ff8",
" are both necessary and sufficient for osteoclast activation through normal regulatory pathways. RANKL binding to RANK on osteoclast precursors, modulated by cytokines, hormones, and osteoprotegerin (OPG, a soluble receptor for RANKL), promote osteoclast differentiation and activation. Findings from studies of both common and very rare disorders of bone remodeling have helped begin to elucidate the signaling protein interactions in the RANKL-RANK activation pathways of osteoclasts and have permitted studies to begin to map out the consequences of disturbances in binding or degradation of proteins that result in excessive RANK signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The SQSTM1 mutation affects these signal pathways.",
"   </p>",
"   <p>",
"    The following observations are of interest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The P392L mutation was first described in French Canadian kindred, where it was present in 46 percent of those with familial Paget disease, compared with 16 percent of unrelated patients with sporadic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. The prevalence of this mutation has been lower in the United States, England, France, and Australia, but probing this genetic locus has led to the identification of new mutations of interest, which cluster about the UBA domain of SQSTM1. The presence of some of these mutations correlates with a more severe clinical phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/42\">",
"       42",
"      </a>",
"      ]. Efforts to define how changes in ubiquitin binding may mediate PDB are underway. While the P392L mutation seems to be carried on preferred haplotypes, somatic mutations may account for a proportion of the sporadic cases of PDB [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early association studies suggested linkage of PDB with the histocompatibility antigen locus on chromosome 6p (PDB1 Gene map locus 6p21.3) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. In families with early PDB, there is a possible mutation in the TNFRSF11A gene, as in familial expansile osteolysis (PDB2 Gene map locus 18q22.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/47\">",
"       47",
"      </a>",
"      ]. Early onset familial Paget disease, like expansile skeletal hyperphosphatasia, may be associated with an allelic variant of FEO39 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/47\">",
"       47",
"      </a>",
"      ], but mutations of the TNFRSF11A gene are rare in families with PDB [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Susceptibility loci are also proposed for 5q31 (the PDB4 locus) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/50\">",
"       50",
"      </a>",
"      ], 2q36, and 10p13 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/51\">",
"       51",
"      </a>",
"      ]. The last locus contains a gene that may account for a large proportion of the cases of Paget disease in families of British ancestry who lack the mutations identified in the SQSTM1 gene.",
"     </li>",
"     <li>",
"      Another locus of interest has been identified on chromosome 9p13-p12 in patients with a rare disease characterized by inclusion body myopathy, PDB, and frontotemporal dementia (IBMPFD) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/52\">",
"       52",
"      </a>",
"      ]. The mutation affects a valosin-containing protein that is associated with clathrin and may function to alter the process of proteosomal degradation. A transgenic mouse model has been described that develops lesions limited to muscle, bone, and brain, as described in human IBMPFD [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/36,53\">",
"       36,53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16031898\">",
"    <span class=\"h2\">",
"     Viral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with the genetic findings, more limited information is available regarding potential environmental influences on Paget disease (PDB), including the possible role of viral infection. Findings of clusters of disease and observations that exposure to unvaccinated dogs, cats, or birds might be associated with a heightened risk of PDB [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/54\">",
"     54",
"    </a>",
"    ] led to the speculation that PDB might have a viral etiology. Some evidence supports a role for a viral infection of the osteoclast [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/55\">",
"     55",
"    </a>",
"    ], but this hypothesis remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The possibility that viral infection may play an important early role in the genetically susceptible host continues to be investigated.",
"   </p>",
"   <p>",
"    The following observations are of interest regarding measles virus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial observations pointed to intranuclear inclusions in pagetic osteoclasts resembling paramyxoviruses, and immunohistochemical probes corroborated this finding [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. Sequences of paramyxovirus transcripts were identified in cells of the osteoclast lineage by in situ hybridization [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/60-62\">",
"       60-62",
"      </a>",
"      ], and the expression of measles virus nucleocapsid protein (MVNP) in normal osteoclasts promoted osteoclast differentiation and phenotype similar to pagetic osteoclasts [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. An animal model has been developed in which the measles virus nucleocapsid protein was targeted to the osteoclasts of transgenic mice, and these mice developed patterns of abnormal bone remodeling with increased bone volume and increased osteoclast activity with some aspects similar to those seen in Paget disease.",
"     </li>",
"     <li>",
"      TRAP-p62P392L transgenic mice and p62P392L-transduced human osteoclast precursors have some characteristics of pagetic osteoclasts (eg, enhanced responsiveness to RANKL and TNF-alpha), but the mutation itself was insufficient to result in a pagetic bone in the mouse or in human osteoclasts with pagetic phenotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/63\">",
"       63",
"      </a>",
"      ]. When these osteoclast precursors from TRAP-p62P392L mice were then transfected with MVNP, a pagetic phenotype was seen.",
"     </li>",
"     <li>",
"      Measles remains a problem worldwide where vaccinations have not reached vulnerable populations [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/5\">",
"       5",
"      </a>",
"      ]. However, PDB is not described as more prevalent in these populations. If measles virus infection is permissive, studies of this model may delineate pathways critical to osteoclast activation that may be triggered by agents other than measles in the microenvironment of bone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22843862\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The osteoclasts in patients with Paget disease are bizarre in appearance, multinucleated, and excessive in number. Accelerated bone turnover results in the abnormal deposition of lamellar bone interspersed with woven bone. The bone is disorganized in appearance, with variably thickened trabeculae rimmed by numerous osteoblasts. The characteristic mosa",
"1ff8",
"ic pattern is formed by randomly arrayed units of lamellar bone, which are delineated by irregular cement lines. The disorganized woven bone increases the bone volume, leading to many of the complications of the disease. The normal marrow is replaced by highly vascular stromal tissue (",
"    <a class=\"graphic graphic_picture graphicRef64880 \" href=\"UTD.htm?16/44/17094\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16031905\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with Paget disease of bone (PDB) are asymptomatic, although estimates vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. When symptoms do arise, these are usually due to overgrowth or deformity of the affected bone at a given skeletal location. Pain may arise either directly, from a pagetic lesion in bone, or from secondary causes, including osteoarthritis, nerve impingement, and tumor.",
"   </p>",
"   <p>",
"    The two main clinical manifestations of Paget disease are pain, presumed to be due to the consequences of bone overgrowth, and deformities in affected areas. However, fractures, bone tumors, neurologic disease, and abnormalities in calcium and phosphate balance can also occur. Intrinsic cardiac disease due to PDB directly does not occur, but extensive polyostotic disease has rarely been associated with high-output heart failure as a secondary phenomenon. In addition, because of the vascularity of pagetic bone, excessive bleeding may occur during orthopaedic surgery.",
"   </p>",
"   <p>",
"    Pain due to pagetic involvement of bone generally develops later in the course of disease and is typically a mild to moderate, deep aching discomfort that persists through the day and at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/67\">",
"     67",
"    </a>",
"    ]. It may worsen with weight bearing and may be present at night. The etiology of the pain associated with the changes in bone is unclear. It may be due to periosteal changes caused by bone enlargement in association with hyperemia or microfractures in weight-bearing bones.",
"   </p>",
"   <p>",
"    The frequency of clinical findings depends upon the population studied (eg, registry versus clinical trial population, or the age of the study patients) and the methods by which data are obtained (eg, by patient or clinician questionnaires or by chart review) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/22,64,68-70\">",
"     22,64,68-70",
"    </a>",
"    ]; thus, estimates of different manifestations vary widely. The reason for this relates to the tendency of patients with Paget disease to be older adults and to assign their musculoskeletal complaints to this disorder of bone.",
"   </p>",
"   <p>",
"    Symptoms and findings likely to be related to PDB among two cohorts of patients included [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/64,69\">",
"     64,69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arthritis (40 to 50 percent)",
"     </li>",
"     <li>",
"      Pain (40 to 45 percent)",
"     </li>",
"     <li>",
"      Bone deformity (12 to 36 percent)",
"     </li>",
"     <li>",
"      Fracture (4 to 16 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other problems that may be attributed to Paget disease of the bone include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/22,64,68-70\">",
"     22,64,68-70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radiculopathy due to nerve compression syndromes",
"     </li>",
"     <li>",
"      Chronic back pain",
"     </li>",
"     <li>",
"      Impaired functional status",
"     </li>",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Joint replacement surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Paget disease has a predilection for the skull, thoracolumbar spine, pelvis, and long bones of the lower extremities. It can be useful to think of the clinical manifestations of PDB in terms of these anatomical correlates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skull &mdash; Involvement of the skull may lead to deformity, hearing loss (due to cochlear involvement), headache, dizziness and spinning sensations, and, rarely, neurological sequelae including hydrocephalus with instability of gait, dementia, or apathy from vascular steal due to heightened bone vascularity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/71\">",
"       71",
"      </a>",
"      ]. Enlargement of the skull, which can occur after many years of disease, may lead to a &ldquo;tam-o-shanter&rdquo; shape radiographically and may result in basilar invagination. Involvement of the mandible or maxillary bones may result in jaw deformity, malocclusion, and periodontal disease (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71522 \" href=\"UTD.htm?23/3/23600\">",
"       image 1",
"      </a>",
"      ) (",
"      <a class=\"external\" href=\"file://www.paget.org/\">",
"       file://www.paget.org/",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/2,25\">",
"       2,25",
"      </a>",
"      ]. Angioid streaks can be found on ophthalmologic examination in up to 20 percent of patients with skull involvement as a component of active and more extensive Paget disease, compared with 15 percent of patients with active disease regardless of location and less than 2 percent of nonselected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. Wide, dilated scalp veins are commonly seen.",
"     </li>",
"     <li>",
"      Spine and pelvis &mdash; Paget disease affecting the spine may lead to spinal stenosis at any level, bone pain, and nerve compression with attendant pain. A vascular steal may cause spinal cord dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/74\">",
"       74",
"      </a>",
"      ]. The abnormal bone may lead to a crippling compression fracture (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51562 \" href=\"UTD.htm?8/19/8497\">",
"       image 2",
"      </a>",
"      ). In the pelvis, Paget disease is often asymptomatic, unless it abuts a joint where softening of the bone may lead to pain, arthritis, and protrusio acetabuli (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62514 \" href=\"UTD.htm?1/8/1156\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Long bones &mdash; Bowing deformities in the long bones and early arthritis of affected joints are common, with a heightened risk of fracture over the lifetime of the individual. The deformities are caused by enlarging and abnormally contoured bones, which result in bowing; the tibia and femur typically bow anteriorly and anterolaterally, respectively. Bowing may result in changes in gait and increased mechanical stresses that increase the likelihood of back and joint pain and of osteoarthritis. Patients with PDB have an increased likelihood of undergoing hip or knee replacement surgery for OA, compared with nonpagetic controls [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/22\">",
"       22",
"      </a>",
"      ]. The skin overlying involved areas may feel warm due to increased blood flow.",
"      <br/>",
"      <br/>",
"      Traumatic and pathologic fractures are the most common complications of pagetic lesions in the long bones. Femoral fractures are more frequent than tibial fractures. The most common femoral site is in the area below the lesser trochanter. Fractures are usually transverse and perpendicular to the cortex. They can be either complete or incomplete (fissure fractures). Fissure fractures tend to occur along the convex surfaces of the curved bones but may progress to become complete fractures over time [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/67,75\">",
"       67,75",
"      </a>",
"      ]. Fracture of pagetic bone may be associated with substantial blood loss.",
"     </li>",
"     <li>",
"      Polyostotic disease &mdash; Polyostotic Paget disease may lead to metabolic disturbances, but these are rare with currently available therapies. Metabolic complications of P",
"1ff8",
"aget disease include high output heart failure and hypercalciuria with a heightened frequency of kidney stones [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/12\">",
"       12",
"      </a>",
"      ]. Casting or immobility may lead to profound osteopenia of the pagetic bone [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21530713\">",
"    <span class=\"h2\">",
"     Bone tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, an osteosarcoma may arise in pagetic bone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55541 \" href=\"UTD.htm?37/47/38654\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/64,77,78\">",
"     64,77,78",
"    </a>",
"    ]. Estimates of prevalence among patients with Paget disease of bone (PDB) range from 0.2 to 1.0 percent. An almost invariably fatal event, the osteosarcoma of PDB classically presents in those with extensive, longstanding, skeletal disease. However, the epidemiology of this may be changing, and polyostotic, active disease may no longer predict those at risk for this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Such patients may report increased bone pain that is poorly responsive to medical therapy, local swelling, and, less often, a pathologic fracture. The osteosarcoma affecting Paget patients probably has a distinct genetic signature from that of adolescent osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/77,79\">",
"     77,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link&amp;anchor=H8#H8\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Paget disease and other benign bone lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Giant cell tumors may arise in pagetic bone and are usually benign [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/81\">",
"     81",
"    </a>",
"    ]. They may present with localized pain, swelling, and limitation of joint motion. In PDB, these tumors typically occur in the skull or pelvis of patients with polyostotic disease. These tumors can also arise in nonosseous tissues, where they are termed extraskeletal osteoclastomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=see_link\">",
"     \"Giant cell tumor of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22843916\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings that result from increased bone turnover are typical of untreated disease in most patients. The following findings characterize this disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum alkaline phosphatase (sAP), like the bone-specific alkaline phosphatase (bAP), is usually elevated in patients with PDB. The degree of elevation generally reflects the extent and activity of the disease, but this correlation is not as consistent as in the past [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/82-85\">",
"       82-85",
"      </a>",
"      ]. A normal or minimally elevated level may be seen in patients with monostotic disease and in some patients with polyostotic disease. [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/86\">",
"       86",
"      </a>",
"      ]. As an example, a normal sAP can be seen in patients with an isolated pelvic lesion, in those patients with several vertebral bodies involved, or in those with end-stage sclerotic disease. In contrast, isolated Paget disease of the skull may produce very marked elevations in sAP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition to the sAP and bAP, other markers of bone turnover are often elevated with active disease, including procollagen type I N-terminal propeptide (PINP), serum C-telopeptide (CTx), urinary N-telopeptide (NTx), and urinary hydroxyproline [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/78,82-85\">",
"       78,82-85",
"      </a>",
"      ]; however, patients with active disease documented by increased radionuclide uptake on bone scintigraphy may occasionally exhibit normal values on testing for these markers. Urinary NTx reflects osteoclast activity (bone resorption), which is inhibited within days to weeks of treatment with a nitrogen-containing bisphosphonate, while the sAP, as a measure of osteoblast function, gradually returns to normal, sometimes over several months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/87\">",
"       87",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=see_link\">",
"       \"Bone physiology and biochemical markers of bone turnover\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum calcium and phosphorus are normal in most patients. Hypercalcemia and hypercalciuria may occur with immobilization or fracture. The finding of hypercalcemia in an ambulatory patient with PDB suggests the presence of a second disorder, such as primary hyperparathyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"       \"Diagnostic approach to hypercalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"       \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22844036\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several imaging modalities, including plain radiography and bone scintigraphy, are useful in patients with suspected PDB, and findings on plain radiographs may be diagnostic, reflecting the abnormal bone turnover characteristic of disease. Additional imaging studies, including computerized tomography and magnetic resonance imaging, may be useful in further evaluating unusual bone lesions or in other selected circumstances, particularly if malignancy is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22844044\">",
"    <span class=\"h3\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain films early in the disease course may show a predominantly osteolytic lesion. Over time, however, there is evidence of an osteoblast response, and the bone thickens and enlarges (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75326 \" href=\"UTD.htm?38/2/38959\">",
"     image 5",
"    </a>",
"    ). In late Paget disease, there may be dense bone by plain film, with little evidence of remodeling by biochemical parameters. Characteristic radiographic findings include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Osteoporosis circumscripta,&rdquo; which describes the osteolytic lesions that may be seen in the skull in early disease",
"     </li>",
"     <li>",
"      Mixed",
"      <span class=\"nowrap\">",
"       lytic/sclerotic",
"      </span>",
"      lesions, which gradually progress over time, resulting in thickening of cortical bone, heightened trabecular markings, and distortion and overgrowth of involved bone",
"     </li>",
"     <li>",
"      Progression of lesions originating in the subchondral bone and moving in one direction through the bone in a pattern sometimes described as &ldquo;flame shaped&rdquo;, with cortical tunneling and trabecular thickening sometimes present (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66075 \" href=\"UTD.htm?22/35/23088\">",
"       image 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pseudofractures, which may be seen as small fissures on the convex surface of long bones affected by bowing [",
"      <a class=\"abstract\" href=\"./clinical-man",
"1ff8",
"ifestations-and-diagnosis-of-paget-disease-of-bone/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Very infrequent identification of new bone lesions over time, although individual lesions evolve as noted above",
"     </li>",
"     <li>",
"      Pelvic involvement that results in protrusio acetabuli, which can give the pelvis a triangular appearance",
"     </li>",
"     <li>",
"      Ileopectineal line involvement, which is sometimes described as appearing in the shape of the number &ldquo;3&rdquo;",
"     </li>",
"     <li>",
"      An ivory appearance of the affected spine in some patients. An affected vertebra is often enlarged in all three planes or may have the appearance of a picture frame. Additionally, vertebral enlargement may cause a loss of the normal lumbar lordosis and may accentuate the dorsal kyphosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22844233\">",
"    <span class=\"h3\">",
"     Bone scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased uptake is seen focally at the sites of active pagetic bone lesions on radionuclide bone scanning and is more sensitive than plain radiography, particularly in early disease. Bone scanning can help establish the extent and distribution of bony lesions. The enhanced radionuclide uptake at pagetic lesions represents increased bone remodeling and blood flow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53321 \" href=\"UTD.htm?38/38/39523\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/67\">",
"     67",
"    </a>",
"    ]. The plain film (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66075 \" href=\"UTD.htm?22/35/23088\">",
"     image 6",
"    </a>",
"    ) demonstrates the radiographic correlates of this in the same patient. Sometimes evidence of Paget disease on bone scan antedates corresponding findings on plain radiographs.",
"   </p>",
"   <p>",
"    The radionuclide uptake may decrease or normalize in the absence of significant disease activity (eg, patients with more longstanding or effectively treated disease). The degree of uptake may increase or decrease in patients with malignant transformation to osteosarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27500927\">",
"    <span class=\"h3\">",
"     Other imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other imaging technologies, such as computerized tomography (CT) or magnetic resonance imaging (MRI), may be helpful in the evaluation of suspicious bone lesions, especially if malignancy is a concern [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/67,89\">",
"     67,89",
"    </a>",
"    ]. CT scanning may be useful for verifying whether the cortices of bone are intact and for defining the consequences of fractures or overgrowth of bone in the spine or skull. MRI may be helpful in distinguishing lytic or intermediate lesions of Paget disease from sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/90\">",
"     90",
"    </a>",
"    ]. Positron emission tomography (PET) scanning for malignancy may be &ldquo;falsely positive,&rdquo; with increased uptake seen in active pagetic bone lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/91\">",
"     91",
"    </a>",
"    ]. The role of PET scanning in this setting is not well defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=see_link&amp;anchor=H4#H4\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\", section on 'Radiographic imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link&amp;anchor=H12#H12\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Diagnosis and staging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16031919\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Paget disease is primarily radiologic. In most patients, the serum alkaline phosphatase is elevated, and additional tests of bone turnover are not required [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/92\">",
"     92",
"    </a>",
"    ]. We diagnose Paget disease of bone in patients with clinical or laboratory findings suggestive of disease upon the demonstration of characteristic radiographic changes at one or more affected skeletal sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27501186\">",
"    <span class=\"h2\">",
"     Role of imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs are usually diagnostic, showing the characteristic deformity of bone, with thickened cortices marked by tunneling, and accentuated trabeculae. Plain films obtained earlier in the course of illness may show a predominantly lytic lesion. Over time, however, there is evidence of an osteoblast response, and the bone thickens and enlarges (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75326 \" href=\"UTD.htm?38/2/38959\">",
"     image 5",
"    </a>",
"    ). In some cases of Paget disease, there may be dense bone by plain film, with little evidence of remodeling by biochemical parameters. (See",
"    <a class=\"local\" href=\"#H22844044\">",
"     'Plain radiographs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A skeletal survey is not required, but it is important to obtain a baseline radionuclide bone scan in all patients with Paget disease of the bone to document the extent and locations of skeletal involvement, as the sites involved rarely change over a patient&rsquo;s lifetime (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53321 \" href=\"UTD.htm?38/38/39523\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We also obtain radiographs of affected sites to identify the musculoskeletal consequences of Paget disease, including fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51562 \" href=\"UTD.htm?8/19/8497\">",
"     image 2",
"    </a>",
"    ), potential malignant lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55541 \" href=\"UTD.htm?37/47/38654\">",
"     image 4",
"    </a>",
"    ), osteoarthritis, or other bone abnormalities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62514 \" href=\"UTD.htm?1/8/1156\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27501193\">",
"    <span class=\"h2\">",
"     Role of biochemical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum alkaline phosphatase (sAP) is usually adequate for assessment and monitoring of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. Occasionally, bone specific alkaline phosphatase (bAP) is measured in patients with liver disease or a characteristic bone lesion but who have normal sAP. In patients with an elevated sAP, serum calcium and 25-hydroxy vitamin D levels should be obtained to exclude other causes of this elevation and in anticipation of treatment with a bisphosphonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27508233\">",
"    <span class=\"h2\">",
"     Role of biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unusual that a bone biopsy is required to document the diagnosis of PDB, unless there is concern regarding the radiographic appearance of the lesion or possible metastatic disease (eg, a blastic lesion such as that seen in metastatic prostatic carcinoma or a lytic bone lesion in a patient with multiple myeloma). A biopsy of bone is required in the setting of monostotic lesions that do not show the characteristic radiographic findings of Paget disease. A biopsy may also be useful in a person suspected of Paget disease but in whom Paget disease would be unlikely, such as an individual from a country in which Paget disease is rare (eg, Korea) or a young adult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21530746\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paget disease of bone (PDB) occurs in an aging population that also has an increased prevalence of malignancy, osteoarthritis (OA), and osteoporosis. Althoug",
"1ff8",
"h the diagnosis of PDB is usually evident from radiographic findings, other conditions may also be present or have overlapping features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoarthritis &mdash; In patients with known PDB and concurrent OA, pain in or near a joint may be due to PDB close to the affected joint",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the OA. Improvement with treatment with an antiresorptive agent, such as a bisphosphonate, favors the PDB as the cause of pain. However, many older patients have pain from this as well as osteoarthritis of the joint, and while a bisphosphonate eases a component of their distress, attention to alleviating the pain from osteoarthritis is also necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/69,93\">",
"       69,93",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"       \"Diagnosis and classification of osteoarthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteosarcoma and other primary bone tumors &mdash; Osteosarcoma related to PDB typically presents with increasing localized bone pain and may be accompanied by soft tissue swelling in the affected area. Monitoring for the evolution of osteosarcoma arising in pagetic bone is not indicated. Magnetic resonance imaging (MRI) can be helpful to define soft tissue anatomy and other changes of a malignancy such as cortical disruption by a mass. The diagnosis of osteosarcoma is made on bone biopsy. Giant cell tumors of bone are benign, but sometimes aggressive tumors can occur with increased frequency in patients with PDB with localized pain, swelling, and limitation of joint motion. In PDB, these tumors typically occur in the skull or pelvis of patients with polyostotic disease and can also arise in nonosseous tissues as extraskeletal osteoclastomas. Imaging studies and biopsy can help distinguish these lesions from PDB. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=see_link\">",
"       \"Bone tumors: Diagnosis and biopsy techniques\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=see_link\">",
"       \"Giant cell tumor of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metastatic disease &mdash; The mixed",
"      <span class=\"nowrap\">",
"       lytic/sclerotic",
"      </span>",
"      appearance of PDB may make it difficult to radiographically distinguish metastatic malignancy in some patients. However, new lesions on bone scan generally do not occur in PDB over time, and metastases rarely occur in sites of pagetic bone. Thus, comparison with baseline plain radiographs and radionuclide bone scintigraphy can be helpful in determining whether a lesion requires further study. A biopsy may sometimes be required if imaging studies, including CT or MRI, are unable to distinguish these conditions with sufficient confidence.",
"     </li>",
"     <li>",
"      Osteomalacia &mdash; Osteomalacia, like PDB, may present with bone pain and an elevated serum alkaline phosphatase. The radiographic findings characteristic of PDB are absent. Pseudofractures may be present in osteomalacia (Looser&rsquo;s zones) but occur on the concave portion of the bone, unlike the fissure fractures in PDB that are present on the convex aspect. Osteomalacia is due to impaired mineralization of bone. The combined radiographic and laboratory features should allow these conditions to be readily distinguished. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link\">",
"       \"Epidemiology and etiology of osteomalacia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of osteomalacia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperparathyroidism &mdash; Hyperparathyroidism does occur in patients with PDB. The presence of hypercalcemia in an ambulatory patient with PDB should raise the question of whether hyperparathyroidism is also present, and appropriate laboratory studies should be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/94\">",
"       94",
"      </a>",
"      ]. Patients with polyostotic PDB may develop hypercalcemia in association with immobilization or a fracture. [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/95,96\">",
"       95,96",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"       \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=see_link\">",
"       \"Patient information: Paget disease of bone (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/59/14258?source=see_link\">",
"       \"Patient information: Paget disease of bone (osteitis deformans) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21530754\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paget disease of bone (PDB) is a fairly common finding in aging bone; it is often asymptomatic. Its onset is typically after age 55, with a slight predominance in men. It is common in England, Scotland, Central Europe, and Greece, as well as in countries and cities settled by European immigrants. Within these countries, there are geographical clusters of disease. Estimates of prevalence in some populations range from 3 percent in patients over 40 to up to 9 percent in older adults. (See",
"      <a class=\"local\" href=\"#H16031877\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PDB is characterized by abnormalities of the osteoclast [",
"      <a class=\"abstract\" href=\"UTD.htm?7/50/7978/abstract/36\">",
"       36",
"      </a>",
"      ]; there are accelerated bone turnover and abnormal bone remodeling. Both genetic and environmental causes are thought to contribute to its pathogenesis. Inheritance appears to be autosomal dominant with variable penetrance, and multiple genetic loci have been associated with PDB. A pathogenic role for viral infection remains controversial. (See",
"      <a class=\"local\" href=\"#H16031884\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16031891\">",
"       'Genetic'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16031898\">",
"       'Viral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22843862\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with PDB are asymptomatic. Symptoms are usually due to overgrowth of the affe",
"1ff8",
"cted bone. Pain may arise directly, from a pagetic lesion in bone, or from secondary causes, including osteoarthritis, fracture, nerve impingement, or, rarely, tumor. Paget disease has a predilection for the skull, thoracolumbar spine, pelvis, and long bones of the lower extremities. The common clinical manifestations include bone pain or chronic back pain, bone deformities, and arthritis and depend upon the region involved. (See",
"      <a class=\"local\" href=\"#H16031905\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteosarcoma is a rare, usually fatal complication of PDB, which typically presents in those with longstanding, skeletal disease. Such patients may report increased bone pain that is poorly responsive to medical therapy, local swelling, and, less often, a pathologic fracture. Giant cell tumors may arise in pagetic bone and are usually benign. (See",
"      <a class=\"local\" href=\"#H21530713\">",
"       'Bone tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings, which reflect increased bone turnover and are typical of untreated disease, include elevated levels of serum alkaline phosphatase (sAP) and bone-specific alkaline phosphatase (bAP). The degree of elevation generally reflects the extent and activity of the disease, although this is not always the case. A normal or minimally elevated AP may be seen in more limited disease. Serum calcium and phosphorus are normal in most patients. Hypercalcemia and hypercalciuria may occur with immobilization or fracture. (See",
"      <a class=\"local\" href=\"#H22843916\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs reflect the abnormal bone turnover characteristic of disease. A predominantly osteolytic lesion may be seen early in disease. Over time, however, there is evidence of an osteoblast response, and the bone thickens and enlarges, with thickened cortices marked by tunneling and accentuated trabeculae at one or more affected skeletal sites. In late disease, there may be dense bone by plain film, with little evidence of remodeling by biochemical parameters. Increased uptake is seen focally at the sites of active pagetic bone lesions on radionuclide bone scanning. Bone scintigraphy is more sensitive than plain radiography, particularly in early disease. (See",
"      <a class=\"local\" href=\"#H22844044\">",
"       'Plain radiographs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22844233\">",
"       'Bone scintigraphy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of PDB in patients with clinical or laboratory findings suggestive of disease is confirmed by the demonstration of characteristic radiographic changes. In most patients, the serum alkaline phosphatase is elevated, and additional tests of bone turnover are not required. We obtain a baseline radionuclide bone scan to document the extent and locations of skeletal involvement; we perform radiographs of affected sites to identify impending fractures, potential malignant lesions, osteoarthritis, or other bone abnormalities. (See",
"      <a class=\"local\" href=\"#H16031919\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27501186\">",
"       'Role of imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27501193\">",
"       'Role of biochemical studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PDB occurs in an aging population that also has an increased prevalence of malignancy, osteoarthritis (OA), and osteoporosis. Although the diagnosis of PDB is usually evident from radiographic findings, other conditions may also be present or may have overlapping features. (See",
"      <a class=\"local\" href=\"#H21530746\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21530762\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to acknowledge Nicky Kelepouris, MD, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/1\">",
"      Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000; 15:461.",
"     </a>",
"    </li>",
"    <li>",
"     Siris E, Roodman GD. Paget Disease Section X. In: Primer on the Metabolic Bone Diseases, Favus MJ (Ed), ASBMR, Washington, DC 2003. p.495.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/3\">",
"      Gardner MJ, Guyer PB, Barker DJ. Paget's disease of bone among British migrants to Australia. Br Med J 1978; 2:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/4\">",
"      G&oacute;mez Acotto C, Mautalen CA. European origin of patients with Paget's disease of bone in the Buenos Aires area. Eur J Epidemiol 2001; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/5\">",
"      Gennari L, Di Stefano M, Merlotti D, et al. Prevalence of Paget's disease of bone in Italy. J Bone Miner Res 2005; 20:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/6\">",
"      Barker DJ, Chamberlain AT, Guyer PB, Gardner MJ. Paget's disease of bone: the Lancashire focus. Br Med J 1980; 280:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/7\">",
"      Guyer PB, Chamberlain AT. Paget's disease of bone in two American cities. Br Med J 1980; 280:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/8\">",
"      Falch JA. Paget's disease in Norway. Lancet 1979; 2:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/9\">",
"      Sridhar GR. Paget's disease in India: is it truly rare? Natl Med J India 1994; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/10\">",
"      Yip KM, Lee YL, Kumta SM, Lin J. The second case of Paget's disease (osteitis deformans) in a Chinese lady. Singapore Med J 1996; 37:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/11\">",
"      Barker DJ. The epidemiology of Paget's disease. Metab Bone Dis Relat Res 1981; 3:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/12\">",
"      DE DEUXCHAISNES CN, KRANE SM. PAGET'S DISEASE OF BONE: CLINICAL AND METABOLIC OBSERVATIONS. Medicine (Baltimore) 1964; 43:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/13\">",
"      Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. J Bone Miner Res 1991; 6:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/14\">",
"      Barker DJ, Clough PW, Guyer PB, Gardner MJ. Paget's disease of bone in 14 British towns. Br Med J 1977; 1:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/15\">",
"      Cooper C, Dennison E, Schafheutle K, et al. Epidemiology of Paget's disease of bone. Bone 1999; 24:3S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/16\">",
"      Detheridge FM, Guyer PB, Barker DJ. European distribution of Paget's disease of bone. Br Med J (Clin Res Ed) 1982; 285:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/17\">",
"      COLLINS DH. Paget's disease of bone; incidence and subclinical forms. Lancet 1956; 271:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and",
"1ff8",
"-diagnosis-of-paget-disease-of-bone/abstract/18\">",
"      Rendina D, Gennari L, De Filippo G, et al. Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy. J Bone Miner Res 2006; 21:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/19\">",
"      Morales-Piga AA, Bachiller-Corral FJ, Abraira V, et al. Is clinical expressiveness of Paget's disease of bone decreasing? Bone 2002; 30:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/20\">",
"      Doyle T, Gunn J, Anderson G, et al. Paget's disease in New Zealand: evidence for declining prevalence. Bone 2002; 31:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/21\">",
"      Tiegs RD, Lohse CM, Wollan PC, Melton LJ. Long-term trends in the incidence of Paget's disease of bone. Bone 2000; 27:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/22\">",
"      van Staa TP, Selby P, Leufkens HG, et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002; 17:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/23\">",
"      Harvey L, Gray T, Beneton MN, et al. Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral aetiology. J Clin Pathol 1982; 35:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/24\">",
"      Menaa C, Barsony J, Reddy SV, et al. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease. J Bone Miner Res 2000; 15:228.",
"     </a>",
"    </li>",
"    <li>",
"     Singer F, Krane S. Paget Disease of Bone. In: Metabolic Bone Diseases, Krane LV, Aa SM (Eds), WB Saunders, Philadelphia 1990. Vol 546.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/26\">",
"      Cundy T, Reid IR. Paget's disease of bone. Clin Biochem 2012; 45:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/27\">",
"      Seton M, Choi HK, Hansen MF, et al. Analysis of environmental factors in familial versus sporadic Paget's disease of bone--the New England Registry for Paget's Disease of Bone. J Bone Miner Res 2003; 18:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/28\">",
"      Barker DJ. The epidemiology of Paget's disease of bone. Br Med Bull 1984; 40:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/29\">",
"      Barker DJ, Detheridge FM. Dogs and Paget's disease. Lancet 1985; 2:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/30\">",
"      Siris ES. Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions. Semin Arthritis Rheum 1994; 23:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/31\">",
"      L&oacute;pez-Abente G, Morales-Piga A, Elena-Ib&aacute;&ntilde;ez A, et al. Cattle, pets, and Paget's disease of bone. Epidemiology 1997; 8:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/32\">",
"      Merlotti D, Gennari L, Galli B, et al. Characteristics and familial aggregation of Paget's disease of bone in Italy. J Bone Miner Res 2005; 20:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/33\">",
"      Morales-Piga AA, Rey-Rey JS, Corres-Gonz&aacute;lez J, et al. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 1995; 10:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/34\">",
"      Chung PY, Beyens G, Boonen S, et al. The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. Hum Genet 2010; 128:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/35\">",
"      Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 2010; 42:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/36\">",
"      Hiruma Y, Kurihara N, Subler MA, et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 2008; 17:3708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/37\">",
"      Whyte MP. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. Ann N Y Acad Sci 2006; 1068:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/38\">",
"      Michou L, Collet C, Laplanche JL, et al. Genetics of Paget's disease of bone. Joint Bone Spine 2006; 73:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/39\">",
"      Daroszewska A, Ralston SH. Mechanisms of disease: genetics of Paget's disease of bone and related disorders. Nat Clin Pract Rheumatol 2006; 2:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/40\">",
"      Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/41\">",
"      Morissette J, Laurin N, Brown JP. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J Bone Miner Res 2006; 21 Suppl 2:P38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/42\">",
"      Rea SL, Walsh JP, Ward L, et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 2006; 21:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/43\">",
"      Matthews BG, Naot D, Bava U, et al. Absence of somatic SQSTM1 mutations in Paget's disease of bone. J Clin Endocrinol Metab 2009; 94:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/44\">",
"      Merchant A, Smielewska M, Patel N, et al. Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res 2009; 24:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/45\">",
"      Breanndan Moore S, Hoffman DL. Absence of HLA linkage in a family with osteitis deformans (Paget's disease of bone). Tissue Antigens 1988; 31:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/46\">",
"      Fotino M, Haymovits A, Falk CT. Evidence for linkage between HLA and Paget's disease. Transplant Proc 1977; 9:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-m",
"1ff8",
"anifestations-and-diagnosis-of-paget-disease-of-bone/abstract/47\">",
"      Cody JD, Singer FR, Roodman GD, et al. Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 1997; 61:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/48\">",
"      Haslam SI, Van Hul W, Morales-Piga A, et al. Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 1998; 13:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/49\">",
"      Hocking L, Slee F, Haslam SI, et al. Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone 2000; 26:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/50\">",
"      Laurin N, Brown JP, Lemainque A, et al. Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 2001; 69:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/51\">",
"      Lucas GJ, Riches PL, Hocking LJ, et al. Identification of a major locus for Paget's disease on chromosome 10p13 in families of British descent. J Bone Miner Res 2008; 23:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/52\">",
"      Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/53\">",
"      Custer SK, Neumann M, Lu H, et al. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet 2010; 19:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/54\">",
"      Khan SA, Brennan P, Newman J, et al. Paget's disease of bone and unvaccinated dogs. Bone 1996; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/55\">",
"      Mee AP. Paramyxoviruses and Paget's disease: the affirmative view. Bone 1999; 24:19S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/56\">",
"      Helfrich MH, Hobson RP, Grabowski PS, et al. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 2000; 15:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/57\">",
"      Matthews BG, Afzal MA, Minor PD, et al. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. J Clin Endocrinol Metab 2008; 93:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/58\">",
"      Mills BG, Singer FR, Weiner LP, Holst PA. Cell cultures from bone affected by Paget's disease. Arthritis Rheum 1980; 23:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/59\">",
"      Rebel A, Basle M, Pouplard A, et al. Towards a viral etiology for Paget's disease of bone. Metab Bone Dis Relat Res 1981; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/60\">",
"      Friedrichs WE, Reddy SV, Bruder JM, et al. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 2002; 17:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/61\">",
"      Reddy SV, Kurihara N, Menaa C, et al. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology 2001; 142:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/62\">",
"      Kurihara N, Reddy SV, Menaa C, et al. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest 2000; 105:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/63\">",
"      Kurihara N, Hiruma Y, Zhou H, et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2007; 117:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/64\">",
"      Wermers RA, Tiegs RD, Atkinson EJ, et al. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J Bone Miner Res 2008; 23:819.",
"     </a>",
"    </li>",
"    <li>",
"     Seton M. Paget's disease of bone. In: Rheumatology, 4th, Hochberg MC, Silman AJ, Smolen JS, et al. (Eds), Mosby (Elsevier), Philadelphia 2008. p.2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/66\">",
"      Josse RG, Hanley DA, Kendler D, et al. Diagnosis and treatment of Paget's disease of bone. Clin Invest Med 2007; 30:E210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/67\">",
"      Whyte MP. Clinical practice. Paget's disease of bone. N Engl J Med 2006; 355:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/68\">",
"      Falchetti A, Masi L, Brandi ML. Paget's disease of bone: there's more than the affected skeletal--a clinical review and suggestions for the clinical practice. Curr Opin Rheumatol 2010; 22:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/69\">",
"      Seton M, Moses AM, Bode RK, Schwartz C. Paget's disease of bone: the skeletal distribution, complications and quality of life as perceived by patients. Bone 2011; 48:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/70\">",
"      Langston AL, Campbell MK, Fraser WD, et al. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 2007; 80:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/71\">",
"      Devogelaer JP, Bergmann P, Body JJ, et al. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos Int 2008; 19:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/72\">",
"      Clarkson JG, Altman RD. Angioid streaks. Surv Ophthalmol 1982; 26:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/73\">",
"      Dabbs TR, Skjodt K. Prevalence of angioid streaks and other ocular complications of Paget's disease of bone. Br J Ophthalmol 1990; 74:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/74\">",
"      Yost JH, Spencer-Green G, Krant JD. Vascular steal mimicking compression myelopathy in Paget's disease of bone: rapid reversal with calcitonin and systemic steroids. J Rheumatol 1993; 20:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/75\">",
"      Redden JF, Dixon J, Vennart W, Hosking DJ. Management of fissure fractures in P",
"1ff8",
"aget's disease. Int Orthop 1981; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/76\">",
"      Wallace K, Haddad JG, Gannon FH, et al. Skeletal response to immobilization in Paget's disease of bone: a case report. Clin Orthop Relat Res 1996; :236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/77\">",
"      Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res 2006; 21 Suppl 2:P58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/78\">",
"      Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 2008; 372:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/79\">",
"      Mankin HJ, Hornicek FJ. Paget's sarcoma: a historical and outcome review. Clin Orthop Relat Res 2005; 438:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/80\">",
"      Deyrup AT, Montag AG, Inwards CY, et al. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med 2007; 131:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/81\">",
"      Rendina D, Mossetti G, Soscia E, et al. Giant cell tumor and Paget's disease of bone in one family: geographic clustering. Clin Orthop Relat Res 2004; :218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/82\">",
"      Alvarez L, Gua&ntilde;abens N, Peris P, et al. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 2001; 29:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/83\">",
"      Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004; 35:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/84\">",
"      Peris P, Alvarez L, Vidal S, et al. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement. Calcif Tissue Int 2006; 79:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/85\">",
"      Shankar S, Hosking DJ. Biochemical assessment of Paget's disease of bone. J Bone Miner Res 2006; 21 Suppl 2:P22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/86\">",
"      Harinck HI, Bijvoet OL, Vellenga CJ, et al. Relation between signs and symptoms in Paget's disease of bone. Q J Med 1986; 58:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/87\">",
"      Harinck HI, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop Relat Res 1987; :79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/88\">",
"      Griffiths HJ. Radiology of Paget's disease. Curr Opin Radiol 1992; 4:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/89\">",
"      Sundaram M, Khanna G, El-Khoury GY. T1-weighted MR imaging for distinguishing large osteolysis of Paget's disease from sarcomatous degeneration. Skeletal Radiol 2001; 30:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/90\">",
"      Sundaram M. Imaging of Paget's disease and fibrous dysplasia of bone. J Bone Miner Res 2006; 21 Suppl 2:P28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/91\">",
"      Spieth ME, Kasner DL, Manor WF. Positron emission tomography and Paget disease: hot is not necessarily malignant. Clin Nucl Med 2003; 28:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/92\">",
"      Selby PL. Guidelines for the diagnosis and management of Paget's disease: a UK perspective. J Bone Miner Res 2006; 21 Suppl 2:P92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/93\">",
"      Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res 2010; 25:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/94\">",
"      Brandi ML, Falchetti A. What is the relationship between Paget's disease of bone and hyperparathyroidism? J Bone Miner Res 2006; 21 Suppl 2:P69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/95\">",
"      Siris ES, Clemens TP, McMahon D, et al. Parathyroid function in Paget's disease of bone. J Bone Miner Res 1989; 4:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/50/7978/abstract/96\">",
"      Adami S, Frijlink WB, Bijvoet OL, et al. Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment. Calcif Tissue Int 1982; 34:317.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5601 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-218.28.111.102-E73EFF4BA8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7978=[""].join("\n");
var outline_f7_50_7978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21530754\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16031870\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16031877\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16031884\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16031891\">",
"      Genetic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16031898\">",
"      Viral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22843862\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16031905\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21530713\">",
"      Bone tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22843916\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22844036\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22844044\">",
"      - Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22844233\">",
"      - Bone scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27500927\">",
"      - Other imaging modalities",
"     </a>",
"    </li>",
"    <li 1f02 cla ss=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16031919\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27501186\">",
"      Role of imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27501193\">",
"      Role of biochemical studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27508233\">",
"      Role of biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21530746\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21530754\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21530762\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5601|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/3/23600\" title=\"diagnostic image 1\">",
"      Lateral skull of elderly woman with Paget disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/19/8497\" title=\"diagnostic image 2\">",
"      Severe spinal stenosis in Paget disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/8/1156\" title=\"diagnostic image 3\">",
"      Paget disease of the L hemipelvis and L proximal femur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/47/38654\" title=\"diagnostic image 4\">",
"      Osteosarcoma in Paget",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/2/38959\" title=\"diagnostic image 5\">",
"      Pagetic tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/35/23088\" title=\"diagnostic image 6\">",
"      L femur with Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/38/39523\" title=\"diagnostic image 7\">",
"      Bone scan of Paget affecting both femurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5601|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/44/17094\" title=\"picture 1\">",
"      Abnormally large osteoclasts in pagetic bone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=related_link\">",
"      Giant cell tumor of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=related_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/59/14258?source=related_link\">",
"      Patient information: Paget disease of bone (osteitis deformans) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10602?source=related_link\">",
"      Treatment of Paget disease of bone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_50_7979="Sensitivity specificity PPV NPV";
var content_f7_50_7979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions of sensitivity, specificity, and positive and negative predictive values",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disease present",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disease absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Test positive",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        A",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Test negative",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        C",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Sensitivity = A &divide; (A + C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Specificity =&nbsp;&nbsp;D&nbsp;&divide; (B + D)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Positive predictive value = A&nbsp;&divide; (A + B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Negative predictive value = D&nbsp;&divide; (C + D)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7979=[""].join("\n");
var outline_f7_50_7979=null;
var title_f7_50_7980="Viral gastroenteritis pathogens";
var content_f7_50_7980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Enteric viruses associated with acute gastroenteritis in humans",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Virus group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Commercial assay available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Proven causes of gastroenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rotaviruses",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caliciviruses*",
"       </td>",
"       <td>",
"        Yes&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Astroviruses",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteric adenoviruses (types 40/41)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Picornaviruses (some, eg, Aichi virus)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Unproven causes of gastroenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coronaviruses",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pestiviruses",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breda viruses",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parvoviruses and parvo-like viruses",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toroviruses",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Picobirnaviruses",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Picornaviruses (eg, echovirus 22)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes",
"     <em>",
"      Norovirus",
"     </em>",
"     and",
"     <em>",
"      Sapovirus",
"     </em>",
"     genera of the Caliciviridae.",
"     <br>",
"      &bull; Assay available only for the",
"      <em>",
"       Norovirus",
"      </em>",
"      genus.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7980=[""].join("\n");
var outline_f7_50_7980=null;
var title_f7_50_7981="Causes of osteoporosis men";
var content_f7_50_7981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of osteoporosis in men",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrine diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Hypogonadism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Primary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Secondary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Delayed puberty",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Estrogen deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercortisolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitamin D deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Growth hormone deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetes mellitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subtotal or total gastrectomy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malabsorption syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hematologic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple myeloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic hemolytic anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic mastocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disseminated carcinoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Connective tissue diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteogenesis imperfecta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ehlers-Danlos syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Marfan's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Homocystinuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heparin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glucocorticoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroxine suppressive therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticonvulsant drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gonadotropin-releasing hormone analogs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclosporine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chemotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anorexia nervosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercalciuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Immobilization",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7981=[""].join("\n");
var outline_f7_50_7981=null;
var title_f7_50_7982="Disease prog CA vs CD";
var content_f7_50_7982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Disease progression in cancer versus chronic diseases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 268px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lynn J. Living long in fragile health: the new demographics shape end of life care. Improving end of life care: why has it been so difficult? Hastings Center Special Report 2005; 35(6): S14-8.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7982=[""].join("\n");
var outline_f7_50_7982=null;
var title_f7_50_7983="ALK gene FISH probe";
var content_f7_50_7983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fluorescence in situ hybridization (FISH) for ALK gene",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFDAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5gI9KuxXwWLbsIfGKpUVUZuGxMoqW4ckknqeaKKKkoKKKKACiiigAqexuDbTgsT5Z6j0qCiqjJxd0KSUlZnVW+okfPG+RntXQad4iiQYuG4PcV5sCyg7GK59DUn2iQKAD+NepQzWpSd0cFXAQqaM9ktLtbsBoZA6HqfSrcYUtkHAFeP6br15p7ZiPB6iuhi8axtbN56MJP7oHWvfw2e0Jx/eaM8mvlVWL9zVHoH22GA/MQB3aoL7XrKCEuJVJ7DNeW3Xia5nRlVNue9ZMl1cS/fkP4VjW4kUVakrmlLJb6zZ2mp+IXvZMrwOwFYlxeKqs0zAeg7msJJJEPDnPvTTlmLMSzHqTXg1sxqVdZas9Wng4U9FsSzzvO+ScKOgqKiivPbcndnYkkrIKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKCQKsW9lNOCVGBVRhKbtFXFKSjuV6KutpN9jMcDP7Yq1pvhy/vpCrL5KjrnrWsMNWm+WMXczdenFXckY+cttUFiewFBO04cFSOxFen6ToFtp9vtCAy45buai1DR7W8BE0Ksw/iA5r1HkdVQUnJX7HCs0p81raHm1LXWP4SgRyxkfYP4M1i6hpEsMjG3RmQdvauCrgK9JXkjqp4ulUdoszKKAQR1orjOkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKVVLsFQZJo3AQnFKiu5OxGI9cVrWOkq7hpCWrftdMDAr2x3rvo4CpU1ehyVcXGGhxWyTOChFSLbsxxzmuqn0xYywIzzVRrMRkYU1TwMoPUlYpS2Mg6c2M5x61CbVxnBzXUw2u6LocUf2cGXJGD7Vq8BfZELF23OPYFGCuPmorodS0zcAADntisGaJ4JCkg59a4K+HlReux10qsai0GUUUVgahRRRQAUUUUAFFFFABRycADJPSirmnwqwaabhB0NXCDnLlRMpKKuzX0bRRLGGYZb1Pauu03REt49x61U8PPGAvzAow4Irq1hztwcrX2eW4CmoKVtT5rG4qfM4tlaKzwowAahgnjk1G4s4oyZoVDPxwK3YYwseR941VNm0dw8sARWl++3c17MsO1yuPzPNVZO/N8iusLhHO3B9DVUkKjHGfUVquZEDGQgnGOKw7qVUYljisq6VNIuk3JsJAhjbPWqDWwZG7qe1WZ5VaJXQqQe2aQXUYGOGyO3auGfJJ6nXHmjscL4j0lbMfaYMhGPzJ6e9YgIPQ5r0LUoxOpGdyHsa5rUNHQKzRLt9MV8zjsDablS2PbwuKvFRnuYVFGCCVYcg4oryT0AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooz65pAQelAC0UUUAB/WtzRdPCp5twCGboKz9MiLSh8Z9K6W3PlqM4JHavRwVFN88jjxVVpcsTQtLZONi4HrW3bWgYfd5rMsJd6jjHtXTacARz1NfWYKlGZ8/iZyiZr6cRnCk5qnc6bt5K4967ERIeoqnqMSmM4PbpXdVwMOVs5aeKlexyAAjBQAn3rV0fw3qepaZc6lbfZ/stufmV5MOe/Aqky+RMxcfKe9OTzIN7W0skayDDhWIDD3rwMXRxMoJYWSjJNXur6dVutz0ozioSurya07J3W/fS/zITCJE3N+lcl4ltXLiSNTsWuzaQJCRnH9K5+/JmYrGQ3tSzCnCcOU2wk5Rnc44HPsaK1NZtwkayYw+cGsuvmKlN05crPbhNTV0FFFFZlhRRRQAUUUUAI33TXXeFLixhu9PlvrNbu0ikVp4CceYoPI/KuSPStPScmFiCQccGunDWcnF7NW7fj09TDERvE9F1S90rUNevbrRrP+z7BmBitzxsGB27c54rWsJxKgGegrz7SElEoeQHb711tjdK7bBxivq8pqKjShTV7JJau7dl1fV+Z89jaV22vw2R0Mcm1xg1ZbkZ21hXN00EeYgD7ntVuw1QvGqyjLDvXvwxEeblZ5c6MrcyJbx2MRCrk+tcvqQ3K2/nHpXWSzE/KF96ybuzSUk9c+lc+MpuotDbDTUHqcZZJM12CudnQiujFqqoF28mr1tp6wvuIGDUdyCHf5SFHQ159HCOjH3jsqYhVJe6Zs0W0EHkCq9xCrWxyMGp5Zh5xGcrWdrF/5Vk4TANc1aUIxcmbU4yk0kcfq0XlXp44b0qpT5ZnnctIcntTK+QqNSk2j6KCaikwoooqCgooooAKKKKACiiigAooooAKKKKACiiigAoopUVpGCoM880JX0B6AquxGFOPU09EBkVcHryTW9aWqhf30bHjt2qa3sYHO3o+c816EMG3Y5JYldTJkIVkR1BA9qbeW6OoMY2t/Ounn02JoxuXBHQ1Wu7MeWMDkdK6Z4OST5jCGJi2rHLfZ5Q2JF2j1p8VozPhj8v8AOtuW2mFrltpA61BEAzAdvauX6qotJm/t21oWrCFVUYHPatCC3LyKT2qrEvGFOMV2M/hu903QrbUpZYpIZtvypyVz0zXfCrQoyhTqyScnaPm+x5mIrxg1zPV7GbboI51HrXQW8wWUDhcdaz9NtFaQMwJ9M1POywTPuHPtX0lCLpx5jzqzU3Y3o7hHHvUM8ivkHgCsCC8cOeuO1TS3Jbjke9df1xSic31ZxZBqKJnJb8KqrKAowpK+lXZrfdzwRVWOIiX5T0PINcFSLcro7INctmUdYkXy1H3VbvWVJJBFblkb5vWuunt4bqPZJGCCPyrhvEMSWjyIrYXsK87MISpL2m6OzCSjU9ww7+4M8uNxKiq1C9OKK+UnJyd2e/GPKrIKKKKkYUUUUAFFFFACjBZQehNdNYjEQSNV3fSuXPSui0edzEjOAccCu7Atc9mcuKXu3Ny23qQH5HpWtZW+yUPnn0rLtpPNbOK17dgpBIr6fDJaHh1m+hqBUZ1VlzmiWCNZAQ2GqJJ5Odyj65p0kwYLnr1r1eaNjgtK5YY4k+98mKczIpBj/Gs6SY7G24ptpKAm6Rsn0oVZXsHs3a5eedd5x25rPuLwujGVcCotQm2qfJPzHvWJPczFCjnOeK4sTinHQ6aOH5tS0ZbfzCUYMT1GelYXicD7K2GABqz9jhjieQkqeuc1yV1K0s0mZC6A8V4GOxLjT5Zrc9bC0U5Xi9iEdBS0UV4J6wUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKoLMqr1PArY07TS52s/luvP1rIjJE0ZX724YrpJJd7JldsgrswkIO7l0ObESkrJE88xhhGznHBHrUALRSLPtPParixNJGDwXParbWfmwEZ5Xt616/spTd0ef7SMdGV21QOg8uPLdMVDC0jszTyBc9BmkkspIovMXv2ArIvbW6uD8obNZ1atSOsldl04Qeidi1qV4AgjDDHTOaoW90kMyjqG4qk1nc+cIpUbce5pz2UkcygH5hXmzrVJS5rHZGnCMeW509swdRtH1res5JTAkPnN5SncFzWHpcRKqCea3rWMRkHGc969vD0I1uWVRX5XdeT7nnzxNSgpxpytzKz80+hrQvsj+X0pEhMzktgg1LbQl4xgdauQIiKVPB78V9FGnz2vseHKajexQ8gK5C1DNCScKcVpSQqDkZ+lPFqGAbPNU6HNogVW2pk+UU4OTTneJVBZfmHetaW22plsEHvjpXO6qhUld/HWsa8HRVzSlJVXY0Y7y3jT5mUMelcT4qtEaczs3DDpRcSmKQEMTRdyf2haYY7XUcH1rxcXiliabpyWq2PTw9B0Zqae5yUqhZCF6U2nSj98w9OKbXyktz3o7BRRRSGFFFFABRRRQAHpWtoMpZ2iJHyjjNZNS2zbLhWJwK1oTdOopGdWHPBo71ZBuDBFTAAwK6Hw4uk3d68et3DQRCPKMpIBNefJfOrrk/L6k1uwSF4hxnPevcpwVTDPD0pSgrWut16N3PIzH2uKnKrVl70uqsvw2NgyIpkCOWiViFY8bhng1VN+BJ8gyPaq20yJ3qW2slA3LnNerzzlZRONQhH4izEzyHkVBc742BY4WpSGUjHTvVK6kEgfcc4oqStHzCCu9BDMucAknPU0Rwh9zseBWONYSI7FQMBxzVDVNduZEMEQSNW6kdcV5s8bSiuaTudscNUk7LQZrWsPcl7a3ULEDgt61jgYGBQBiivn6tWVaXNNnr06caceWIUUUVmWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABkjBBwRyK3LeSSZ45GXBA61hMMitrT7oNbop6DgmurCtczTZz4haXSOhtp90wEigLjtTJZpoZD5anYTyT3psM9tDj5s5q7IFlg4PB5Br6CN5R0ep5L917aCpd27oBvIx1z2qG+1C0iClG3H0FU5kij46epJrMneAsQGFZVcTOMbaXNKdCMnfUS6vGvLvcg2IOlSW0Ss5Z33d6x7i5OWSIAeppLa5aI4YnHrXlLEJzvLU7vYvl00OqsDiQAHit6GUYUVx2nXgLgk5HtW9BNkj5utexg665dDzsRSd9TrLeciIBKuw7mTceT3rn7WcAA7ua37W4UQjoc19Jh6inuzxq0HHZD2dRHlV+amJLhuSMe1NnbAyvU0kUJIDnIat7u+hlZJal0PkDuKqahYQTIzP0I7dqsybo0GMHNVrmUqnDdRV1LOLUlciF07xOSvtHj3Ntk596wtYkj0+2xFlm+7muk1DzEZmHfrXD+IJW3pCen3q+PzGUaMW4qzPo8EpVJJSd0ZRYsSx6nmkoor5k9sKKKKACiiigAooooAKOtFGGYqkas0jnaqqMkk+lAHrn7OPhJvFXjVb+/gWXStJUySCRNySyEEInPHB+b/gPvSfEvRZPB3ju/wBMYf6Lcn7XZsSPmjckkYHTDblx/s19F/BXwevgvwDYWUiAX84+03bYIJkbnBB/urtX/gNc3+0v4OPiHwQ+rWaZ1LRwZ12gbnh48wZ9AAW/4CfWvhMBxpOOfO7vRkvZr5PSXzfXs9djWtgozo267nz5b36P+7YgN7VbjnAyM155bX08QBRgfrV6DXJo2zJHn3Br9ZpZrFaTPEngH9k7OWcYJGQaxbm+hgdhJJh27VQbXEK8EnPb0rGvJzdTb2GB2FLFZirXhqyqGDd/eFeZftDsBlc5GKhZizEnvSCivElJy3PSUUgoooqSgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClUsh3KT9KSigDTivrdrciTKyCpP7QlljUQsQBx1rIqa2uGgzhA2a6o4iWzdkYSordGhKWaMmViT6VBBFvOQOTwKqz3DysScLTo7uaOPYm0D1xzQ6sHLUSpyS0EukEc5Xv3xUNBJYlmOWPU0tc8nd3N4qysOikaF9yH8K1bLU97qjDY3bJ4rHoq6daVPYidOM9zubS7DsEBy3rW7YXe1NrckV5np121ncBySUPBro4dTXaGVs59697BZimrvRnlYnB9EehJIs8SkMDgVLFJtQ7247CvP4dUkibKyED0zXQWGuQTR4mOHHXNe7QzKnN22Z5VXBThqtUbxnwmSaqzuZRlVIrHu/FOn2u5d+5vQViaj4yjeAi3Vtx6AdqWIzPDwTUpodHA1pPSJr6vdRWluzSOofHRjXnV9dNeXLSuAB0AHpRe3c19IHuGJx0BNQCvkMfjnipWirRPocJhVQV3uFFFFeedgUUUUAFFFFABRRRQAVZ0y+utK1O11HT5FivLWQSwu0auFcHIOGBGQeeRVailKKknGSumB9P/s4/ELxT4w8T6raeJNV+228FoJI0+zxR4beozlFB6E1ifHf4l+MfDHxEu9K0TWRb6f5ETrCbSFwu5eeWQk5Pv3qh+yF/wAjprv/AF4D/wBGLXP/ALT3/JXbn/r1h/8AQTXwVHL8I+I6lD2UeTkvblVr6a2ta51OUvYp36nlbszyPI5Bd2LNgADJ9AOBSUUV98coYooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApaSigAooooAKKKKACiiigApVZk+4xX6UlFCdtg3JfPm4+b8aR7ieRdryHb7VHRVc8trk8q7CBR6Z+tKAPSiipKCiiigAooooAKKKKACiiigAooooAKKKKAPVf2d/GOh+C/Eer3niO7e2imtRFEVheTc28Ej5QccDvWR8c/EmleLPiJLqug3D3Fk1vGm9o2T5lBBGGAPpXA0V5scqoxx0swTfO1y9LW06Wv07l875eQKKKK9IgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiig8DPagAoHJOBk+1SwQPN2wKvWsDxtygIIxwK1hSlIzlUUTMOR1U/lRn866GK2LLu8v5/So30Z57jLJgHmt3gpv4dTJYmPUwqK2bvQ5Yn+UfLjtWTNDJA2HXjPWsalCpS+JGsKsZ/CxlFFFYmgUUUUAFFFFABRRRQAUpGAOQc0lA5IAxk00JhRSng4PWkpDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooACfbJ9KsWlpLcShShx2osYy77yvA6V2Hhyy84tOUxtruweE9vNI5cRiPZRbKy6cLW3VGTMje3Sr+m6Y5ILLkYrZMXmEAjJ9a1bRIkiCgYYd6+ooZfBy8keFVxcuU5trKRWbYB1pgRkcknHaut0rTr3W5rqHSrYTS20fmy5bAC9M1y9yDE5DKc5II9DUTdD2kqVOaco25lfVX2uul+goVJS0krf5DJVLooX73cmsq+s45QTMoGDW7a27TIQh7Vn31k4xHL3PJrOvSco3aN6VRKVkzi7ixaN2EXzc1U5yQRgiu0n04eVtj5965rUbMxEso5HWvnsThJUtUj1qGIU9LlCigUVwnWFFFFABRRRQAUYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAo44z0zRR1wOuaAZs2ZWKZUXG2u10lDCmQpAYdK4/R7WOadBIcCvQLcKoVUUbVH519TlNNy977jwcfNL3Rbfe5fBwPWpJLpYFIbB4pzk/NtHFVLy3MsZIyD717knKC93c8xWk/eEttTnsbv7Vpt1NbXBQpviOCVPUH86ZAhmyxO5mJJz+tVobVmGNpyD6VqW1vLGnzcVx0KC9pKqoJOVruyu7bXfkdNatJwjByuo6LyTd7L56kltCEOYxg1V1O26vzjPNa6p5ajc201JNAs9v7V6UqHPDlOFVuWVzmoEMoKKo2+tc/r+niKTew+Q8EV29vbiB3z90jpXLeI33u6EdeleTjqEY0fe3PQwtVur7uxwc6LHMyr93qKZU96nluuRye9QV8bUXLJo+ki7oKKKKgoKKKKACiiigAooooAKKKKACiiigAooooAKKKCaACirAtv3QOf3h7VNYaZLcOPMBAz0Faxozk7JGbqRSu2UaK6GXw4FPG786xr+0eyl2vnb61dXC1aSvNCp14VHaLK9FAOenSiuc1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClQEyIAMndSVJbkfaI88c04q7SE9mdbpkajYwADDtXe+Er6wtpmN9D5p/h4zivPrQlDyeRW3pd0u8jgMO5r6anThiKTw820paOzs/kz53G0vaRaZ1sgjmvZ5Io/LjLZCg8Cs4rKJmMzYHPy54/CrVrK5QqRzjnPFRyLyCw5969+eFi407NpQ2V3rpZc3f5nHh8VLDwqU1GL51a7V2rfyt7N99yWCFQG3DrVi1gwrs7Ek9BUcDs3X7oqfcpXKsQRXbTUdzik3sQumXzg5B61ejAEXy45qLJkHPWgMUPTIrWCs79yJO+hVuuEbArktajEkgKAcV1WoN+6YgjPYVzcgbcxYZryswSl7p34T3feON16ECHecAg1i9q6LxSR5KgDHPSudr4fHJRrNI+owrbppsKKKK5DoCiiigAooooAKKKKACiiigAooooAKKKKACtbRtPaaMzOvBPFZDHCmu50BY/siKxAJAxmu7L6Kq1bS6HLi6rpw0Kw0ry18wKWz1zV6yWOJD8vP8q3I41eEoME1l3tuwU7RgZ5r6J4VUfeieOq7qe7IsS3EYtxkruHSue1iFbhDIR0/WrTQyPhMHBqK6tzEuCG+XtXPiJurFprQ1oxVOWj1ORljMb424WmVoanGrBTHy+elUWRozh+tfOVYcsmj2YT5khtFFFZGgUUUUAFFFFABRRSbhnGaAFooooAKKKKACiiigAooooAKKKKACgMVZWHUGig57daEDOj0tmcAk/U13/wu8PHxP41srBUJtID9punAyAinOD/vHC/jXm2n3QjgYuRwM19b/s/eE20DwcuoX0LJqWqHznDqA0cfRF/L5sf7VZ8RZ6smyqdaD/eS92Hq93/26rv1t3OOjhfb17PZbnN/GzQxpWvW2sQYW1vwIZFGflkRcDjoBtUD6iuER0Pzu26vpXxpoMXiXwzfaXNwZUzG2cbZByh+mQM+2a+VppJbGSS1u0ZLiBzFIhBBDA4P8q6/DbiP+0spWGrP95QtH1j9l/L4fku55+dYH2df2kNpfn1NASSB28tcrSTzjZ8ow3eqdvebVL54JxUsqhlMpwCa/QlUvH3WeM4WepbjaXyxtJGRVuGXZAdwyw65rPjnEQVmYD2qhf6uSSoIANaPERpK7ZKoyqOyRPczJNNjpzxis3UZFSNgud3TNM+1BYi38Vc3rmsNFxHhmJ6E9K8jF4yMIOUj0cPhpSkkjE1q4Mtz5eeFOTVCnSMZJWkf7zc00ZZtqgsfQV8ZUm6k2z6SEeSKQUhIFWIbO4mOPLKD1NbEGikxDEZZvpWlLDVKmyM514Q3ZgZHrRXSx+HssFaM5NVb3w9PET5DA4/hatZYGvFXsRHF0m7XMSildWjkZJAVYcEGkrj8jpCiiigAooooAKKKKACiiigBQQGUsMgHJrorC4WQRsrbdvQCucPSt3TrcSopjHT0rswblzWRzYlK2p3FmomgypIP1qyLQNG2Tk1R0+ZI4FG0jA6VoQP53KkLjrmvs6XLKKufN1LpuxnSwCHhhgCs3UZ1EeTwen1rp2WGY/eyw4rlvFAEO0gfLn8q5cZD2dNyT0N8NLnmkzkdUJWYEcZqlyTliSe5NWtQO+QkkHHTFVR0r4+s7zZ9FS+EKKKKyNAooooAKOe3NFWILVpCrOdq9QKqMXJ2RMpKO4qQIFAcFi3U+latnpaGLftx6U63tUkwFycVv6dbEwhWBGO1evhcIpPVHn18Q4rRnAUUUV4x6QUUUUAFFFFABRRRQAUUUUAFFFFAD4pWhbK+ua9m+BXjjxJq/wAVtB0/Udc1C5spFmVreSZjGQsEhAK9OCoP4V4tXov7O3/JavDn0uP/AEnlrzs5s8ur80U7Qna6Tt7r27fIdOK50/NHtX7RniXVtB1Pw9HpOqXVis4kLiGQruxjGcdeteLXWqzX9/NdX9w1zdSnMkrnJYgY/kBXoH7YRI1Dw0QcERy8/iteB219LC53/MPWp4JxVOhlNF8iUrNXsrtcz3e7MMfh3UqNpnoGlzq7sCeh4zV97jOSzDiuBtdZEZIzjPc0t9rhdFWA7jX3Uc1pwpnkywE5TO1nlR1++c1lXQQjO/5/rXKDWrwAgbcH1qrPeXEwIkfA/wBmuatmsJrRG9PASjuzZ1LVmhQxRsGk/lWAxZ2Lucue9IB19TQelePWryrO8j0aVKNNWRZ0+ze8mCgHyx94iuvs7C3t41RIhn1PU1m+HUAtwuOvNdDAoZwDk47+lezl+GjGKl1Z5mLrty5eiLVtZhAshiDr3GM1rJbqQAqBeOmOlbHhbTrK+ikW4uWgnA+U8AGn/ZlimdWYOFOAR3r2svdKpiqtCMpc0bXTjZK/WLtqn27njYnMIVIRoqCUoXvJXvJPa/TTo0Y6WhOSByKyNWgZiSq4wK6u4XahZetUrHTrjWNSjsbcL58xwu44FduOhSo0ZTqPljFNt9El1MqFZ81zy3U7bzY3BUebng1gkFWKt94da9M8WeFb3T9SntXws8DYkVTkfga881S3e1vSkmSTzmvisZSTjGvDWMkmmtmnqmfUYWre8HuunYq0UtJXnHaFFFFABRRRQAUUUUAFbvhqaKOGVZJgGzkKeKwqRl3EdjnrWtGq6U1NK5nVpqpHlZ6RpDq4LZO48c+lT+aBMY1woHf1rL0yZYrIY+YgAetSxK8kwYjrX1lOq+SKW54M6fvNs1klK5OMkd6xdWkF7uhbIyeRWxHIC3OAF461ja5f29mSo2iRqrFSSpe89CKCfPotTmNbs4rQIIiRn171mVPfTtc3Jdz06VBXyNeUZTbgrI+hpJqK5twooorI0CiiigB8UTTSBF/Ote20+QODIxOOKraPEpkEpJzXTwgY4716mDw0ZLmkcOJrOLsiAW7RR7k5+lW7K5liISQNk9Kt20asCrdccYpY4gsuH5x3r2adFwalFnmSqKV0zzeitptEUooVm3nvWbe2U1lJtlUlOzDvXzNTD1KavJaHuQrQm7JleijtRWBqFFFFABRRRQAUUUUAFFFFABXVfCzxLaeD/iDpOvalFcS2loJd6W6hnO6J0GASB1Yd65Wisq9GOIpSoz+GSafo1ZjTs7o9S+OvxH0n4hzaRJpFnqFs1oHEn2oIAQcYxtY+leW0UVlgsHSwNCOHor3Y7detxyk5O7CiiiuokKKKKACkbpS0N0oA6rSZUNojR9SK6fTmRwMjkVy+kRxrBCIyenIxXa2Nrst0cDIIr6/LYykl6Hz2Nkos0bJ1A+bG33rREybRjAq14C8PS6/4ktbfO22iImnI/ujt+PSuh+Mfh86TrEWoWkapY3QCFFGAjgf1rolxJhcPmlPJpv8AeTi5L9I+rV2vTzR57wM6lB4lfCnb/gnGXd5FGh3N+FZz6gC6mJmRx0ZTgj8axtYkmiYsASorPtr0vJ8+R6V04jH3k4SRdLBrl5kdBcXTbmLPJLI/LO7Ek/U1wvi6JZJvNVhkdq1vEF3LHYbomx6nvXFvdzTbt+WB714OaYqHL7BLTp2R6uBoSv7W5DRRRXzp7IUUUUAFFFFABRRRQAUHpRRQBf0zUWtBsdiFznd6V1UV+saIQwIcZz61w2M9aMsMYdsDoM9K7cPjp0Vbc5a2FjUd9jsby+P2R5I2AOa5GeZ7mZpJTuPamlnIwXYjuKQVGJxUq9i6NBUhaSiiuU3CiiigApD0paRulAG7o1v5luGAIHrXQWke0YXJPes/R0UWaDd/D+ta2lzo04Rhz3xX0mEpxSjfqeLiJttsvxRFI8KME96ie3kVS27JHauiW3DW+4KBxVRYdqsWGc17ssLZI8qNe7OJXzfPCBuE7VDqd3uTZIuQPaugi01BdyKCRgcZqhqdqgyJFBJ4FeJVoVI02epCrBzRxzW7u5MY4PIBqAgqxVgQw7V0CW5WUhVPHc1U1GFZtz4wVHWvFqYayutz04VruxlUUDkcUVxnQFFFISMgdzQAtFWILOabp8orUg8OvJCX8xi3pit6eGq1PhRlOvCHxMw6K6GPwzOx4R2qpf6Fc2xB2FQegNXLBV4x5nHQmOJpSdkzJopXVo32yLtakrlehvuFFFFABRRRQAUUUUAFW7KxmuCrgAID371Bbx+dKAOg5NdLaRY24OPaurDUPau72OevV5FZGtpVsjsh24GMGu2sWhjtucEKOhrndEhJBK88elbVjFIJt2du3lTjNfcZdD2aTS3Pl8ZLnbVz334U6F/ZegC7nj23V5+8IIwVXsP61teN9EXxB4bvLLAEpXfE2M7XHSvMPhz4n1++8Z2tjf6q89mY2/deWijgcdBmtL42+JtZ8P3ulJo2oPaLMrFwsatuwf8AaBr8EzfIc4nxdCM68FiKn7yMk5csUrtR+G+ijbb9T6nC4nDLL/di+RaPu+738zw+8SSR5YJ1Mc8TFJI26qw6isJ7dVnwrEkH8BXS6jfTXt7Jd3svn3cx3SyhQu4+uAAKzJ4+Sy4z71+3VYOolKdubrba/W17O3a6Pn6UuV2Wxh62Q1uYTnPtXJyu3MZAAU44711uouPKkYYLKOtcdkliT1Jr5zMX76se1g17oUUUV5p2hRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFDciiigDd0y5BtOOAB0q1bXXlSBk61zKyMgKrnBqzZ3JDhXOGJwDXoUsU1Zdjknh73Z6jpeq/aoVjGVIHOau7S3Q8VwayyWkgUyfMOeK3tM1Z3OHwRX0+EzGNVKMzwq2Ecfehsb7SQoHfaN+K5y9DTSsxTjtW1corISD8w6U2CDe37wfLXVXg6r5DClJU1zHJXMUjOSOO1U/LwCkuMnpXZXcESsQqBvese7t0cl2AAHevJr4Rxd7noUsRzI4e8RI7pljOe5quTjFdBqGn2rhnUtuHQip9C0JZQXbLP2JrwngqlSryx6nqrFQhDmZiQWEkhUuMA9h1rUh0sllO3PbkV0djpRaRVA3MTjFdZY6LHaHe+1uO/rXs4PJXUPNxGZqBzOj+H2IDyYCdR61tR2sUJHlr82addavDBOEA6dQKsRqLkCeP7jGvcoUKNNclLVo8upVqT96eiLcMIcDyyo9akNikiFZ0Rs96kt0SOMDAzSzXCRYByWPYV6qhFR9489ylf3TiPFfhWIQtLCvy9enSvOZ4mt5THJ17H1r3pit7bSx9D6GuF8ReFy6FkKkdeOor5bOMnU/32HR72W5i4/u6zPPaSnzwvbztDJ95f1plfItNOzPoU76oKKKKQwoPtRTok8yVV7E800ruyE3ZXOh0qyRUUuAMjNdPpmnxzspwMD1rHtQAqHqAAK1be5Nvhgflr6nBwhTtzLQ8LESnK9mdja28UEKqgHHtU0xVUyBxXJSa/IqAIOf5VF/bFxOw3N+Ar3v7RoxXLFHlfUqjd5HpHwqm3fEmxUN1ik4/Ctj9o9C2paHj+4/8xXEeAfEFloPjK01XVPNW2jjdWMSFiCRxwK6D4peKtN8Y3mmy6I07LbqwcyxFOuOma/PMfl+LxHGGHx0aUnSjTacrOydp6N/NHtUqkKeXSpt632+44CKL5fQCsPxDulTbCWUDr2rqUG0ngCuf8TMYYS0WCe4xX2WNp2os4MNK9VHEXks8X7vPynvVOp7uQyFdwIPvUFfG1XeR9LTWgUUUVkWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFT2N3LYXBmgWNmIx865xUFFDSejFKKkrM11uJr9mnkdPMPULxWvpcqx4z97vXJKSrblYqfUVPDdzxNkNuHoa7cPio0rabHLUw3MrI9hEasOcGkuGMUeVGMD86wE1tvPKnaq+tQ3evRFCMsT619jLHUVFtM+eWFqN7F+WVnJHQfrWdflIshe45yaqRasrDLHB681j6trSPJ5calmHUjoK8rEY2nyczZ3UcNNyskXPNRm8vuemK6nQIyiKAowK8ykupmkDrhcdK7Tw3rDzWgLONw4PrWGW4ym6tpGuMw8lTujubBFS9ygGDVu+hM1u6gkMASOawLK5KxF9w3A5681qwarFNHhztccH3r62lWhKHK3a58/UpTUuZK9jjbyM/aSGByD3rpvDjEK0JOVYZFVtSsVu5RLbNkdxWnoliI4hKzHeDjArjwuHlTr3Wx04itGVLUv8AkgIwBOeuay5pIiTtlG8Vd1CWZEKKvDdxVKLT4H2uwYetehW5pPlgjjpaLmkyu9y5YBSQ3t3q4AzQnce2BT2tbd5BnOR3FT28RnlS1hkjVmOAXOAKxl+5hKpVdopX+SKlNW0PHvF9lLZ6n5jjMb/xDoKxQc161410ybT55LG9MExeMtlOeP6GvJdpUsv90kV8Bjo0pSVfDy5oT1TPrMvxHt6K8gooorhO4Kltf+PlKip0b+XIHxnFVFpNNikrpo6+AkwrtHOK07GB5F+bGKwdLvBKuExg10mmEqwL8jFfT4RxqNO54eIUoXQx7BnJ2p+NW7LS3Qh5Bha2LWVeoAK47VaimXJB6Hsa9qlgqV+Zs8yeJnaxkFV3EIvtTlEscbGMirt0sIJcDaaybi6REO09KdRKm7tig3PZEi3ErH94mMVneJWjWyZ/4sdBUcuoFlyxIUVga9rMToYkRi3SvMxeMhGlJNndh8PJ1E0jnJ5TLKSR0plHqe9FfHt3dz6JKysFFFFIYUUUUAFFFFABRRRQAUUUUAFFBIHWjIx1FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGtcuw6MajgJL4PPFFFei/iORfCUrqR95XccZqLAA4oorgm7ydzphsNH36tadI8d4uxiueuKKKcXaaCa91nWWE0mwDeavLI/HzHrRRX09FvlR4dRK5ZSeWLJjdlPsa0La8uBsxK3Wiiu6jOSlozkqxTWqNGa5mKrlzVuJiYmyeooor16bbbuedNJLQhi6t9KpOSZDknrRRUSexpDc57xUzR6ZcurMHIPzZya87j+4PpRRXxmef7xbyPpcs/gv1Fooorxj0QooooAQSPEwMbFT7V0Ok3lw8I3zMeaKK6cHOSqJJnPiYpxvY6fRZpAWO9s1vtI2xTnmiivtMHJ+zPm8QlzlOZ2beGJIrJlUbzxRRWeI13NKWmxla4xS3G04rkCxZ2LEk5oor5fM3+8PbwPwBRRRXnHaFFFFABRRRQAUUUUAFFFFAAaO5oooAtW8SEglQSRU8cETTYKDGKKK7YRVloc0m7la9jSNwEUCq9FFc9ZJT0NabugooorI0CiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluorescence microscopy image using ALK break apart probes of cells from a NSCLC tumor, demonstrating an ALK gene rearrangement. The red and green probes hybridize to regions that flank the highly conserved translocation breakpoint within the ALK gene. Arrow: In the setting of an ALK rearrangement, these probes are separated, and splitting of the red and green signals is observed. In the wild-type intact ALK gene, the closely apposed red and green probes result in a yellow signal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_50_7983=[""].join("\n");
var outline_f7_50_7983=null;
